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Summary 
The response of mammalian cells to DNA damage has been an area of great 
interest, as loss of genomic integrity is often implicated in tumorigenic and oncogeneic 
events. Critical to the ability of healthy cells in maintaining genomic integrity are the cell 
cycle checkpoints that act as a brake against inappropriate cell division in the presence of 
DNA damage. Recent publications have implicated the p38 MAPK as a critical kinase for 
the establishment and maintenance of a DNA damage-induced cell cycle arrest in G2. 
The ability of cancer cells to establish a cell cycle arrest in response to genotoxic agents 
is one of the reasons for their resistance to chemotherapy. Cancer cells with the ability of 
under-going a reversible cell cycle arrest in response to genotoxic agents such as 
Adriamycin have the ability to survive chemotherapy and continue proliferation post 
therapy, leading to poor patient outcome.  
In this study, we investigated whether inhibition of p38 with a potent and 
selective p38 inhibitor (LY479754) could act as a chemo-sensitizer in response to 
genotoxic agents such as Adriamycin and to environmental stress such as UV irradiation. 
To lend physiological context to p38’s role at G2 DNA damage checkpoint arrest, we 
also examined the role of Chk1, a canonical member of the ATM/ATR pathway, in DNA 
damage-induced G2 checkpoint control.  
While examining the role of p38 in the G2 checkpoint pathway, we found that 
inhibition of p38 by biochemical or siRNA was unable to affect G2 cell cycle arrest 
induced by Adriamycin, UV or MMS.  Inhibition of Chk1, on the other hand, led to the 
abrogation of DNA damage-induced G2 arrest in p53 functionally null cancer cells.  
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We also discovered a strong link between p38 activity and the increase in cell 
survival signaling in response to both DNA damage and TNF-α stress. Investigation of 
the link between p38 and the regulation of apoptosis revealed that p38 plays a significant 
role in the early induction of anti-apoptotic signaling in response to DNA damage and 
TNF-α stress. Inhibition of p38 led to the strong down-regulation of BCL2 and BCL-xl, 
members of the BCL2 anti-apoptotic protein family and up-regulation of pro-apoptotic 
proteins such as FADD and TRADD.  
These results imply that, while p38 activation is associated with DNA damage G2 
arrest, its activity is not required for the execution or maintenance of the checkpoint. 
Instead, p38 activation in response to DNA damage and to TNF-α stress is linked to the 
strong induction of anti-apoptotic signaling in immediate response to stress.  Inhibition of 
Chk1 kinase activity serves as an appropriate counter point to p38 inhibition, as loss of 
Chk1 activity in a p53 functionally null cancer cell prevents the establishment or 
maintenance of an effective checkpoint-induced G2 arrest. 
 The data suggests that both inhibition of p38 and Chk1 may be useful therapeutic 
strategies for oncology treatment in combination with chemotherapeutic agents. It also 
suggests that while both kinases are activated in a similar manner to DNA damage, the 
downstream effect of each protein’s activation is fundamentally different. Understanding 
the functional role of both proteins in response to DNA damage may aid in the 
development of successful and relevant therapeutic strategies for cancer. 
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Chapter 1: Introduction 
 
1.1 Role of Signal Transduction in response to Extra-Cellular Stimuli 
Mammalian cells do not live in isolation, making it necessary for them to respond 
to and coordinate a wide degree of extracellular stimuli from their external environment. 
Cells respond to changes in their external environment by activating a complex series of 
intracellular signaling pathways. This allows cells to change physiological processes in 
response to external stimuli (12). 
While there are many types of external stimuli, the two largest groups of stimuli 
can generally be classified as growth stimuli, and stress stimuli (376). The signals from 
these major categories stimulate a rapid transmission of signal from the exterior of the 
cell to the interior (68). There are many components that make up the cellular machinery 
responsible for efficient signal transduction. As the stimuli originate external to the cell, 
cell surface receptors play a critical part in the detection of the stimuli. Once the stimuli 
is detected by the cell surface receptors, rapid conformational changes in the receptor 
recruit both extracellular and intracellular binding partners that are responsible for the 
transduction of the signal (184). The transduction of the signal from the cell surface to the 
internal compartments of the cell requires a series of complex post-translational 
modifications or translocations of intracellular signaling proteins (66,117). The end result 
of the rapid induction of signal transduction pathways depends on the nature of the 
external stimuli, with most resulting in significant physiological effects including 
transcriptional activation of specific genes, or activation of specific protein networks that 
may result in cell division or cell death (68). 
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Figure 1.1: A broad scheme for Signal Transduction in mammalian cells 
 
1.2 Types of External Stimuli 
Signal transduction involves the reception and internalization of external cell 
stimuli. While there are many different types of external signaling moieties, the two of 
greatest interest to this research are factors that stimulate cell growth and factors that 
initiate stress response.  
 
1.2.1  Growth Signals 
A growth factor is broad classification of proteins whose expression results in the 
induction of growth and proliferation (105,471).  Another term often associated with 
growth factors is the term cytokine. A cytokine was originally used to classify secreted 
factors that influenced hematopoetic and immune system cells (225,484).  As research in 
this area progressed, however, it became clear that many cytokines also influenced the 
function of other cell types as well.  Cytokines do not always induce cell growth, for 
instance, FasL, a common cytokine, induces apoptosis. The term cytokine today is used 
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in a neutral context, as a cytokine may have either a growth inducing or non-growth 
inducing role (1,394) 
A large number of secreted factors are classified as growth factors. Included in 
this group are proteins such as EGF (epidermal growth factor), PDGF (platelet derived 
growth factor), FGF (fibroblast growth factor), VEGF (vascular endothelial growth 
factor) and the TGF (Transforming growth factor) family of proteins (39,89,358).  A 
general effect of growth signals is the induction of cellular proliferation pathways that 
eventually act to stimulate progression through the cell cycle.  Induction of proliferation 
signals is usually accompanied by strong transcriptional activation and secretion of 
additional growth factors, leading to positive feedback loops for increased cellular 
proliferation (160,336,386).  Growth factors can also elicit other cellular responses such 
as new blood vessel formation, wound healing and others.. The dysregulation of growth 
factor production is associated with the onset of diseases, specifically cancer. The 
establishment of the tumor microenvironment and the onset of angiogenesis is highly 
associated with dysregulated production of cytokines and growth factors (101,339,457). 
 
1.2.2  Stress Signals 
Another major class of external stimuli that are sensed by cells is stress signals. 
Cells can be exposed to a large number of stresses on a regular basis, and have developed 
complex signaling networks to respond appropriately to each type of stress. (225,438) 
The types of stress that can be experienced by a cell can range from mechanic stress such 
as shear stress, foreign organism invasion such as bacterial and viral infection, to 
chemical and environmental damage such as ultra-violet (UV) radiation, osmotic stress or 
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genotoxic agents (21,22,82,87,135,335). While the specific cellular response to different 
stresses is inherently different, the overall response to stress exhibits a general 
pattern.The cellular surveillance mechanism assess the degree of severity of a stress, this 
response then triggers a halt to the cell cycle in proliferating cells and induces an 
appropriate cellular repair pathway. However, if the stress or damage is too great, the 
apoptotic pathway is activated (55,217,247,310,352). 
The cellular response to stress is an area of great interest, as incorrect or 
inappropriate response to stress leads to the onset of many diseases. The hallmarks of 
cancer as defined by Weinberg et al (138), depict that cancer cells have acquired the 
ability to escape anti-proliferative and pro-death signals while maintaining endless 
replicative potential.  
 
1.3 Signal Transduction Receptors 
Signal transduction receptors play a major role in the transmission of external 
stimuli to the inside of the cell. A large number of signal transduction receptors are found 
on the surface of the cell and are termed cell surface receptors. Cell surface receptors are 
responsible for the detection of external stimuli, and for the activation of intracellular 
signaling pathways. (145,192,233,333) Cell surface receptors can comprise of simple ion 
channels that respond to changes in extracellular ion concentrations to the more complex 
protein structures activated by ligand binding relationships (83).  
Signal transduction receptors can be grouped broadly into three general classes. 
These classes are:  
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i. The first class of receptors penetrates the plasma membrane and has intrinsic 
enzymatic activity. Examples of this type of receptors include the receptor 
tyrosine kinases (RTK), the serine/threonine kinase receptors, the tyrosine 
phosphatases and the guanylate cyclases. Epidermal growth factor receptor 
(EGFR), the platelet derived growth factor receptor (PDGF) and the insulin 
growth factor receptor (IGFR) are examples of RTK 
(145,147,153,286,319,404). Similarly, transforming growth factor beta 
receptor (TGF-  receptor) belongs to the serine/threonine kinase receptors 
class, CD45 to tyrosine phosphatase receptors class and natiuretic peptide 
receptors to guanylate cyclases (100,418,463).  Receptors with intrinsic 
tyrosine kinase activity have the capability to auto-phosphorylate themselves 
as well as their down-stream substrates.  
ii. Receptors belonging to the second class are coupled intracellularly to GTP-
binding and hydrolyzing G-proteins. The G-protein coupled receptors 
(GPCRs) have a characteristic 7 transmembrane spanning domain and are 
sometimes referred to as serpentine receptors (153,196,255,447).  Adrenergic 
receptors, odorant receptors and certain hormone receptors (angiotensin, 
vasopressin and bradykinin) are examples of GPCRs. 
iii. The 3rd general class of receptors is found intracellularly and upon ligand 
binding migrates to the nucleus where the ligand-receptor complexes directly 
modulate gene transcription (287,359).  These receptors are known as nuclear 
receptors, and generally have both a ligand binding domain and a DNA 
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binding domain. Examples of this class of receptors include the large steroid 
and thyroid hormone receptors (e.g. Estrogen receptor) (142,276,301). 
Having introduced the major classes of cell surface receptors involved in 
receiving exogenous signals, we will now discuss the intracellular mechanism involved in 
the transmission of the external signal.  
 
1.4  Intracellular Signaling Cascades 
The cytoplasmic receptors activate a cascade of intracellular signaling pathways 
to perpetuate the signal away from the site of ligand/receptor binding, into the cell proper. 
These intracellular signaling cascades are critical for the efficient and fast response to 
extra-cellular stimuli. Many of the intracellular signaling cascades that respond to 
extracellular growth or stress signals are not direct substrates of receptors with kinase 
activity such as the RTKs or serine/threonine kinase receptors (141,325). Instead 
intracellular adaptor molecules and other signaling kinases link receptor activation with 
the down-stream effector molecules (49). As this thesis is focused on the role of p38 
MAPK, we will focus on reviewing the intracellular signaling cascades responsible for 
p38 activation, with some brief overview of other parallel signaling pathways.  
 
1.4.1  Mitogen Activated Protein Kinase Activation Cascade (MAPK Cascade) 
Mitogen-activated protein kinases (MAPKs) are important signal transducing 
enzymes and have been implicated in cell migration, invasion, proliferation, 
angiogenesis, cell differentiation and cell survival (5). MAPKs are serine/threonine 
protein kinases mediating the response of cells to extracellular stimuli to critical 
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regulatory targets within the cell (297,338). At least four distinctly regulated groups of 
MAPKs are expressed in mammals, extracellular signal-related kinases (ERK)-1/2, Jun 
amino-terminal kinases (JNK1/2/3), p38 proteins (p38α/β/γ/δ) and ERK5 (59). A major 
function of MAPK pathways is the control of gene expression by either direct 
phosphorylation of transcription factors, but they can also target coactivators and 
corepressors (109). All MAPKs are activated through a dual phosphorylation on an 
exposed surface loop, normally referred to as the phosphorylation loop. All MAPKs are 
activated by a dual phosphorylation on a threonine and tyrosine residue following a Thr-
Xxx-Tyr dual phosphorylation motif (130).  The basic structure of the MAPK cascade is 
well conserved in all eukaryotic cells and it consists of a 3-layer activation cascade 
consisting of a MAPKKK activating a MAPKK, which in turn activates a MAPK (348). 
The MAPK cascade is detailed in Figure 1.2.  
 
 
Figure 1.2: Canonical overview of the MAPK signaling cascade 
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The most prominently studied MAPK cascade is the pathway leading to the 
activation of ERK1/2 by RTKs (54,461). Stimulation of RTKs leads to the recruitment of 
the adaptor protein Grb2 and association and activation of the RAS-GEF Sos, which 
subsequently activates membrane-associated Ras. Ras in turn induces the serine/threonine 
kinase activity of the MAPK kinase kinase (MAPKKK) Raf-1 which phosphorylates and 
activates the MAPK kinases 1/2 (MAPKK, MEK 1/2). Finally, MEK1/2 activate ERK1/2 
by phosphorylation of threonine and tyrosine residues in the regulatory TEY-motif 
(23,65). Thereafter, ERK1/2 either translocate into the nucleus to regulate gene 
expression or effect cytoplasmic or membrane bound effectors, such as influencing 
transmembrane protein processing by phosphorylation of the intracellular domain of the 
metalloprotease ADAM17 (393).  
The JNK-family MAPKs are also known as stress-activated kinases as their 
activation result from response to environmental stress and radiation and growth factors 
(419,427,439). 
With the focus of this thesis being the role of p38 in DNA damage response, the 
basic structure of the stress induced p38 MAPK cascade will be discussed, starting with 
LPS stimulation of the Toll receptors (TLRs).  
 
1.4.2 Upstream activation of p38 MAPK  
The TLRs are activated in response to the presence of LPS in a cell’s external 
environment. The p38 MAPK was first discovered as a 38-kDa protein that was 
phosphorylated in response to the presence of LPS (225,262). We begin my exploration 
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of the mechanics of p38 activation by examining the intracellular signaling arising from 
LPS stimulation. Besides LPS stimulation, p38 has been shown to be strongly activated 
by many other secreted factors including TNF-α, IL1 and certain growth factors and 
hormones. The canonical signaling pathways leading to the activation of the MAPK 
cascades and p38 specifically are depicted in Figure 1.3.  
 
 
Figure 1.3: Canonical p38 MAPK signaling pathway: Receptors and signaling 
cascades leading to ERK, JNK & p38 MAPK activation 
 
1.4.3 Cytoplasmic Adaptor Proteins 
Connecting the receptors to intracellular signaling networks are the intracellular 
adaptor proteins. These proteins are often recruited to the site of receptor activation by 
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conformational changes in the intracellular domain of the receptor, which facilitates 
recruitment and binding (84). 
The key intracellular adaptor proteins for the TNF receptor family are the RIP 
protein and the TRADD protein (251,329). Together they are responsible for the 
activation of the downstream signaling cascade that includes recruitment and activation 
of TRAF2 and eventually the activation of IKKs and NFkB. The TNFR signaling 
pathway is tightly associated with extrinsic induction of apoptosis and the production of 
inflammatory cytokines (252). 
For the TLR, the key intracellular domain responsible for recruitment of adaptor 
proteins is known as the Toll/Interleukin receptor (TIR) domain. The TIR domain is 
responsible for the recruitment of adaptor molecules to the cytoplasmic face of the 
receptor as well as to facilitate homo or hetero-dimerization of the receptors (294). The 
common adaptor molecule shared by all the different TLR is called Myeloid 
differentiation response gene 88 (MyD88). MyD88 is an adaptor molecule that is 
recruited to the cytoplasmic domain of TLR through homophilic interactions of TIR 
homology domains between TLR and MyD88 (6). MyD88 functions to recruit the 
interleukin receptor associated kinase 1 and 4 (IRAK1 & 4) and is a key adaptor 
molecule for the TLR pathways because it contains both a TIR domain as well as a death 
domain. However The TIR domain has been most commonly associated with host 
defense in plant and mammalian cells, while the death domain is normally associated 
with induction of apoptotic stimuli (85). It has also been shown through MyD88 deficient 
macrophages that LPS can induce an inflammatory response both in the presence and 
absence of MyD88 (10). The kinetics of the activation of inflammation in MyD88 
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deficient cells is significantly slower than wild type cells. This suggests that LPS can 
signal through both a MyD88 dependent and independent pathway (10). 
IRAK1,4 a serine/threonine kinase, is a key adaptor molecule mediating the LPS 
and IL-1 signaling cascade (345). Upon activation, IRAK1/4 dissociates from the 
receptor complex in order to associate and activate their downstream substrates, which 
include TRAF6. (302) IRAK1/4 has been shown though mouse knockout studies to be 
vital for the induction of the NF B, JNK and p38 MAPK stress induced pathways 
(188,211). IRAK1/4 has also been shown to be responsible for the translocation of the 
key adaptor molecule TAB2 from the membrane space to the cytoplasmic space (322). 
The complexities of cell signaling pathways at this level are tremendous, however 
much of this complexity could be due to the way scientists have probed the various 
components of cell signaling pathways. Over-expression studies have been shown to 
induce associations and correlations in-vitro when no such associations are observed in-
vivo. There are numerous possible binding partners that could be recruited to the 
TLR4/MyD88/IRAK1/4 cytoplasmic complex, the most important protein involved in 
p38 MAPK induction from the TLR pathway however is TRAF6 (260,322). IRAK1/4 
signaling has also been shown to mediate the translocation of TAB2 from the plasma 
membrane to the cytosol (322). TAB2, as discussed later is a key component of 
transforming growth factor  associated kinase 1 (TAK1) activation.  
Tumor necrosis factor associated factor 6 (TRAF6) was identified through yeast 
two-hybrid assays as a key binding partner to members of the TLR adaptor complex 
(395). Gene knockout and dominant negative over-expression of TRAF6 in mouse 
models, has shown the importance of TRAF6 for response to inflammatory stress and the 
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activation of NF B, p38 and JNK pathways (290). TRAF6 is cited as a key upstream 
molecule that interacts and facilitates the phosphorylation of various Mitogen Activated 
Protein Kinase Kinase Kinases (Alias: MAPKKK, MAP3K, MEKK). Upon activation, 
TRAF6 forms a complex with 2 ubiquitin molecules Ubc13 and Uev1A (170). 
Collectively these molecules form a ubiquitin conjugating enzyme (E2), where TRAF6 
serves as the ubiquitin ligase. TRAF6 is a key adaptor/scaffold protein that helps link 
upstream activating kinases like IRAK1/4 to its downstream substrates such as the 
MAP3K family of proteins (170). 
 
1.4.4  MAP3K family 
The highest level of the hierarchical MAPK activation cascade is the MAP3K 
(MAPKKK) family of protein kinases. In humans there are 21 proteins that currently 
identified to play a role as a MAP3K (71). Based on protein homology modeling, studies 
have identified up to 4 separate groups of MAP3Ks, suggesting distinct yet overlapping 
down-stream signaling pathways (71). Some of the best studied MAP3Ks are the RAF 
family of proto-oncogenes and the TAK1 family of proteins. As TAK1 is shown to 
activate the MAPK cascade leading to p38 activation, its role in signaling is studied in 
greater details below.  
TAK1, a member of the MAP3K family of kinases is activated by various stimuli, 
including stress, growth factors and cytokines (88). Activated TAK1 dissociates from its 
inhibitory associated proteins and leads to the activation of the p38 and JNK MAPK 
pathways as well as the NF B pathway, as shown in mouse knock-out studies  (166). 
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Immuno-precipitation and yeast two hybrid studies of activated TAK1 indicate 
that it normally associates with 2 binding proteins, TAB1 and TAB2. As explained earlier 
in this review, TAB2 translocates from the membrane to the cytosol during LPS and IL-1 
stimulation, and is linked with the transient association with TRAF6 (369). 
TAB1 was originally identified as a binding partner of TAK1 and is associated 
with the activation of TAK1. TAB1 however, has also been shown through immuno-
precipitation and mouse knock-out studies to be able to activate p38, independent of 
TAK1 (402). This suggests a more extended role for TAB1 beyond being a binding 
partner of TAK1, leading to TAK1’s activation (236). 
TAK1 is just one of many MAPKKKs that have been implicated in-vitro and in-
vivo to activate p38 MAPK. TAK1 activates a number of MAPKK like MKK6, MKK3 
and MKK4, which lead to the activation of p38 (98). 
 
1.4.5  The MKK6, MKK3, MKK4 kinases 
The kinases that directly phosphorylate the MAPKs are referred to as MAP kinase 
kinases, and are variously abbreviated as MAPKKs, MEKs, or MKKs (477). MKK3 and 
MKK6 have been implicated as the major upstream activators of p38 MAPK in vitro and 
in vivo (265). MKK6 appears to phosphorylate all 4 p38 MAPK isoforms, whereas 
MKK3 phosphorylates only p38α, p38 , and p38  (98). In addition to MKK3 & 6, a 
recent gene-targeting study revealed that MKK4
-/-
 fibroblast cells exhibited defects in 
both JNK and p38 MAPK phosphorylation in response to TNF, anisomycin or 
hyperosmotic stress, suggesting a possible in vivo pathway from MKK4 to p38 MAPK 
(437). 
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1.5  The p38 MAPK 
The p38 MAP kinases are a family of serine/threonine protein kinases that play a 
critical role in cellular responses to external stresses (64). They belong to a set of core 
intra-cellular signaling pathways that are critical for the internalization of a host of 
external signals. The p38 MAPK family of proteins was first discovered in response to 
LPS stimulation in murine cells (225). Since its discovery in relationship to cytokine 
production, the p38 MAPK proteins have been implicated in response to biological 
processes such as inflammation, immune response, pulmonary disease, osmotic stress and 
hypoxia (186,200). The 4 isoforms of p38 MAPK are p38 , p38 , p38  and p38 . The 
best-characterized isoforms of p38 are the  and  isoforms (98). The p38  and p38  
proteins are ubiquitously expressed in all cell types, but p38  and p38  are expressed in a 
more restricted fashion and only in limited cell types (476). 
To be fully activated, p38 needs to be dual phosphorylated on the threonine 180 
residue (Thr180) and the tyrosine 182 residue (Tyr182) by its upstream activating kinases 
(476). 
 This study will focus on the p38α and  isoforms of p38, as they are the best 
characterized and understood isoforms of p38. This study does not discount isoform 
specific effects of p38 in response to stress and DNA damage, however as the reagents to 
closely study the  and  isoforms are not easily available, we have decided to set aside 
the isoform specific differences for now and focus on the main isoforms of p38 for now, 
namely the α and  isoforms. When we refer to p38 from hence forth, we will be 
referring to the α and  isoforms.  
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1.5.1  Sub-cellular location of Activated p38 
Cytoplasmic p38 has also been shown to translocate to the nucleus upon 
activation (347).  Activated p38 has also been shown to be exported from the nucleus 
while associated with one of its downstream substrates MAPKAPK2. This suggests a 
dual location for activated p38 (347).  
 
1.5.2  Downstream Targets of substrates of p38 MAPK  
Like all members of the MAPK family, p38 MAPK is a proline-directed kinase, 
phosphorylating its substrates on serine/threonine-proline motifs. The structural basis for 
this motif selection is unknown, since a portion of the activation loop, for example, 
occludes the Ser+1 pocket in the unphosphorylated p38 structure (97). 
The targets of p38 can be divided into 3 categories: Cytosolic proteins, Transcription 
Factors that are directly phosphorylated or activated by p38 and other kinases that are 
activated by p38. These 3 classes of molecules describe the majority of p38’s activity in a 
host of different cell lines and cell types. This list does not currently differentiate 
abundance of these substrates in different cell types. 
 
1. Cytoskeletal and Cytosolic Proteins:  
The study of p38 MAPK’s effect on cytoskeletal proteins was first studied using p38 
inhibitors. The inhibitor was found to have profound effect on cell migration in epithelial, 
smooth muscle and endothelial cells. SB203580 was found to block cell migration 
substantially in these cells (481). The exact p38 substrates responsible for this effect on 
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cell migration still have yet to be elucidated. The direct cytosolic substrates of p38 that 
have been elucidated are: (116,227,431) 
a. Microtubule associate protein (Tau)  
b. Cytosolic phospholipase A2 (in Platelets) 
c. Angiotensin II mediated regulation of NHE1 in vascular smooth muscle 
cells  
d. F-Actin (Endothelial Cells)  
e. HSP27 
 
Upon activation and association with these substrates, p38 serves to 
phosphorylated and activate these molecules. The direct effect of p38 phosphorylation on 
most of these molecules is not well characterized with the exception of Hsp27 and Tau. 
Under non-stress conditions, HSP27 forms large oligomers that, together with hsp70, 
act as molecular chaperones to stabilize and refold various proteins (11,223).  
 
2. Nuclear Substrates: p38 phosphorylates and activates many transcription factors 
directly and through intermediate nuclear kinases, controls the expression of a 
large number of genes. p38 also has significant influence on transcriptional 
control elements such ATF 1/2 and CHOP/GADD 153 and multiple CREBs 
(cyclic AMP response element binding proteins) (30,137,441,479). Through its 
role as an activating and regulating kinase of a large number of transcriptional 
control elements, the p38 MAPK pathway is an integral part of many signal 
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transduction pathways. These pathways include most of the stress response and 
many of the growth response pathways.  
  The nuclear transcription factors targeted by p38 include: 
a.  ATF-1/2 (30,409) 
b. Myocte enhancer factor 2A& 2C (MEF2A/2C) (479) 
c. ELK-1/4 (SAP-1) (152) 
d. NF B (97) 
e. CHOP/GADD153 (441) 
f. Ets-1 (400) 
g. MAX (Myc binding partner) (303) 
h. p53 (163,356) 
 
3. The p38 MAPK controls an important cis element, the AP-1B binding site and 
through AP-1 regulates the expression of many genes. Transcriptional control 
regions containing elements for both CREB and ATF1 are strongly influenced by 
p38 since the p38 pathway phosphorylates both elements. There are at least three 
known CREB kinases downstream of p38: MK2, MSK1, and RSK-B.  
a. Downstream Protein Kinases:  
i. MAPKAPK-2 (MK2) & MAPKAPK3 (MK3) (462) 
ii. MNK-1 (40) 
iii. MSK-1 (Alias: RSK-B, RLPK) (79) 
iv. PRAK (209) 
b. Transcriptional control elements controlled by p38 include:  
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i. c-jun (309,335) 
ii. c-fos (70) 
iii. ATF1,2 (398) 
iv. Cyclic AMP response element binding protein (CREB) (79) 
Having described the major components of the p38 signaling network, we now 
switch to describing the physiological responses to growth signals, and stress signals that 
are associated with p38 activation.  
 
1.6  Physiological response to Growth Signals 
Having detailed the intracellular signaling components that make up the p38 
MAPK pathway, we shift focus to explore the physiological effects of growth signals and 
of stress signals.  
 The general response of increased growth signals is the induction of the 
mammalian cell cycle (376). The cell cycle is the process which cells use to undergo cell-
division, where one cell divides into two identical daughter cells. Regulation of the cell 
cycle is necessary to control the rate of proliferation as well as the accuracy of 
duplication.  
 
1.6.1 The Mammalian Cell Cycle  
The mammalian cell cycle consists of a set of tightly regulated and ordered events 
that occur in sequence, culminating eventually in cell growth and cell division into two 
daughter cells (346,376). The molecular pathways and systems that govern this tightly 
regulated system have been the subject of intense study, as dysfunction in the cell cycle 
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control has been implicated in human diseases, especially in tumorigenesis. Uncontrolled 
proliferation is one of the key hallmarks of cancer as defined by Weinberg et al (138), in 
their landmark paper describing the various properties underpinning the occurrence and 
growth of cancer. Loss of cell cycle checkpoint control and regulation is one of the main 
mechanisms employed by cancers to gain limitless potential to proliferate (49,263,425). 
Before we explore the role of p38 MAPK in the control of DNA damage cell cycle 
checkpoint control, it is necessary to first layout concisely the current understanding of 
the mammalian cell cycle. In this chapter, we will describe the basic molecular signaling 
components that govern cell cycle progression. We will also discuss the various 
checkpoints that are positioned at critical junctures throughout the cell cycle to prevent 
premature advancement through the cell cycle. These checkpoints play a critical role in 
halting the cell cycle and function to ensure the integrity of the genomic code. A pictorial 
scheme of the mammalian cell cycle is provided in figure 1.4 below. 
 
Chapter 1: Introduction 
 
 
Author: Mark Phong   Page 34 of 291 
 
 
Figure 1.4: Overview of the Mammalian Cell Cycle: Key cyclins and CDKs required 
for transition through the cell cycle 
 
The mammalian cell cycle is conveniently divided into 4 ordered phases, namely 
the G1, S, G2 and M phase. Besides these 4 phases that comprise the normal cell cycle 
for growing cells, an additional state called the G0 or quiescence phase is also available 
for cells that are no longer proliferating and are outside the regular cell cycle (9,346,425). 
Normal progression through the cell cycle requires that a cell completes each phase in 
order starting from G1. Each phase of the cell cycle is governed by a number of 
regulatory proteins called cyclins and their interacting family of kinases called cyclin 
dependent kinases (CDKs). The cyclins are a family of proteins that are centrally 
involved in cell cycle regulation which share structurally conserved “cyclin box” regions 
(346).  As the name suggests, CDKs require cyclin to properly function, and until 
recently it was suggested that each phase of the cell cycle had its own unique pair of 
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cyclin/cdk interactions that drove the proliferating cell from one stage of the cell cycle to 
another (284). Recent data now suggests that for some of the critical cyclin/cdk 
interactions have built in redundancies and cyclin/cdk complex may play a role at more 
than 1 component of the cell cycle (341). In the next few sections of this review, we will 
explore the transitions between each phase of the cell cycle. Understanding the key 
regulatory mechanism that governs these transitions will highlight the impact of defects 
on the ability of cells to proliferate in an uncontrolled manner, often leading to 
tumorigenesis.  
 
1.6.2  The G1 to S transition  
The G1 phase is the longest phase of the normal mammalian cell cycle. For cells 
that have a regular doubling time of 24 hours, the G1 phase can span for 10-12hrs or 
more, usually half or more of the total doubling time (266). Much of what is currently 
know about the mammalian cell cycle was originally derived through studies in 
experimental systems such as yeasts, fly and Xenopus oocytes (76,113,261). Yeast 
genetic studies revealed many of the key regulators of the cell cycle, including 
Cdc2/cyclinB complex, now known CDK1 (100). The main goal of cells in the G1 phase 
of the cell cycle is to prepare for DNA synthesis in the ensuing S phase. The entire 
genome is replicated once and once only per cell cycle (456). Genetic studies in yeast 
have yielded insight into the molecular activity in the pre-replication stage of the cell 
cycle. During G1/S transition, complexes called pre-replicative complexes or pre-RCs are 
formed at thousands of sites across the genome. The pre-RCs are formed by the 
interaction of CDC6, minichromosome maintenance proteins and the origin-recognition 
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complex (ORC). The presence of pre-RCs on the chromatin renders the DNA replication 
competent and facilitates the signal transduction pathway that pushes the cell through the 
G1 restriction point, or start in yeast, into S phase (183,224,228,243,330). 
There are numerous regulatory proteins that govern the exit from the G1 phase. 
The principal cyclin active during the G1 to S transition of mammalian cells is cyclin D, 
and it has been found to associate with two corresponding CDKs, which are CDK4 and 
CDK6. The best studied regulatory substrates of the cyclin D and CDK4/6 complex is the 
Retinoblastoma protein (Rb).  
Rb is a critical protein whose activity controls progression through the G1/S 
transition point. Rb has been found to actively interact with many other critical proteins 
during G1/S transition, these proteins include E2F family of transcription factors, and the 
p53 tumor suppressor protein (421). Rb was first predicted to exist through studies of 
families with Retinoblastoma in 1971 by Knudson et al (204).  Cytogenetic studies 
performed later found a large number of Retinoblastoma patients with lost heterozygosity 
at the 13q14 locus, the genetic locus of the Rb protein (205). Rb’s role as a tumor 
suppressor protein was solidified by examination of patients with small cell lung cancer 
(SCLC). It was found that approximately 20% of patients with SCLC had a resulting loss 
of Rb at the Rb locus (203). Rb tumor suppressing activity stems primarily from its role 
in governing the transition of the cell cycle forward into S-phase (132). In normal 
growing cells in early G1, the Rb protein is found to be active in a hypo-phosphorylated 
form. In this form, it interacts with and suppresses E2F1 transcriptional activity, which is 
responsible for activating the transcription of many pro-proliferation genes, such as 
cyclinE (433). The Cyclin D/CDK4/6 complex phosphorylation of Rb at multiple sites, 
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leads to its inactivation and the decoupling of Rb from the E2F1 transcription factor 
family (112). Rb not only regulates the E2F1 transcription factor, but also plays a role in 
the regulation of the activity of the RNA polymerase pol1 and pol2 (257,299,433,465). 
The combination in the regulation of the transcription factors and the RNA polymerase 
together makes Rb a critical regulator in G1 to S transition. The phosphorylation of Rb by 
the cyclin D/CDK4/6 complex is an essential step in the forward progression of cells 
through the Rb mediated G1/S restriction point (20). Loss of Rb, as in the case of patients 
suffering from cancers such as retinoblastoma and SCLC, inactivates a critical anti-
proliferation checkpoint leading to the ability of these cells to escape anti-proliferative 
signals and become cancerous (465,466). 
 
1.6.3  Transition through S-Phase  
The primary activity during the S-phase of the mammalian cell cycle is DNA 
replication (159). As discussed in section 1.6.2, cells in G1 have prepared for S phase by 
increasing cell mass to prepare for DNA synthesis and subsequent cell division and have 
assembled the pre-RC complexes on their chromatin (13). The subsequent transition of 
pre-RC formation to the initiation of DNA synthesis provides another level by which 
CDKs exert regulatory control on progression through S-phase. During G1 phase the 
loading of the pre-RC complex signals the chromatin ready for DNA replication. Once 
cells move past G1 into S phase, however, the pre-RC must be reconfigured to form the 
pre-initiation complex or pre-IC (91). The pre-IC in yeast is composed of the CDC45 and 
the MCM complex (228). This protein complex is required for the initiation of DNA 
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replication. In animal cells, loading of the MCM complex to chromatin is governed by 
the activity of cyclin E/CDK2 (228,272,357). 
The key cyclins active during S-phase of the mammalian cell cycle are Cyclin E 
and Cyclin A, both of which are found to interact with CDK2 (162). Through genetic 
studies in mice, it has been shown that cyclin E/CDK2 is required primarily for the 
passage through the G1/S restriction point. Studies have shown the cyclin E/CDK2 
complex also phosphorylates Rb, however, the dynamics of cyclin E/CDK2 
phosphorylation is believed to be subsequent to the initial phosphorylation event by 
cyclin D/CDK4/6 (214). This suggests that cyclin D/CDK4/6 phosphorylation begins the 
process of Rb inactivation. Then, additional phosphorylation of Rb by cyclin E/CDK2 
promotes complete inhibition of Rb at the G1/S transition point (46).  
While CDK2 is a key kinase required for normal progression into S-phase, 
homologous knock-outs of CDK2 in mice have shown that loss of CDK2 does not 
prevent cell cycle progression, suggesting that there are sufficient compensatory 
pathways in mammalian cells through other CDKs for S-phase progression. Loss of 
CDK2 is not without effect however, CDK2
-/-
 mice are sterile, suggesting an 
irreplaceable role of CDK2 during germ cell development (250). Another observation 
noted for CDK2
-/-
 mice was their delayed kinetics for entry and completion of S-phase. 
So while some of the essential kinase functions of CDK2 can be compensated, loss of a 
critical S-phase CDK is not without effect and consequence on an organism(264). Studies 
from genetic knock-outs of CDK2 have suggested that the CDK2 function is required for 
germline cell proliferation, but can be largely compensated by other CDKs in somatic 
cells. 
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The cyclin A/CDK2 complex regulates initiation of the DNA replication and 
restricts the initiation of replication as a once only event within a cell cycle (273). Cyclin 
A/CDK2 is activated in early S-phase and remains active until early M phase. While 
cyclin E plays an important role during G1/S transition as discussed earlier, there are 
reports suggesting that cyclin A can substitute for cyclin E function at the G1/S 
restriction point (280). However loss of cyclin A2 cannot be substituted for by other 
cyclins, as loss of cyclin A2 results in embryonic lethality (291). Cyclin A2 has been 
found to be at both the G1/S transition as well as the G2 transition. Cyclin A2 activity is 
also required for initiation of DNA replication (origin firing) as well as chromosome 
replication (171,187,342). 
 
1.6.4 The G2 to M transition  
After completion of DNA replication, mammalian cells undergo a 2
nd
 gap phase 
in the cell cycle prior to mitosis and division (110). As discussed in section 1.6.3, cyclin 
A/CDK2 activity is important for progression through S-phase and completion of DNA 
replication. The cyclin A/CDK2 complex remains active during G2 phase (221,273,456). 
By the end of S-phase, DNA is replicated and repackaged into adjoining chromosomes. 
At G2 phase, cells hence have 2 copies of each chromosomes or measured as a 4N DNA 
content. 
The G2 phase is thought to be a final staging phase prior to the act of cell 
division. The main cyclin/CDK complex that governs the transition from G2 to M is the 
cyclin B/CDK1 (cdc2/cdc28 in yeasts) complex (151,221). This is believed to be the last 
major cellular checkpoint prior to the entry into mitosis which is demarcated by the 
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formation of polar spindles and a metaphase plate.  The importance of accurate and error 
free cell-division is paramount to survival of an organism. The cyclin B/CDK1 complex 
governs the last checkpoint prior to entry into mitosis, sensing incomplete DNA 
replication and DNA damage resulting in both single and double strand 
breaks.(344,349,397) The signaling cascades that signal into the G2 checkpoint have 
been an area of intense research, as defects in G2 checkpoint have been exploited by 
cancers as a mechanism to evade growth inhibitory signals. The key intracellular kinases 
that suppress the activity of the cyclin B1/CDK1 complex are identified as Myt1 and 
Wee1 kinase. These kinases restrain CDK1 activation by maintaining inhibitory 
phosphorylation at Thr14 & Tyr15 (387). As cells progress through G2 phase, the 
CDC25 family of phosphatases are activated to remove the inhibitory phosphorylation on 
CDK1 (397). Simultaneously, the Wee1 & Myt1 kinases are inactivated through 
ubiquitin-mediated proteolysis. The consequence of down-regulation of Wee1 & Myt1 
and the up-regulation of the CDC25 phosphataes culminates in the rapid activation of 
CDK1 (378). Network analysis of CDK1 activation dynamics has suggested a closely 
regulated positive feedback loop aiding in its rapid activation (242). CDK1 has been 
shown to phosphorylate its inhibitory kinases Myt1 and Wee1, leading to their 
deactivation and eventual degradation by poly-ubiquitination (143). Once CDK1 activity 
progresses beyond its activation threshold, this positive feedback mechanism drives down 
the activity of its inhibitory kinases leading to maximal activation of CDK1. There are 
numerous kinase signaling pathways including Plk1 and the p38 pathway that have been 
implicated in the activation dynamics of CDK1 and the entry into mitosis.   
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The active cyclin B1/CDK1 complex triggers initiation of mitosis, promoting, 
nuclear envelope breakdown, DNA condensation and formation of polar spindles (174). 
A key marker used in this study and others to mark the transition from G2 into mitosis is 
the phosphorylation of Histone-H3 on its ser10 residue (403). We use this mitotic marker 
as a critical biochemical marker to study the potential role of p38 on the G2 DNA 
damage checkpoint. Another key kinase that plays a regulatory role at the G2 transition is 
the polo-like kinase, Plk1. Plk1 has been shown to play a significant role in G2, 
especially in preparation of centrosomes for separation during mitosis (222,305). Plk1 is 
involved in the recruitment of -tubulin to the centrosome, a required component of the 
mitotic spindle. Plk1 has also been shown to regulate several centrosome associated 
proteins including Nlp (ninein-like protein), Katanin and the microtubule stabilizing 
protein TCTP (47,296). Besides being involved in the active recruitment of key 
components of the microtubule machinery to the centrosome, Plk1 is also implicated as a 
key component of the G2 DNA damage checkpoint (172,415).  
There are other signaling pathways besides the Plk1 pathway that are believed to 
regulate the activation and maintenance of the DNA damage G2 checkpoint. One of the 
pathways recently implicated in the regulation of G2 to M transition is the p38 MAPK 
pathway. Elucidation of the putative role of p38 MAPK in the regulation of the G2 DNA 
damage checkpoint is a key area of my graduate research. we will, therefore dedicate an 
entire section of this literature review to highlight the key signaling and mechanistic 
components of the G2 checkpoint.  
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1.6.5  Transition through Mitosis 
The final stage of the cell-cycle is the act of cell division. In terms of total time, 
the act of cell-division is a very rapid and spectacular event (122). All the inter-dependent 
events during inter-phase, culminate in a series of complex processes during mitosis to 
segregate DNA equally and to complete cell division into two daughter cells. The key 
kinase that regulates the entry into mitosis have been identified as cyclin B1/Cdc2 
complex, now commonly known as CDK1 (241,340,412). As reviewed in the preceding 
section, a delicate balance of inhibitory kinases and activating phosphatases keeps CDK1 
in check until cells are ready to undergo mitosis. Upon reaching the threshold of activity, 
CDK1 triggers cells into mitosis (366). CDK1 undergoes a nuclear translocation at the 
beginning of mitosis. The translocation of CDK1 from the cytoplasm to the nucleus 
correlates with chromosome condensation and nuclear envelope breakdown (318). 
Besides CDK1, early mitosis is also driven by the activity of the S-phase cyclin-A . As 
mentioned in previous sections, cyclin-A plays a critical role during S-phase, driving 
successful DNA and centrosome duplication. Cyclin A levels however stay high 
throughout G2 and into early mitosis, also correlating with chromosome condensation 
and nuclear envelope breakdown (148). As cyclin A is degraded post nuclear envelope 
breakdown, cyclin A, like the mitotic cyclin B, also forms a complex with Cdc2 drives 
some of the early events during mitosis, including chromosome condensation and nuclear 
envelope breakdown (129,215,273,274). 
The next major features noticeable during mitosis after nuclear envelope 
breakdown is the formation of polar mitotic spindles and the formation of the metaphase 
plate (485). Active CDK1 is found localized to the centrosomes at the end of G2. The 
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localization of activated CDK1 at the centrosome is an indication that high CDK1 
activity is critical for the initiation of centrosome separation (72,212,242). Centrosomes 
duplicated during S-phase now move quickly to opposing ends to form the bipolar 
mitotic spindle. Sister chromatids are moved and oriented in a bi-directional fashion and 
attached to the mitotic spindle (133). The correct orientation and attachment of all 
chromosomes to the mitotic spindle is the single most important event during metaphase 
(108). Incomplete or inaccurate attachment of sister chromatids to the mitotic spindle 
often leads to aneuploidy, as frequently associated in cancer cells (311). The spindle 
checkpoint is the key mitotic checkpoint that ensures that all sister chromatids are 
appropriately aligned and attached prior to separation (78). Some of the key regulatory 
proteins responsible for the spindle assembly checkpoint include Mad2 and BubR1. 
Mad2 is found active at the sites of unattached kinetochore proteins (478). The 
kinetochore is a centromere protein complex that microtubules associate with for sister 
chromatid separation by the mitotic spindle. Mad2 and BubR1 actively signal to inhibit 
the activation of APC/cyclosome activity (107,154). These inhibitory proteins ensure that 
all chromosomes are attached to the mitotic spindle before activation of the anaphase 
promoting complex (APC/cyclosome complex). While the exact mechanism governing 
Mad2 and BubR1 activity are not yet fully discovered, active Mad2 is believed to bind 
and inhibit cdc20, a key co-activator of the APC/cyclosome complex (122,277). Another 
co-activator Cdh1, is believed to be responsible for progression through late anaphase 
and onto to the start of cytokinesis (389). Some of the key signaling proteins that feed 
into the spindle checkpoint include the polo-like kinases Plk1 and Plk2, and the aurora 
kinases (401,455). These signaling kinases are believed to be part of complex feedback or 
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feed forward signaling networks that contribute to the regulation of APC/cyclosome 
activity to ensure that all chromosomes are attached to the mitotic spindle before 
chromosome separation can occur, and is commonly referred to as the spindle assembly 
checkpoint (115,234,446,459,464). 
 The anaphase promoting complex is an ubiquitin ligase that is the key driver for 
the completion of mitosis. One of the main roles of the APC/cyclosome complex in 
mitosis is the destruction of cyclin B1 and inactivation of CDK1 (167). Destruction of 
cyclin B1 generally marks the end of metaphase and the beginning of cytokinesis (244). 
Inhibition of the APC/cyclosome complex by members of the polo-like kinase family 
facilitates the maintenance of high levels of active CDK1 complex for the period of time 
necessary for the correct attachment of chromosomes to the spindle (120,140). 
Inactivation of the spindle checkpoint occurs only when all chromosomes are oriented 
and attached in an appropriate fashion to kinetochores (485). Upon attachment of 
chromosomes, the inhibitory signaling by Mad2 at each respective kinetochore is 
silenced. Inactivation of Mad2 releases cdc20 from inhibition, and facilitates the 
activation of APC/cyclosome complex (107). The other major co-activator of the 
APC/cyclosome complex is the Cdh1 protein. Cdh1 is found to complex with 
APC/cyclosome and believed to aid in substrate specificity to APC mediated proteosomal 
degradation. Cdh1 is negatively regulated by CDK1 complex through phosphorylation 
(73,74). As already mentioned, multiple signaling pathways cooperate to ensure that APC 
is not activated pre-maturely. The combination of the spindle associated proteins such as 
Mad2 and BubR1 and the activity of CDK1 act in concert to inhibit activators of APC 
until the appropriate moment (244). 
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Inactivation of the spindle assembly checkpoint, releases the APC/C complex 
from inhibitory control leading to the rapid degradation of cyclin B1 and inactivation of 
CDK1. The APC/C complex has multiple binding partners even during mitosis. The 
interaction between APC/C and cdc20 in early mitosis is dependent on high CDK1 
activity (237,368). APC/C, cdc20 complex is activated by phosphorylation by Plk1 and 
CDK1, facilitating a positive feedback loop driving the destruction of cyclin B1 to initiate 
the rapid DNA segregation process during anaphase. Cdh1 is, however, prevented from 
associating with the APC/C complex by inhibitory phosphorylation by CDK1. This 
highlights the importance of delicate balance and control in the progression of mitosis. 
Cdh1 is unable to bind to APC/C until CDK1 activity is inhibited by the destruction of 
cyclin B1. This carefully choreographed sequence of events highlights the importance of 
signaling pathways in the control of APC/C activity (8,368,475). 
 Upon activation, APC/C with its co-activator cdc20 target cyclin B1 for 
proteosomal degradation (365). Degradation of cyclin B1, leads to inactivation of CDK1, 
and marks the transition of cells from metaphase to anaphase. Activated APC/C targets 
the protein securin, located on kinetochores for proteosomal degradation. Degradation of 
securin releases the protein separase from inhibition (124,292). Activated separase 
cleaves Scc1 (Sister chromatid cohesion 1), a member of the cohesin complex, which 
results in the loss of sister chromatid cohesion. This facilitates the separation of sister 
chromatids from each other, leading to two independent sets of chromosomes.  
Upon completion of chromosome separation, cells have moved beyond metaphase 
into anaphase and telophase, which is marked by the events of spindle elongation, spindle 
disassembly and cytokinesis (424). The APC/C
cdc20
 complex that has been the main 
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driver responsible for the events leading to separation of sister chromatids attached at the 
mitotic spindle, disassociates and APC/C forms a new complex with Cdh1. Cdh1 is 
inhibited from binding to APC/C by CDK1 activity prior to chromosome segregation 
(73). Destruction of cyclin B1 by the APC/C
cdc20
 complex leads to the inhibition of 
CDK1 activity, when coupled with the activity of the phosphatase cdc14, leads to the 
activation of the APC/C
Cdh1
 complex, the complex responsible for driving the signaling 
network responsible for mitotic exit (219). The APC/C
Cdh1
 complex drives the completion 
of mitosis through proteolytic degradation of key mitotic proteins. Following 
chromosome separation APC/C
Cdh1
 targets cdc20 and securin for degradation (134).  
Unlike cdc20, the Cdh1 complex with APC/C stays active through the subsequent G1 
phase and is only then inactivated at the beginning of S-phase to prevent re-activation of 
mitotic activities in G1. The APC/C
Cdh1
 complex is believed to be essential for the 
formation of pre-RCs during G1 phase and for the suppression of mitotic cyclins and 
kinases during G1 phase (19,161,370,445). The APC/C
Cdh1
 complex is one of the key 
components of the mitotic exit network, a network of signaling and associated motor 
proteins responsible for the division of a cell into two identical daughter cells.  
The key features of mitotic exit also include ordered dephosphorylation of CDK1 
substrates by mitotic phosphatases. Failure to dephosphorylate CDK1 substrates has led 
to prolonged and failed mitotic division (114,453). 
The microtubule motor proteins belonging to the kinesin and dynenin family of 
motor proteins are responsible for bipolar mitotic spindle formation, DNA segregation 
and cytokinesis (450). The Plk1 signaling pathway has been implicated as being a key 
signaling kinase in late mitosis, and is believed to be responsible for driving events 
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leading to cytokinesis (115,140,401,459). Recent knock-out studies have highlighted the 
importance of Plk1 in late mitosis. Loss of Plk1 often leads to arrest in early mitosis, 
however, impairment between interactions of Plk1 and the mitotic kinesin Pavarotti has 
been shown to lead to failed cytokinesis. Plk1 has also been shown to interact with Mklp2 
and NudC proteins, the two key motor proteins responsible for cytokinesis (240). 
As this thesis focuses on the role of p38 in DNA damage response, specifically at 
the G2 to M transition point, we will next review the signaling networks that comprise 
the cellular response to DNA damage, with a focus on the G2 checkpoint governing the 
entry into mitosis. 
 
1.7  Physiological Response to Stress 
Cells are faced with many different forms of stress throughout their life, making 
an appropriate response to different forms of stress critical for long term viability and 
survival. While cells may respond differently to various forms of stress, it is possible to 
generalize the response of cells to most common types of stress. Stresses ranging from 
mechanical, chemical or environmental damage cause physical damage to the cell and 
elicit strong activation of similar stress response pathways in a cell (22,288,458). Cellular 
response to changes in external environment such as immune system activation and the 
presence of inflammatory cytokines largely depend on similar signaling networks 
(60,63). This suggests a high degree of overlap between stress pathways responsible for 
sensing changes in the external environment and internal damage.  
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In the following sections we will briefly detail the role of p38 MAPK in response 
to inflammatory cytokine stimulation and its role in cytokine production. The focus will 
be on the pathways responsible for sensing internal damage to the cell.  
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1.7.1 Response to Inflammatory Cytokines  
One of the phenotypic effects mediated by TNF-  through p38 MAPK signaling 
is the production and secretion of inflammatory cytokines in numerous macrophage and 
lymphocyte cell lines (449).  
Studies have shown that TNF-  or LPS induced inflammatory cytokine 
production is mediated through a p38 MAPK mediated response. Mouse mutagenesis 
studies have identified MAPKAPK-2 as one of the principal p38 substrates that is 
responsible for the production and secretion of inflammatory cytokines (407). Mouse 
knockout studies have shown that mice lacking MAPKAPK-2 are resistant to LPS 
induced stress response and a decrease of ~90% TNF-  and IL6 production (210). The 
effects of MAPKAPK-2 are thought to be mediated via a mechanism involving cytokine 
mRNA turnover and its effect on protein translation (388).  
 
1.7.2  Effect of p38 MAPK on ARE binding proteins 
The p38 MAPK’s effect on cytokine production involves ARE binding proteins 
bound to AU-rich elements (ARE) in the 3’ untranslated region of an inducible cytokine 
like IL-1, TNF-  and IL-6. The AREs are known to target mRNAs for rapid 
deadenylation and degradation and may enhance decapping (45). The p38 MAPK 
pathway stabilizes many otherwise unstable ARE-containing mRNAs encoding proteins 
involved in inflammation(452). It is postulated that some ARE binding proteins facilitate 
the degradation and turnover of these cytokine mRNA. Whereas other ARE binding 
proteins are known to stabilize the mRNA through their association with the ARE. The 
activation of the p38 MAPK pathway facilitates the phosphorylation of these ARE 
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binding proteins and hence leads to cytokine mRNA stability either through 
disassociation or association.  
The effects of ARE binding proteins is unique to certain cytokines. TNF-  
mRNA instability for example is associated with the presence of heterogeneous nuclear 
ribonucleoproteins (hnRNPs) bound to their ARE regions(57). The activation of the p38 
MAPK pathway leads to MAPKAPK-2 dependent phosphorylation of these hnRNPs and 
their subsequent disassociation. The disassociation of the hnRNPs confers stability to the 
mRNA and allows their translation (25).  
The effects of ARE binding proteins on IL6 and IL1 secretion are opposite to 
what has been seen with TNF-  secretion. The binding of hnRNPs is seen to confer a 
degree of stability to the mRNAs that allow their subsequent translation. The p38 MAPK 
pathway through MAPKAPK-2 mediates the binding of these hnRNPs. The evidence for 
this was a 10-fold decrease in IL6 mRNA stability in MAPKAPK-2 deficient mice (448). 
There is evidence also, however, that MAPKAPK-2 is not the only kinase downstream of 
p38 that regulates post-transcriptional activity of inducible cytokine mRNA. MAPKAPK-
3 and MAPKAPK-5, two other downstream targets of p38, are also capable of 
phosphorylating hnRNPs in the absence of MAPKAPK-2(434).  
Bollig et al has identified 18 macrophage ARE binding proteins that are involved 
in cytokine mRNA instability (25). The phosphorylation of some of these ARE binding 
proteins is attributed to MAPKAPK-2, a direct kinase substrate of p38 MAPK. 
Kontoyiannis et al, showed that IL10’s inhibitory effect on TNF-  production was 
mediated principally through a p38/MAPKAPK-2 pathway, further confirming 
MAPKAPK-2 involvement in cytokine mRNA stability (208).  
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The p38 MAPK working through its downstream kinase substrates MAPKAPK-2, 
3&5 is a key mediator of inducible cytokine stability and expression. The mechanisms 
through which it controls TNF- , IL1, and IL6 mRNA expression is through the 
phosphorylation of ARE binding proteins (374). The activation of the p38 MAPK 
pathway also increases the transcription of inflammatory cytokine mRNA through its 
action with the AP-1 binding site and its activation of the ATF-2 transcription factor 
(454).  
 We intend to investigate p38 MAPK’s role in inflammation response as a 
secondary question in this thesis. We will explore p38’s role in inflammatory stress 
response to give a physiological context to p38’s putative role in DNA damage response. 
As p38 is a critical kinase in stress response, it is conceivable that p38 activation during 
DNA damage may be a general, protective stress response and may not necessarily be 
specific for the DNA damage response, per se. we will explore this topic in detail in 
chapter 4 of this thesis, where we analyze whole genome gene expression data to gain a 
mechanistic understanding of p38 in inflammatory stress response through perturbation 
of p38 activity with a selective kinase inhibitor. 
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1.7.3 The sensing of DNA Damage: Role of ATR and ATM 
 The key members of the DNA damage checkpoint pathways have been identified 
to be members of the PIKK (or phosphatidylinositol 3’ kinase like kinase) family of 
proteins. The most prominent members of this family are the ATM (Ataxia-
Telangiectasia Mutated) and ATR (Ataxia Telangiectasia mutated and Rad3 related) 
proteins (361). Traditionally it was convenient to divide the response to the different 
classes of DNA damage between these two key sensors that share sequence homology. 
Early studies attributed response to double strand chromosomal breakage primarily to 
ATM while response to single strand breaks and other DNA lesions was assigned to ATR 
(392). More recent studies, however, have shown that such a simplistic view of the DNA 
damage response pathway was inaccurate. ATR has also been found to play a key role in 
the activation of cell cycle checkpoint arrest and DNA repair and/or apoptosis induction 
signaling in response to DSB events. While ATM has also been shown to be active to 
damage that does not ordinarily cause DSB (2,443). This section of the review will detail 
some of the key components responsible for detection of DNA damage. 
ATM was identified as the gene mutated in the inherited cancer predisposition 
syndrome ataxia telangiectasia and is a key player in the response to double strand 
chromosomal breaks (DSB) (256). ATR was identified to be the sensor of a much wider 
variety of DNA damage including detection of DNA lesions induced by UV irradiation 
and stalled replication forks induced by chemical genotoxics such as hydroxyurea (HU) 
and topo-isomerase II inhibitors such as Adriamycin (Doxyrubicin HCL) (43,92,104). 
Both ATM and ATR have been found to localize to areas of DNA damage. This 
localization has been shown to be the result of other adaptor and co-binding proteins. The 
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initiation of ATM mediated signaling has been shown to require the protein RPA. 
Extensive studies by various groups have shown that the PIKK family of signaling 
proteins works in concert with these co-initiators in a multi-protein complex. It has also 
been shown that the loss of certain key members of these multi-protein complexes greatly 
inhibits the ability of cells to respond effectively to DNA damage, often leading to 
disease phenotypes such as tumorigenesis.  
 ATM is a key sensor of DSB in eukaryotic cells. Studies utilizing ionizing 
radiation (IR) have shown that cells exhibiting defects or mutations in ATM are 
hypersensitive to IR (270). IR causes primarily DNA double strand breaks, implicating 
ATM as one of the primary sensors of DNA DSB events. Extensive studies conducted in 
yeast and other simple multi-cellular organisms have identified numerous adaptor and co-
factor proteins necessary for full ATM function. The Mre11-NBS1-Rad50 (MNR) 
complex is essential for activation of ATM (99). Studies have shown that loss of 
components of the MNR complex lead to inefficient ATM activation including its 
inability to auto-phosphorylate itself. It is interesting to note that while Nbs1 is part of the 
MNR complex, which is required for ATM activation, Nbs1 itself has been found to be a 
target of ATM. Phosphorylation of Nbs1 by ATM is suggested to have an important role 
in efficient transduction of DNA damage signal to downstream effector molecules 
including Chk2, one of the primary substrates of ATM (178). 
In mammalian cells, the ATR protein is essential for cell viability even in the 
absence of exogenous DNA damage (444). This role in a normal cell cycle has been 
attributed to the tremendous rigors involved in replicating larger genomes found in 
mammalian cells. Such replication often requires an ATR dependent response to ssDNA 
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formed in almost every cell cycle (90). Conventional thought had originally associated 
ATR activation and function in response to lesions formed on DNA, as well as to stalled 
replication forks. DNA lesions could be grouped according to the chemical nature of the 
base modification. DNA lesions include dimers, mismatches, base modifications such as 
oxidation, methylation and depurination, bulk lesions, intra and inter-strand cross-linking 
such as that caused by UV damage (131,384). Responding to stalled replication forks 
such as caused by hydroxyurea (HU) was one of the primary roles first identified for the 
ATR protein. Early studies that showed that ATR was preferentially activated by stalled 
replication forks and that ATM was preferentially activated by DSB, led to the belief that 
these 2 key sensors of DNA damage had independent and separate roles in activating a 
cellular response to DNA damage (361). 
Recent studies in yeast and other model organisms, however have painted a 
slightly more complicated picture. Studies have shown that there is close inter-play 
between ATM and ATR for the detection of DSB events in genome. There is much 
evidence to indicate that the activation of an ATR dependent response to a chromosomal 
DSB is triggered by the recognition of ssDNA moieties (2,392). The formation of ssDNA 
is a common product, found at locations of base excision repair and stalled replication 
forks. DSBs are often processed by 5’ to 3’ exo-nucleases also resulting in the formation 
of ssDNA. This makes ssDNA a common and useful checkpoint initiation signal for the 
DNA damage checkpoint pathway. A key adaptor protein called RPA has been shown to 
be vital for ATR activation of downstream signaling components in the event of DNA 
damage. The recruitment of ATR to sites of double strand breakage in the genome is 
assisted by adaptor proteins, Ddc2 and the ATR interacting protein ATRIP (199).  
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In yeast, Mec1 (ATR) and Ddc2 form a complex in cells independent of DNA 
damage and genetic studies with Mec1  and Ddc2  cells show the same defects, namely 
the complete loss of checkpoint arrest and a failure to activate the downstream signaling 
components of the DNA damage pathway, such as Rad9, Rad53, Chk1 or Pds1 (Securin) 
(96,281,306). Studies on Mec1 have suggested that its kinase activity is not tightly 
regulated by DNA damage. However Ddc2’s role in checkpoint activation is thought to 
be the recruitment of Mec1 to damaged DNA. This suggests that Mec1 can only interact 
with its substrates while bound to damaged DNA, which may help prevent spurious 
checkpoint activation in undamaged cells (75).  
Through its role in processing ssDNA generated by exonucleases in the event of 
DSB, the ATR protein has been shown to be a key integrator of numerous exogeneous 
DNA damaging agents including UV, MMS and Adriamycin (383). While the end result 
of these different DNA damaging agents range from inter and intra strand fusions and 
thymidine dimers formed by UV damage to nucleotide base alkylation caused by MMS, 
the by product of most of these agents was the production of single strand DNA (ssDNA) 
and a stalled replication fork. The activated ATR complex phosphorylates a number of 
key downstream signaling substrates. These substrates include the Chk1 kinase, Brca1 
and the p53 tumor suppressor protein (331). Translation of these findings into the context 
of human cancer cells, could provide the next step in deeper understanding of the 
molecular pathways  
 Having identified the main players in the sensing of DNA damage, we now focus 
on identifying the main players in the transduction of the DNA damage signal to the 
downstream effectors of cell cycle checkpoint arrest.  
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1.7.4 Signal Transduction of DNA Damage Signal 
 After DNA damage is detected by upstream sensors such as the ATM/ATR 
complexes, a kinase signaling cascade then amplifies and relays the signal to checkpoint 
targets leading to cell-cycle arrest, DNA repair and/or apoptosis induction (259). The task 
of relaying and amplifying a damage signal is crucial in the ability of cells to maintain 
genomic stability. The tiered nature of the signal transduction pathways allows the 
damage signal to be rapidly transmitted, with built in feedback mechanism allowing 
authentic signals to be amplified while spurious signals are more likely to be damped out 
and ignored. A number of prominent signaling pathways have been identified as 
substrates to ATM/ATR signaling. These include the Chk1/Chk2 pathways which have 
been implicated as one of the primary signaling transduction pathways activated in 
response to DNA damage leading to cell cycle arrest, repair and apoptosis (308). Besides 
the Chk1/2 pathways, other key players identified in response to DNA damage are the 
Brca1 SMC1 and p53 pathways (429,470). Both Brca1 and p53 play prominent roles in 
maintenance of cellular genomic integrity and are classified as tumor-suppressors. While 
most of the work in the past has been focused on understanding this handful of signal 
transduction and integrators of DNA damage signals, recently a new crop of possible 
players in DNA damage response have also been identified. A study by Mu et al, using 
advanced proteomics techniques has recently identified up to 20 new phospho-protein 
substrates of ATR signaling (285). Additional studies have also started focusing on the 
MAPKs, specifically the p38 MAPK as another possible key signaling pathway that plays 
a role in the transduction of DNA damage signal. This review will briefly cover the 
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current state of knowledge on these signaling pathways and how activation of these 
pathways leads to effective cell cycle checkpoint arrest. 
 
1.7.5 Chk1 and Chk2 are substrates of ATM/ATR signaling  
Some of the signal transduction pathways responsible for transmitting the DNA 
damage response signals are highly conserved evolutionarily from yeast to humans. 
Much of the early work in unraveling the complex signaling networks involved in DNA 
damage response was conducted in budding yeast Saccharomyces cerevisiae or fission 
yeast, Schizzoscharomyces pombe and with Xenopus egg extracts (258,411). The primary 
signaling cascade following activation of Mec1 (ATM/ATR checkpoints) in yeast is the 
Chk2 family of kinases Rad53 whose activation also requires the adaptor protein Rad9 
(96,343). Studies in yeast have shown that without Mec1, Rad53 is not functional. Hence 
activation of the PIKK (ATM) mediated phosphorylation of Rad53 serve several 
functions, namely the activation of the Rad53 (Chk2) kinase activity, the promotion of 
oligomerization, trans-autophosphorylation and the creation of an interface for the 
Rad53-Dun1 interaction (314,390). Activated Rad53 also interacts with numerous 
nuclear import factors. Nuclear import and localization has been identified as a necessary 
part of Rad53 activation and the transduction of DNA damage signaling (314).  
 Similar to Rad53, activation of Chk1 also requires Rad9 for its activation and 
function (144). Structural analysis of the Rad9 protein shows that the activation region of 
the Rad9 protein for Rad53 is different from Chk1 (391). Chk1 does not have an FHA 
domain like Rad53 and it can be activated by an allele of Rad9 without the SQ/TQ cluster 
required for Rad53 activation. Conversely, an N-terminal truncated mutant of Rad9 is 
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unable to activate Chk1 but is able to activate Rad53 in response to a single DSB in S. 
Cerevisiae. Structural modification studies on Chk1 have suggested that similar to Rad53, 
Chk1 requires oligomerization and probably autophosphorylation for full activity (218). 
The Chk1 kinase is one of the primary substrates of ATR following DNA damage 
response. Understanding the role of Chk1 activation in DNA damage response has helped 
advance the understanding behind the underlying mechanism of cell cycle checkpoint 
arrest following DNA damage (131).  
 
1.7.6 Other known targets of ATM/ATR signaling 
 The Chk1 and Chk2 (Rad53) pathways are the best characterized members of the 
canonical DNA damage response pathway. Recently, additional signaling proteins have 
been implicated as key players in the transmission of DNA damage response. Protein 
targets such as BRCA1, SMC1 and p53 have been implicated as targets of ATM/ATR 
signaling and are known to play a crucial role in checkpoint arrest and DNA repair (86). 
The role of p53 has been well studied for its role in G1-S DNA damage checkpoint 
control. Briefly, p53 is stabilized by phosphorylation which allows it to separate from its 
negative inhibitor MDM2. Stabilization of p53 activates the p53 damage response 
transcriptional pathways, leading ultimately to the activation of the Rb protein 
(42,61,216). This section will not focus on these specific mediators of p53 dependent 
DNA damage response, but will instead point readers to other recent excellent reviews on 
this topic (430,486). 
Recently a lot of interest has focused on the possibility of members of the MAPK 
family of proteins especially p38 MAPK and its downstream substrates in playing a 
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major role in initiation and maintenance of cell cycle checkpoint response to DNA 
damage (35,48,313). The p38 MAPK plays a significant role in response to endotoxins, 
and in inflammatory response. The p38 MAPK has also been implicated in active 
immune response and antigen presentation to T-lymphocytes. Beyond its well established 
role in inflammatory response, a new role for p38 has been suggested in DNA damage 
response. A more detailed review of p38 and its possible roles in DNA damage 
checkpoint control is included as a separate section below.  
 
1.8 Effectors of Cell Cycle Arrest 
 Having introduced the key signal transduction pathways activated in response to 
stress and DNA damage, we now will discuss some of the common physiological 
consequences resulting from the activation of DNA damage response pathways. 
The DNA damage response (DDR) signal transduction pathways transmit and 
amplify the initial signal from the sensors of DNA damage to the end effector proteins or 
pathways that initiate and maintain the checkpoint arrest. In eukaryotic cells there are 3 
major checkpoints during interphase and they are termed the G1-S, intra-S and G2-M 
checkpoints (4,308,382). Each of these specific checkpoints has a specific set of effector 
molecules responsible for their activities which will be reviewed briefly in the following 
sections. In addition, as the focus of this thesis is centered on the role of p38 MAPK, a 
separate section will focus on examining the literature evidence for its role in G2 cell 
cycle checkpoint arrest. 
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1.8.1 The G1/S Restriction Point 
 Entry into S-phase from G1 is critical to cells, marking a point of no return to a 
new round of cell cycle (377). Thus, not surpringly mammalian cells have developed 
elaborate regulatory mechanisms governing G1/S transition. While cyclin D1/CDK4/6 
complexes are key activators of the G1/S transition, there are two equally important 
counter-balances to the CDK family of proteins, namely the CDK inhibitors (363). The 







) family of proteins (24). Both p21 and p16 inhibit CDK4/6 
activity to keep Rb in a hypo-phosphorylated form, in response to DNA damage (213). 
The p14
ARF
 protein product of the CDKN2A locus does not interact with the cyclin 
D/CDK4/6 complex but instead has been found to interact with MDM2, leading to p53 
activation (146,246). These two key proteins as well as PI3KCA (PTEN), guard against 
damage to the genome and help to maintain genomic integrity (33,139,307,371,377). As 
this family of CDK inhibitors is critical to the healthy maintenance of the genome, it is no 
surprise that the gene locus for CDKN1A, CDKN2A and PI3KCA are some of the most 
frequently mutated and copy loss areas of the human genome (189). A majority of human 
tumors studied were found to have a loss or mutation of either one or all of these gene 
loci, rendering the G1/S restriction point deficient. 
A second key tumor suppressor that governs the G1/S transition along with Rb 
pathway is the p53 tumor suppressor protein, a protein most often implicated in 
tumorigensis and the response to DNA damage (232,327). The goal of this thesis and 
review is not to exhaustively review the role and function of the p53 protein in the cell 
cycle. Instead we will point readers to a number of in-depth reviews on p53 
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(34,202,289,373). Here we will highlight some of the functions of p53 in relation to DNA 
damage and cell cycle control relevant to my research.  
The p53 protein is a tightly regulated protein that requires a series of 
phosphorylation events in order to be activated. In its inactive state, p53 is found tightly 
bound to the MDM2 protein, which suppresses its transcriptional activity (53,155). The 
p53 protein has been implicated as a principal mediator of stress response to a host of 
environmental and other damages to DNA. The p53 response, functions through the 
trans-activation of a number of key downstream genes as a transcription factor 
(351,380,432). Some of the best understood response genes to p53 activation include the 
p21
CIP/Waf1
, a protein responsible for the activation of G1/S as well as G2 checkpoint 
arrest (150,206,344). Other genes that are direct targets of p53 regulation in response to 
DNA damage are the GADD45 protein, a growth arrest & DNA damage inducible gene, 
and the primary negative regulator of p53 function, MDM2 itself (180,360). The central 
nature of p53 in DNA damage checkpoint response has resulted in it being one of the 
most highly mutated genes found in cancers (193,372). Some studies have shown that 
functional inactivation of p53 is found in more than half of all human tumors. Such a 
high propensity of functional inactivating mutations highlights the importance of p53 as a 
critical protein in the maintenance of genomic stability  (42,216,279,321,355). 
There are a number of reports to suggest that p38 may play an active role in the 
regulation of the G1/S transition in response to DNA damage. The current opinion of the 
field is that p38 may act to modulate the G1/S checkpoint through interaction and 
regulation of p53 activity (201,269,410).  Inhibition of p38 has been shown to affect the 
levels of p21 mediated regulation of Rb, contributing to the failure of checkpoint control 
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in response to DNA damage. More published papers show that p38 may play a role at the 
G1/S transition point (69,81,282,283,410). While we are mindful of the important role of 
p38 at the G1/S restriction point, the point of this thesis was not to study p38 at the G1/S 
restriction point. 
 
1.8.2 The Intra-S Checkpoint 
 In response to single or double strand breaks during S-phase, the intra-S 
checkpoint activates to halt cell cycle progression during DNA replication. The cyclin 
A/CDK2 complex is a critical for S-phase progression (273). It is shown that CDK2 
inhibition leads to a significant halt in cell cycle progression (215). In response to 
environmental, chemical or physical damage, the ATM/ATR pathway activates a number 
of checkpoint signaling proteins that lead to the inhibition of the cyclin E or A/CDK2 
complex (162,482). These signaling pathways include the well studied Chk1 and Chk2 as 
well as activation of p53 via ser15 and ser33 phosphorylation. Activation of the Chk1, 
Chk2 pathway regulates CDK2 activity through phosphorylation of the CDC25 
phosphatase protein family (121). The CDC25 phosphatases are key regulatory proteins 
that remove inhibitory phosphorylation on key checkpoint proteins such as Rb and 
CDK1. The negative regulation of the CDC25 family of phosphatases during S phase 
inhibits CDK2 activity through inhibition of cyclin E/A binding and complex disruption 
(18,334,350). Besides the Chk1 & Chk2 signaling pathways, activation of the p53 tumor 
suppressor pathway is another key factor during intra-S phase arrest. Increased p21
waf1
 
activity has been linked to decreased CDC25A levels (187). Increased levels of p53 
activity have also been implicated in decreased cyclin A/CDK2 complex activity. The 
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mechanism of p53 mediated cyclin A/CDK2 inhibition is still under investigation, the 
complexity of the feedback mechanisms governing p53 activity during G1 & S phase 
leads to difficulty in fine determination of cause and effect of activation of this pathway 
(7,344). In response to UV damage during the G1/S phase, increased p53 activity is 
associated with cell cycle arrest in S-phase. Increased levels of ATM/ATR signaling in 
response to DNA damage leads to strong checkpoint activation. From canonical pathway 
activation, this implies a top down activator/effector relationship between signaling 
kinases and cell cycle effectors like CDK2. However, studies to establish the importance 
of CDK2 in G1/S transition have shown that p53 and ATM/ATR pathways are activated 
in response to direct CDK2 inhibition in the absence of external stress (482). This study 
highlights the importance of understanding the cause and effect relationship of complex 
signaling pathways in checkpoint activation. Additional in-depth review of the activation 
mechanism of ATM/ATR and the p53 pathway are covered in the section on DNA 
damage checkpoint activation. The activation mechanism of p53 in G1/S phase is an area 
of complex work, which has made it an ideal target for complex mathematical modeling.  
 Similar to a putative role of p38 at G1/S transition, p38 has also been implicated 
in the regulation of the intra-S checkpoint. As p38 has been reported to have the ability to 
phosphorylate and stabilize p53 activity, p38 can be considered to have a putative role in 
the activation of the intra-S checkpoint. The activity of p38 has been shown to increase in 
conjunction with stalled replication forks. This increase in activity in correlation with 
intra-S checkpoint activation is consistent with a role for p38 at the intra-S checkpoint 
(182,279,480). 
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1.8.3 The G2-M Checkpoint  
The G2 checkpoint is the final checkpoint during interphase, and regulates the 
entry into mitosis. It is imperative that cells halt the cell-cycle and not enter mitosis with 
DNA damage. Mitotic spindle separation with damaged DNA often results in 
catastrophe, resulting in imbalanced chromosomal segregation and the perpetuation of 
genomic DNA errors (194). The key players in the G2 to M transition are the cyclin 
dependent kinase CDK1 and its regulatory subunit cyclin-B. For CDK1/Cyclin-B 
complex to be active, an inhibitory phosphorylation on tyrosine 15 must be removed by 
the CDC25 class of dual-specificity phosphatases from CDK1 (Cdc2) (241). In 
mammalian cells, there are 3 isoforms of CDC25, CDC25A,B & C (28). The 3 isoforms 
of this family of phosphatases have been shown to have both over-lapping and 
independent functions in the control of cell cycle progression. The main CDC25 
phosphatase isoforms that regulate entry into mitosis are the CDC25B and C isoforms 
with CDC25A primarily involved in the regulation of CDK2/CyclinE, governing the G1-
S transition (241,350).  The canonical representation of a G2 checkpoint arrest caused by 
DNA damage is activation of ATM/ATR checkpoint as depicted in figure 1.5 below.  
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Figure 1.5: Canonical representation of Chk1 & Chk2 activation in response to 
DNA damage leading to deactivation of CDK1/CyclinB1 complex leading to G2 
checkpoint arrest 
In response to DNA damage, both Chk1 and Chk2 phosphorylate CDC25B and C 
on multiple residues on their non-catalytic N-terminal domain (190). This 
phosphorylation at the N-terminal on CDC25 provides a binding site for 14-3-3 proteins, 
sequesters the CDC25 phosphatase away from the nucleus and leads to eventual 
ubiquitination. In human cells Chk1 and Chk2 phosphorylate CDC25C at Ser216, leading 
to cytoplasmic localization and blocking the interaction with CDK1 (17,241,397). This 
sequestration of CDC25C prevents the removal of the inhibitory phosphorylation by 
Wee1 and Myt1 on CDK1, leading to a G2-M checkpoint arrest. The active 
CDK1/CyclinB1 complex is responsible for numerous vital events during mitosis such as 
nuclear envelope breakdown, centrosome separation, spindle assembly, chromosome 
condensation and golgi fragmentation (245,304,318,366,412). Hence the 
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dephosphorylation event of CDK1 by CDC25B/C is a critical event prior to entry into 
mitosis. The other protein strongly linked to CDC25 and CDK1 activity at the G2-M 
transition is the Polo-like kinase 1 (PLK1).  
Plk1 is found localized to the centrosomes during G2/M phase of the cell cycle, 
and is activated in concert with CDK1/CyclinB1 during transition from G2 to mitosis 
(455). This tight correlation has led to conclusions that Plk1 is linked with the 
CDK1/CyclinB1 complex in driving cells into mitosis. Studies with Topo-II inhibitors 
have shown that an ATR dependent inhibition of Plk1 kinase activity leads to G2 
checkpoint arrest. Furthermore, Plk1 kinase activity has been shown to decrease with 
ATR and Chk1 dependent activation following DNA damage. These observations serve 
to associate Plk1 kinase activity with the CDK1/CyclinB1 complex as a cooperative 
complex whose activation leads to cells entering mitosis (102,455).  
 
1.8.5 Role of p53 in G2-M Transition  
 The p53 tumor suppressor protein plays a pivotal role in DNA damage checkpoint 
response, especially at the G1/S transition checkpoint. The role of p53 at the G2 to M 
transition point however has not been well studied. There is growing evidence that p53 
may play a significant role in the control of G2 to M transition. Studies have shown that 
ATR and Chk1 can both stabilize and activate p53 through phosphorylation of its N-
terminal domain. Activated p53 induces transcription of p21, Wee1 and Myt1, all direct 
or indirect inhibitors of CDK1. The activation of p53 also leads to decreased transcription 
of CDC25C, the phosphatase required for activation of the CDK1/CyclinB1 complex. 
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Taken together, activation of p53 transcriptional pathways lead directly to the inhibition 
of CDK1, leading to the activation of the G2-M checkpoint arrest (14,312,344).  
In various publication, in-vitro kinase and phenotypic assays were employed to 
highlight that p38 could interact with p53 and phosphorylate it on a number of serine 
sites. These serine sites include ser15, ser33, ser44 and ser389. As phosphorylation at 
these sites are known to induce p53 protein stability and loss of inhibitory binding of p53 
to MDM2, these studies suggest that p38 is an important upstream kinase capable of 
activating p53 in response to DNA damage (37,51,56,313).   
 
1.8.4 Role of p38 in G2-M Transition 
 The p38 MAPK is one of the key responders to environmental stress, its role in 
inflammatory response and response to bacterial invasion have already been discussed in 
this review. Seeing how p38 plays a critical role in general stress response, there has been 
increasing interest in understanding if p38 may also play a role in response to DNA 
damage and perhaps play an important role in cell cycle control (3,27,230). 
 A number of key publications in the last 8 year implicate p38 as a key component 
of various DNA damage checkpoints. Initial reports began to implicate p38 in response to 
environmental damage including UV damage and ionizing radiation 
(38,163,320,364,396). The initial basis of this, was due to the fact that p38 activity could 
be induced rapidly in response to environmental and chemical damage to mammalian 
cells. Further to the rapid activation, strong chemical inhibition of p38 has resulted in 
significant biochemical and phenotypic changes. Taken together, these observations 
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strongly implicated p38 as a key responder to environmental and chemical induced DNA 
damage.  
 
Figure 1.6: Putative new role for p38 at G2 checkpoint, acting through direct 
regulation of CDC25B phosphatases 
 
 The two major pathways that are implicated as being impinged by p38 signaling 
are the p53 tumor suppressor pathway at the G1/S restriction point and the CDC25 
phosphatases at G2 checkpoint. Both p53 and members of CDC25 family of protein 
phosphatases are believed to be regulated through direct interaction with p38 or indirect 
phosphorylation through its direct downstream substrate MK2 (38,163,191,356,483). At 
the G2 to M transition checkpoint, a complex network of positive and negative regulators 
of CDK1 controls the entry into mitosis. Recent work by numerous authors has suggested 
that the CDC25B and CDC25C isoforms are phosphorylated and activated by p38 or its 
downstream kinase MK2. Activation of CDC25 family of phosphatases facilitates the 
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release of inhibitory phosphorylation of CDK1 at tyr14 and tyr15. As mentioned in a 
previous section, the loss of phosphorylation at these two sites enables CDK1 to bind to 
cyclinB1 to form the active cyclinB/CDK1 complex. The line of evidence linking p38 to 
the CDC25 family of phosphatases consists of both biochemical and structural data. 
Immunoprecipitation pull-down of p38 on DNA damage treated samples were found to 
be positive for CDC25B (230,254). Furthermore, chemical inhibition of p38 with high 
concentrations of SB203580 (10 M and above) have shown phenotypic effects including 
increased ph-Histone H3 levels, suggesting that under those conditions, unsynchronized 
cells enter mitosis with the inhibition of p38 (36,51,220,254,313). It has also been 
reported that p38 is activated in unperturbed entry into mitosis (48).  
While the volume of articles implicating p38 in G2 DNA damage checkpoint 
control is growing, there are still aspects of p38’s role at G2 cell cycle checkpoint that 
warrant a more in-depth analysis. A recent publication by Mikhailov et al (267), has 
reported that the p38 MAPK pathway has no function at the G2 cell cycle checkpoint in 
transformed cancer cells. This publication and other aspects of the prior body of literature 
warrant a revisit of p38’s role in the establishment and control of the G2 cell cycle 
checkpoint in response to DNA damage. This thesis will focus on exploring p38’s role in 
response to DNA damage at G2 in a cell-cycle centric manner, employing a combination 
of chemical biology and standard molecular biology techniques.  
1.85 Transgenic Mouse Models of p38 
In addition to traditional in-vitro human and mouse model systems, there have been a 
number of studies that have utilized transgenic p38 knock-in or conditional knock-out 
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systems to study in-vivo the role of p38 in G2 checkpoint arrest and in general stress 
response (168). 
Studies by Bulavin et al in transgenic mouse models have shown a role for p38 MAPK 
pathway activity in the regulation of G2 checkpoint in response to a number of stresses 
including DNA damage (80). 
1.9 The Induction of Apoptosis in response to DNA damage 
 The cellular response to DNA damage consists of at least three distinct responses, 
the first response is to halt the cell cycle to prevent the perpetuation of any damage to the 
DNA. Concurrent to the halt of the cell cycle, the DNA damage repair pathway assesses 
the damage to the genome and attempts to repair the damage.  DNA damage repair 
consists principally of two major mechanisms, the first being nucleotide excision repair 
or base excision repair. The second major mechanism of DNA damage repair consists of 
non-homologous end re-joining. As the molecular mechanism of DNA damage repair is 
not the focus of this thesis, we will not be reviewing the underlying signaling pathways 
leading to DNA damage repair. Instead we point readers to a number of recent reviews 
that describe in detail the pathways and components responsible for the repair of DNA 
damage.  
 
1.9.1 The Canonical Apoptosis Pathway  
 If damage to the cell is too severe, the 3
rd
 major response to DNA damage is 
triggered. If the damage to the cell is too severe to be repaired or tolerated, the cellular 
mechanism for programmed cell death is triggered. It is commonly believed that this 
cellular self-destruct mechanism is a physiologically necessary response in order to 
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preserve the overall integrity of a multi-cellular organism. Apoptosis or programmed cell 
death is an elaborate biological mechanism that helps maintain cellular homoeostasis in 
mammalian organisms (158). It is a biological process that functions to ensure correct 
developmental and growth in embryonic and early development. It is also used by the 
immune system to maintain cellular systems in an orderly fashion, by targeting cells with 
abnormal phenotypes for cell death. Escape from apoptosis is considered a hallmark of 
cancer by Weinberg et al, cancer cells develop mechanisms to escape extrinsic induction 
of cell death by the immune system (138). 
 The programmed cell death or apoptosis pathway has two canonical pathways of 
activation. There is the extrinsic apoptosis pathway that relays signals from cell surface 
receptors such as Fas-receptor to the intracellular caspase protein network, which is 
responsible for execution of the apoptosis signal (94). The extrinsic apoptosis pathway 
relies on the activation of a number of cell surface receptors, including the TNF-receptor 
superfamily, and the Fas/death domain receptor family of receptors. These cell surface 
receptors trigger the canonical extrinsic apoptosis pathway. The extrinsic apoptosis 
pathway is often used by the immune system in mammalian organisms to stimulate 
unhealthy cells to die through programmed cell death (158). 
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Figure 1.7: Canonical Apoptosis Pathway: Activation of apoptosis from both 
extrinsic and intrinsic apoptosis pathways 
 The central molecular players in the induction of cell death are the caspase 
proteins. The caspase proteins are divided into two functional classes, the initiator 
caspases and the executioner caspases. The caspase family of proteins is a number of 
closely conserved cysteine peptidases, many of which share a common CARD or caspase 
caspase recruitment domain motif (118). Caspases in normal unperturbed cells are found 
in an inactive pro-form. All caspases undergo proteolytic cleavage for activation. For the 
extrinsic apoptosis pathway, the initiator caspases, casp8 and casp10 are recruited to the 
intracellular domain of the death receptors such as Fas-Receptor. This forms the death 
inducing signaling complex (DISC) which comprises FADD and other adaptor molecules 
that lead to the sequential catalytic activation of casp8 and casp10. Initiation of casp8 or 
casp10 leads to the activation of the down-stream intracellular caspase pathway, which 
ultimately leads to the catalytic activation of the executioner caspases, casp3, casp6 and 
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casp7. One of the immediate downstream substrates of activated casp3 or casp7 is parp, a 
pro-survival protein. Catalytic cleavage by casp3 or casp7 leads to the deactivation of 
parp’s pro-survival function and ultimately leads to cell death. Parp-cleavage is a 
commonly used biochemical marker of apoptosis induction and is often referred to in this 
thesis as we study p38’s potential role in the regulation of apoptosis induction 
(118,367,430). 
 The second major activation pathway for apoptosis is commonly referred to as the 
intrinsic or mitochondria apoptosis pathway and does not normally rely on external 
signals for initiation of apoptosis. The main cellular organelle responsible for intrinsic 
apoptosis signaling is the mitochondria. Central to the activation of mitochondria 
dependent apoptosis is the permeabilization of the mitochondrial membrane that allows 
the escape of several pro-apoptosis factors including cytochrome c. Cytochrome C is the 
critical trigger factor for the conformational activation of apoptosis inducing factor 
(APAF-1). APAF-1 subsequently binds to and oligomerizes pro-caspase9, which 
undergoes proteolytic cleavage to activate. The formation of a cytochrome c, APAF-1 
and cleaved-caspase9 complex results in the formation of the mitochondrial apoptosis 
initiation complex known as the apoptosome (169). 
 The mitochondrial sensitivity to apoptosis is regulated closely by the BCL2 (B-
Cell leukemia/lymphoma 2) family of pro and anti-apoptotic proteins. These proteins 
share common protein homology, in conserved BCL2 homology (BH) domains. The anti-
apoptotic members of the BCL2 family include the BCL2 and the BCL-XL proteins. 
These two proteins show high degree of conservation across all 4 BH domains. The pro-
apoptotic members of the BCL2 family include the Bax protein (BCL2 associated X-
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protein) and the Bak protein (BCL2 antagonistic killer). These proteins show 
conservation in the BH1 to BH3 domains. The anti-apoptotic members of the BCL2 
family act to restrain the pro-apoptotic members through direct inhibitory binding. Bax 
and Bak must disassociate from the inhibitory binding of BCL2 prior to their activation 
and subsequent permeabilization of the mitochondrial membrane. Subsequent 
permeabilization of the mitochondrial membrane facilitates the assembly of the 
apoptosome, culminating in the activation of the executioner caspases, caspase3 and 
caspase7 (177,317). 
 Caspases are regulated through a negative feedback mechanism through direct 
inhibitory proteins known as inhibitors of apoptosis proteins or IAPs. These IAPs 
represent an integral checkpoint in the activation of programmed cell death. IAPs 
regulate the execution of the apoptosis signal through direct binding and suppression of 
active caspase activity. IAPs hence have the ability to halt an active apoptosis pathway, 
and the signaling pathways leading to the deactivation of IAP regulation is an area of 
intense study. IAP pathways are exploited by cancer cells to mitigate the effect of 
apoptosis signaling. Over-expression and significant copy number gains of IAPs such as 
Survivin and XIAP have been reported in a large number of solid tumors. Abnormal 
inhibition of pro-apoptotic BCL2 members has also been attributed to selective pressure 
associated with tumor formation (15,381). 
 The importance of p53 in the proper functioning of mitochondrial apoptosis has 
been revealed through numerous knock-out and tumorigenic model studies (50,173). The 
p53 protein is considered one of the essential mediators of DNA damage induced 
apoptosis induction. The p53 protein functions primarily as a transcription activator, upon 
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separation from its primary inhibitory protein MDM2, p53 acts to transactivate the 
transcription of numerous pro-apoptotic protein transcripts. The central role of p53 as a 
tumor suppressor has resulted in the tumor selection pressure to inactivate p53 by a 
combination of genetic (truncating nonsense) mutations, copy number deletion and over 
expression of its direct regulator MDM2 (HDM2 in human cells). As a result, p53 is 
genetically inactivated in over 50% of tumors and is often functionally inactivated 
through over-expression of its negative regulators in the remainder of tumors.  
 
1.9.2 The role of p38 in Regulation of Apoptosis 
The role of p38 MAPK in the regulation of apoptosis induction has been an area 
of interest for many years. The p38 MAPK signaling pathway is one of the principal 
responders to external stress inducing elements including TNF-α and LPS. The 
connection between activation of p38 and inflammatory pathway signaling, led to the 
studies implicating p38 as a key responder to TNF-α and Fas-L induced cell death 
signaling (126,128,238,295,300). 
The Mammalian immune system acts as a surveillance mechanism against 
abnormal growth phenotypes, and the principal means to deal with cells exhibiting such 
properties is the activation of the extrinsic apoptosis pathway via the death receptor 
signaling pathway. The primary ligands used for this purpose include TNF-α and Fas-L. 
The key signaling pathways instigated by TNF-α treatment include the NF B pathway 
and the 3 major MAPK pathways including p38. Studies involving p38 gene knock-out 
and siRNA gene knock-down have revealed that in these physiological conditions, p38 is 
essential for the effective activation of caspase3 and apoptosis (26,126,435). 
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Furthermore, p38’s role in activation of AP1 family of transcription factors leads to a 
positive feedback loop between p38 activity and increased TNF-α production. In this 
sense, p38 is a central positive activator and amplifier of TNF-α induced death signaling. 
Studies have also found an association between TNFα and Fas-L induced apoptosis and 
p38 mediated modulation of BCL2 anti-apoptotic proteins. In response to TNFα 
stimulation, studies have shown that inhibition of p38 leads to a decrease in BCL-xl 
protein levels and increased expression of Bax protein (185,195,293). These studies 
suggest that p38 activity is directly connected to extrinsic apoptosis pathway stimulation 
due to suppression of anti-apoptotic factors and increased expression of pro-apoptotic 
factors. As death receptor mediated apoptosis is tightly connected to the immune system 
and to the production of inflammatory cytokine production, p38 MAPK’s association 
with these phenomena is in-line with p38’s role in inflammation response. 
Numerous studies have also reported that p38 plays an active role in the induction 
of apoptosis in mitochondrial dependent apoptosis. Studies have shown that p38 either 
directly or indirectly is able phosphorylate p53 on a number of key serine residues 
including ser33 and ser46. Phosphorylation on these residues is associated with 
stabilization and activation of p53 in response to stress and cell damage. Through its 
regulation of p53 activity, p38 is implicated as an activating kinase of mitochondrial 
dependent apoptosis in response to hypoxia, nitric oxide and DNA damage 
(31,62,179,198,469). Many of these studies have focused on p38 activity being necessary 
in a p53 wild-type environment, where p38 activates a p53 dependent apoptosis pathway 
(31,62,77,226,435). In addition to its role in regulation of p53 dependent apoptosis, 
studies have highlighted p38’s interaction with the BCL2 family of pro and anti-apoptotic 
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proteins to induce apoptosis in conjunction with hypoxia, UV and other environmental 
stresses (111,123,293,375,413). These studies implicate p38 in apoptosis induction 
through a p53 independent, but BCL2 dependent mechanism. These studies suggest that 
in line with p38’s role as a central responder to external shocks and stress, p38 activity is 
tied directly to apoptosis induction in both normal and transformed cells. The majority of 
the evidence for p38’s role in positive induction of apoptosis has been derived from 
normal or untransformed cells, where the activation of death domain receptors is a 
primary mechanism for p38 induced cell death. Studies in tumor cells have focused on 
the loss of sensitivity of cells to death inducing stimuli such as FasL upon inhibition of 
p38.  
The role of p38 in regulation of apoptosis does not stop as a simple mediator of 
death domain receptor induced apoptosis. While high activity of p38 in response to 
extrinsic apoptotic signaling via the death receptors is associated with significantly 
increased cell death, there are an increasing number of studies that have implicated p38 
activity as cytoprotective, especially in tumor cells (44,93,136,235,239,278,328,405). 
Numerous studies have found that in certain cellular contexts, inhibition of p38 
significantly increases apoptotic potential in tumor cells. This suggests that loss of p38 
activity drives cells towards an apoptotic phenotype. It has been suggested that the 
transactivation potential of p38 in response to inflammatory cytokine induction has been 
co-opted by tumor cells to promote increased cell survival and to perpetuate an inflamed 
micro-environment, suitable for increased angiogenesis and tumor development (414). It 
is in this context that many p38 inhibitors have been developed with the hopes of 
reversing angiogeneic factors sustaining a tumor. A second context that many researchers 
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have found inhibition of p38 as a potential useful therapeutic strategy is in combination 
with genotoxic agents. In numerous cancer cell models, researchers have found that 
inhibition of p38 with SB203580, synergizes well with numerous chemotherapeutic 
agents. These observations lead to the conclusion that in certain physiological contexts in 
tumors, p38 activity does not behave as a pro-apoptotic factor but as a pro-survival factor. 
The studies that suggest p38 acts as in a cyto-protective role, were often performed in 
conjunction with DNA damaging alkylating, methylating agents or microtubule/spindle 
poisons (248,323,474). It is possible that these genotoxic agents do not impinge on the 
death domain receptor signaling pathway and instead evoke a cellular survival response 
where p38 switches from a death promoting kinase to a survival promoting kinase. Some 
evidence that p38 may impact pro-survival pathways include its ability to phosphorylate 
and activate ph-CREB (79,420). CREB signaling is often implicated in pro-survival 
settings, and there have been numerous reports of tumors using CREB related pro-
survival pathways to escape genotoxic agents such as temozolomide in glioblastoma. 
(315) 
This conflicting evidence of p38’s role in the regulation of apoptosis may at first 
seem contradictory. There are however many examples of proteins having dual and at 
times opposing functions in biology (e.g. TGF  and NF B), where the cellular and 
physiological context of a protein’s activity may need to be considered when determining 
its function. 
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1.10 Aims of this Study 
The primary aim of this study is to investigate the role of p38 MAPK in DNA 
damage response. Specifically we aim to understand if p38 activity is required for the 
establishment and maintenance of a G2 cell cycle checkpoint arrest in response to DNA 
damage in cancer cells.  
In addition to DNA damage induced G2 checkpoint regulation, we will also 
explore if p38 activity plays a role in other physiological processes in response to DNA 
damage in cancer cells. Lastly we seek to understand if there are mechanistic similarities 
between p38’s role in DNA damage response and its principal role in inflammatory stress 
response.  
 To answer these questions, we will employ a cell-cycle centric approach using a 
specific p38 inhibitor (LY479754) as well as RNAi technology (siRNAs & shRNAs) to 
specifically test the effect of p38 pathway inhibition on the ability of cancer cells to 
respond to DNA damage and TNF-α inflammatory stress.  
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1  Laboratory Chemicals and Biochemicals  
 
Table 2.1: Table of Laboratory chemicals and biochemicals 
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2.1.2  Kits and commercially available buffers and systems 
we used the following commercially available products for assays run during this 
study. We used the Invitrogen
TM
 X-Lock mini-gel system as the primary western blotting 
module. We used the Novex pre-cast gel system as the primary gel system for protein 
electrophoresis.  
 
Table 2.2: List of Commercial assay kits, buffers and systems 
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2.1.3  Primary Antibodies 
 
Table 2.3: Table of primary antibodies 
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 The primary antibodies listed in table 2.4 were used in all primary protein 
analytical assays including western blotting, acumen high content imaging, FACS (flow 
cytometry analysis) and immuno-fluorescence and confocal imaging. 
Antibody Dilution: 
 All antibodies were diluted to manufacturers recommended levels for specific 
application 
 All CST antibodies for western blotting were diluted at 1:1000 
 Antibodies were diluted to 1:500 for Acumen High Content Imaging applications 
unless otherwise specified. 
Secondary Antibodies and DNA stains 
 
Table 2.4: Table of secondary antibodies and reagents 
Antibody Dilution: 
 Secondary antibodies for western blotting were diluted at 1:10,000 
 Secondary antibodies for Immuno-fluorescence were diluted at 1:1000  
 Propidium Iodide and Hoescht stain were diluted at 1:500 
HRP linked antibodies were used for western blotting applications as previously 
described, Alexa488 linked antibodies were used for acumen HCA assays and for FACS 
applications. Combinations of Alexa488, Alexa568 and/or Alexa680 were used for 
immuno-fluorescence imaging applications.  
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DNA staining with propidium iodide was used in both acumen HCA and FACS 
assays for accurate cell count and determination of DNA content (cell cycle state). DNA 
counter staining with Hoescht was used in immuno-fluorescence applications for staining 
of nuclei.  
2.1.4  Biochemical Inhibitors 
 
Table 2.5: Table of biochemical inhibitors used in this study 
 
2.1.5  Cell Culture Media and reagents 
All cell culture media and additives were purchased from Gibco (Invitrogen).  
I. Cell Culture Reagents 
 
Table 2.6: Cell culture reagents 
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Table 2.7: Cell-Line Models used in this study 
 
III. Growth media conditions for Cell-Lines:  
1. HeLa: 
 DMEM Media 
 10% FBS 
2. A549: 
 RPMI-1640 Media 
 10% FBS 
 1% Sodium Pyruvate 
3. Calu6: 
 MEM Media 
 10% FBS 
 1% Sodium Pyruvate 
 1% MEM non-essential Amino-Acids 
 1% L-Glutamine 
4. U2OS:  
 McCoy-5A Media 
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 10% FBS 
5. Hela shMK2-/- or shGFP-/-: 
 DMEM Media 
 10% FBS 
 1% Sodium Pyruvate 
 1% Puromycin 
2.1.6  siRNA Oligonucleotides 
Small interfering 21-nucleotide RNA duplexes (siRNAs) were purchased from 
Qiagen sciences. The siRNA duplexes used in this study are listed in the table below. For 
every endogenous gene target, a minimum of 2 independent siRNA duplexes was used to 
confirm gene target knock-down.  
 
Table 2.8: Table of siRNA duplex reagents used in this study 
2.1.7  Buffers  
1. Modified RIPA Buffer for cell lysis 
 RIPA Buffer, (Santa Cruz Biotechnology cat: sc-24948) 
 1X Complete-EDTA protease inhibitor cocktail (Roche, cat: ) 
 1X Halt Phosphatase Inhibitor Cocktail 
 10mM Sodium pyrophosphate 
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 2mM Sodium orthovanadate 
 10mM Sodium Fluoride 
 1mM phenylmethylsulfonyl fluoride  
 0.5 ug/ml Okadaic acid 
2. Loading Buffer (Western Blotting) 
 4X LDS Loading Buffer 
 1X Sample Reducing Buffer (DTT) 
 Final concentration of 1ug/ml protein lysate, dilution in modified RIPA Buffer 
3. 2X Prefer Fixative Buffer 
 Prefer fixative diluted from 16X Prefer Stock (Anatech Ltd, MI USA) to 2X 
final 
 100% ethanol diluted to 2X ethanol (40%) final 
 1X PBS  
4. 1X Prefer Fixative Buffer 
 Prefer fixative diluted from 16X Prefer Stock (Anatech Ltd, MI USA) to 1X 
final 
 100% ethanol diluted to 1X ethanol final 
 1X PBS  
5. 4% Paraformaldehyde (PFM) Fixative Buffer 
 16% PFM stock diluted to 4% PFM in PBS 
6. 1X Wash Buffer (Western Blotting) 
 1X TBS-Tween 
7. 1X Blocking Buffer (Western Blotting) 
 2% ECL blocking reagent in TBS 
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8. 1X  Primary Antibody Buffer (Western Blotting) 
 5% BSA in 1X TBS-Tween 
 0.01% Sodium Azide  
9. 1X Secondary antibody Buffer (Western Blotting) 
 2% ECL Blocking reagent in 1X TBS-Tween 
 Or 5% low-fat milk in 1X TBS-Tween 
10.  1X Stripping Buffer (Western Blotting)  
 1X Restore Plus Strip Buffer (Pierce, Cat No. 21059) 
11. 1X Wash Buffer (Acumen or FACS) 
 1X PBS  
12.  0.1% Triton-X 100 Buffer (Permeabilization buffer, Acumen) 
 Triton-X 100 diluted to 0.1% in PBS 
13. 1X Antibody/Blocking Buffer (Acumen or FACS)  
 1% BSA in 1X PBS-Tween 
 0.01% Sodium Azide 
14. 1X Antibody/Blocking Buffer (Confocal) 
 2% BSA in 1X PBS-Tween 
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2.1.8  Analytical Instruments and Systems  
The following analytical instruments and systems were used during the course of this 
study. 
Table 2.9: Table of Analytical Instruments and Systems used in this study 
 
2.1.9  Computational Programs and Tools 
 All statistical modeling and analysis used in this study were carried out using the 
R-Statistical analysis tool (www.R-Project.org) with associated Bioconductor modules 
(www.bioconductor.org) or author generated custom code and scripts. Spreadsheet and 
tables were generated using the Microsoft Excel program.  
 Genomic and gene annotation was derived from Ensembl’s BioMart database 
based on Ensembl build 38 reference data. Ensembl build 38 uses the current NCBIv36 
human genome build. Access to Ensembl’s BioMart was based on pre-written R and perl 
based APIs.  
 Functional pathway annotation was accomplished using the web-based NIH 
DAVID tool (http://david.abcc.ncifcrf.gov/) and canonical pathway and gene network 
analysis was done using the Ingenuity Pathway Analysis (IPA) software program.  All 
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author created images were produced using Microsoft Powerpoint, the freeware software 
tool GIMP
®
 or Paint.Net. 
 Dynamic modeling and simulation was carried out using the Matlab
®
 software 
suite, with user written simulation code. Kinetic constants for pathway simulation were 
derived from Literature survey or from public kinetic pathway databases. 
 
II. Methods in Molecular Biology 
2.2  Methods in Mammalian Cell Culture 
 
2.2.1  General Cell Culture  
Cell lines were grown in a humidified 95% air, and 5% Co2 environment in a cell 
culture incubator. Cells were grown in Falcon T75 or T150 flasks and passaged at regular 
intervals when cells reached approximately 80% confluence.  The cell growth media 
conditions for the cell-lines were described in section 2.1.5 of this chapter.  
Cells to be passaged upon reaching 80% confluence, were first washed once with 
10ml 1X warm PBS. This was followed by 1ml trysin-EDTA solution which was allowed 
to sit for 1 minute prior to being aspirated out. Cells were then placed back in the 
incubator for 5mins to allow cells to detach from the surface of the flask. Cells were then 
washed with warm growth media and counted using a nucleo-counter. New flasks were 
seeded with approximately 0.5x10
6
 cells and placed back in the incubator to grow.  
 
2.2.2  Thyimidine Block/Release Synchronization 
 Cells were synchronized using a double thymidine block/release cycle technique. 
The result of a successful double thymidine block/release cycle was the homogenous 
synchronization of cells at the G1/S boundary upon the 2
nd
 release from thymidine block. 
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The protocols for synchronization of cells with excess amounts of thymidine are well 
established and understood (231,451). The general protocol used is as follows.  
1. Cells were treated with 3mM Thymidine for 12 hours 
2. Wash out thymidine 2x with warm growth media 
3. Trypsinize and replate at 30% cell density, incubate for 16hours 
4. Replace growth media with 3mM Thymidine for 12-14 hours.  
5. Wash out thymidine 2x with warm growth media.  
6. Check that cells are at G1/S boundary. 
 
2.2.3  CDK1 Block/Release Synchronization 
 Cells were synchronized using a CDK1 inhibitor block/release technique. Cells 
synchronized with a CDK1 inhibitor arrest at the G2 to M boundary and upon release 
transition into mitosis. The protocol used was similar to what was previously described 
(423), using the commercially available Roche CDK1 inhibitor RO-3306. The essential 
steps for this method are as follows:  
 1. Cells grown in 6-well dishes are incubated with 9uM RO-3306 for 21 hours 
 2. CDK1 inhibitor (RO-3306) is washed out 3x with warm growth media.  
 3. Cells are incubated with growth media and watched for entry into mitosis 
 
2.2.4  RNA Interference  
 Transfection of 21-nucleotide siRNA duplexes (Qiagen Sciences, Germantown 
MD,USA) for targeting endogenous genes was carried out using Lipofectamine 
RNAimax (Invitrogen, Carlsbad CA, USA) and 5ug siRNA duplex per well as previously 
described in low serum (Opti-mem) media (467).  
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 Transfection occurs for 48hours following which transfection efficiency is 
assayed using RT-PCR or western blotting assays. High efficiency of gene silencing was 
achieved using Qiagen validated siRNA duplexes, where experimental validation for 
gene silencing is performed by manufacturer. For every gene knock-down in this study, 2 
independent siRNA duplexes was used to confirm gene knock-down effect.  
 
2.2.5  Biochemical compounds 
The use of biochemical inhibitors and chemical genotoxic compounds in this 
study was performed as previously described (467).  Biochemical inhibitors and 
compounds were diluted to final concentrations from 100uM working stock in 100% 
DMSO. Working stock was derived from 10mM master stock solution in 100% DMSO. 
All biochemical inhibitors and compounds were stored at -20
o
C.  
 Chemical inhibitors and genotoxic compounds were diluted to final concentration 
in whole growth media just prior to addition to 6-well or 96 well dishes for assay. DMSO 
was matched by volume in the control samples as appropriate DMSO control in all 
assays.   
 
2.2.6  Cell Seeding Density for various assay plates 
 The cell seeding density and plate type for various assays is described in the table 
below.  
 
Table 2.10: Cell seeding density for assay plates 
Chapter 2: Materials and Methods 
 
Author: Mark Phong   Page 93 of 291 
 
 
2.3  Protein Analytical Techniques 
2.3.1  Lysis of cells with custom/modified RIPA buffer 
 Prior to lysis, cells were grown to 80% confluence and were treated with 
biochemical inhibitors, chemical agonists, or UV irradiation as per figure legend. Cells 
were washed with ice cold PBS and then lysed for 10mins on ice with custom/modified 




2.3.2  Determination of protein concentrations in cell lysates 
Protein concentration in cell lysates was determined using the BioRad RC DC 
colorimetric protein assay in 96-well micro-titer format. Protein levels were read using a 
spectramax spectrophotometer plate reader.  
 
2.3.3  SDS-polyacrylamide-gel electrophoresis (SDS-PAGE) 
SDS-PAGE was conducted as previously described (422) using the Invitrogen X-Lock 
system. Invitrogen NuPage Bis-Tris or Tris-Glycine gels were used for all SDS-PAGE 
applications. All SDS-PAGE gels were run as per manufacturer’s instruction. Two 
protein ladders were incorporated for all gels:  
 1. MagicMark XP (HRP ladder) 
 2. SeeBlue Plus 2 (Visible Ladder) 
 
2.3.4  Transfer of proteins onto nitrocellulose membranes 
 For immunoblot (western blotting) analysis, proteins were transferred onto 
nitrocellulose membranes as previously described (467). Transfer was performed using a 
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“semi-dry” X-Lock transfer device by Invitrogen. Transfer of denatured proteins, was 
performed using manufacturers recommended transfer buffer containing 20% methanol at 
recommended voltage and current for 1 hour. Following transfer of protein onto 
nitrocellulose membrane, membranes were stained with Ponceau S reversible protein 
stain to ascertain efficient protein transfer.  
 
2.3.5  Immunblot Detection 
After electroblotting, the transferred proteins are bound to the surface of the 
nitrocellulose membrane, providing access for reaction with immunodetection reagents. 
Remaining binding sites were blocked with either 5% low-fat milk or 2% ECL advance 
blocking reagent (Amersham) for at least 1 hour at room temperature. The membrane was 
then probed with a primary antibody diluted to a final concentration of 1:500 to 1:1000 in 
antibody buffer and incubated overnight at 4
o
C. The membrane was washed 3x 10mins in 
1X wash buffer on a rocker and then incubated with secondary HRP-linked antibody 
diluted to 1:10,000 in secondary antibody buffer for 1hour at room temperature. 
Following secondary antibody incubation, membranes were washed in 1X wash buffer 
(Western Blotting) on a rocker for 3x 30mins at room temperature.  
 Luminescent substrate detection was performed using the ECL Advance or ECL 
plus chemi-luminescent kit (Amersham). Chemi-luminescent signal was detected using a 
high resolution GE Gel-blot imager.  
 Membranes were stripped of bound antibodies by incubating for 1hour in 1X 
stripping buffer at 50
o
C. Stripped membranes were re-blocked in 1X blocking buffer and 
re-probed with a different primary antibody. 
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2.3.6 Total Protein Loading Control for Immunoblotting  
 For biochemical inhibitor studies, total p38 was used for loading control as total 
p38  protein levels are stable and unaffected by the different biochemical inhibitors used 
in this study.  
 For RNAi studies, the -actin house keeping gene was used for loading control, as 
RNAi leads to protein ablation of target proteins including p38  
 
2.3.7  Acumen Multi-Parametric Cytometry High Content Analysis (HCA) 
Prior to Acumen HCA, cells were grown in black 96-well BD Falcon opti-lux 
micro-titer plates. Cells were strained using a 40-micron cell strainer prior to seeding to 
aid in dis-aggregation of cell clumps. Cells were seeded at approximately 30,000 cell/ml 
density in 100ul volumes per well.  
Following treatment with chemical inhibitors, chemical agonists and/or UV 
irradiation, cells were fixed without aspiration of media with 2X prefer fixative buffer 
(Anatech Ltd, MI USA) for 30mins at room temperature (for study of mitotic index) or 
with 1X prefer fixative for 30mins with removal of cell media for cell studies. Black 
micro-titer plates were then washed once with 1X wash buffer (PBS), using an automated 
BioTek micro-titer plate washer.  
Following fixing of cells to the surface of micro-titer plate, cells were 
permeabilized using 0.1% Triton-X 100 permeabilization buffer for 10mins at room 
temperature. Triton-X 100 buffer is washed out once with 1X wash buffer using an 
automated BioTek micro-titer plate washer.  
Fixed and permeabilized cells are now accessible to immuno-detection reagents, 
and to minimize non-specific immuno-detection, cells are blocked in 1X blocking 
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solution for at least 1 hour at room temperature on an orbital shaker. Following blocking 
step, cells are incubated with primary antibody diluted to a range of 1:200 to 1:1000 in 
1X antibody buffer overnight at 4
o
C. After incubation with primary antibody overnight, 
plates are washed 3X in 1X wash buffer using an automated BioTek washer. Incubation 
of Alexa488 linked secondary antibody diluted to a final concentration of 1:1000 in 
antibody buffer occurred for 1 hour, at room temperature in the dark. Secondary antibody 
was washed out with 3x wash in 1X wash buffer.  
DNA staining for DNA content was achieved with 500nM propidium iodide 
buffer with 200ug/ml DNAse free RNAse-A. Stained 96 well plates were scanned with 
Acumen Explorer (TTP, UK), a laser scanning cytometer with 488 nm laser excitation 
and 4 PMTs as detectors. We used 7x7 mm whole wellscan for 96 well plates at 1µm(X) 
x 2 µm(Y) resolution. Emission signals were collected with channel-1 (500nm-530nm) 
mean fluorescence intensity for cyclin B1, channel 3 (575 nm-640nm) peak fluorescence 
for DNA condensation and channel 4(655 nm-705 nm) total fluorescence for DNA 
content. Single cells were identified with gating DNA content covering 2N to 4N range. 
Total single cells, 2N cells, 4N cells and cells between 2-4N (S phase cells), cells with 
DNA condensation, and channel 1 (Alexa488) positive cells were individually identified. 
Percentage of each subpopulation was calculated based on total cell populations. 
 
2.3.8  Immuno-Fluorescence Microscopy and Confocal Microscopy  
Cell culture and sample preparations for immunofluorescence microscopy were 
done as previously described (467). Briefly, cells were grown on cover slips or in LabTek 
4-well chamber slides. After cell treatment with chemical inhibitors, chemical agonist or 
UV irradiation, cells were fixed with 4% PFM buffer for 30mins. Cells were 
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pemeabilized with 0.2% triton-X 100 buffer for 10mins, followed by blocking in 2% 
BSA blocking solution for at least 1 hour. Primary antibody mixtures were incubated 
overnight at 4
o
C at a final concentration of 1:50 to 1:1000 depending on antibody 
optimization step or as per manufacturer’s recommendation. Alexa488 linked and 
Alex568 linked secondary antibody were incubated for 1 hour at a final concentration of 
1:1000 for 1 hour at room temperature. DNA counterstaining was achieved with 500nM 
Hoescht stain in DI water. 
Cell imaging was acquired with a Bio-Rad MRC600 confocal microscope at 40X 
(air or oil) or 60X (oil) magnification.  
 
2.3.9  FACS analysis 
Cell culture and sample preparation for FACS analysis were done as previously described 
(467). Briefly, cells were grown on 10cm diameter dishes or 6-well plates to 80% 
confluence, and treated with chemical inhibitors, chemical agonist or UV irradiation as 
per figure legend. After chemical treatment, cells were detached from plate bottom with 
tryspin-EDTA, collected into a Falcon spin tube and were fixed with 1X prefer fixative 
buffer or 4% PFM buffer for 30mins. Fixed cells were pelleted via centrifuge at 
1200RPM for 5mins and washed with 1X PBS wash buffer. Cells were permeabilized 
with 0.2% Triton-X 100 for 10mins, and cell pellet was collected via centrifuge at 1200 
RPM for 5mins and washed with 1X PBS wash buffer. Cells were blocked in 5% low-fat 
milk for at least 1 hour and then incubated with primary antibody at final dilution of 
1:200 to 1:1000 depending on optimization step, overnight at 4
o
C. Following washing 3x 
in 1X PBS wash buffer, Alexa488 and/or Alexa568 linked secondary antibodies are 
added in sequence for 1 hour at room temperature. RNAse digestion was carried out with 
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200ug/ml DNAse free RNAse-A for 30mins. DNA counter staining is achieved with 
1mM propodium iodide for DNA content analysis.  
 Multi-parametric FACS analysis was carried out on the BD LSR-II Flow-
Cytometry system. A minimum of 10,000 independent events was required for a 
successful data capture run.  In this study we gated using a band-pass filter for 530/30 for 
the Alexa488 emission, a band-pass filter of 575/26 for the PI stain and a 488/10 filter for 
the side scatter filter. We used the ratio of forward scatter vs side scatter to determine the 
population of interest. 
 
2.3.10  cDNA microarray hybridization (Affymetrix Arrays) 
Total RNA from Calu6 cells was isolated with RNA STAT-60 (Tel-Test) 
according to the manufacturer's protocol.  5 micrograms of total RNA were labeled and 
hybridized to Affymetrix U133plus2 arrays according to the Affymetrix protocol.  Each 
sample was hybridized to a single microarray.  All samples were assessed for RNA 
quality such as microarray scaling factors, background levels, percent present calls, ß-
actin and GAPDH 3'/5' ratios, etc. Samples with 3'/5' ratios above a threshold 3 were 
excluded from further analysis. 
Signal intensities representing gene expression values were obtained from 
Microarray Suite version 5.0 (MAS5) using the default settings, except 2% trimmed 
mean was set to 1500.   
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III. Mathematical & Statistical Methods in Computational Biology 
2.4  Statistical Analysis of Microarray Data 
To apply statistical analysis to the experiment, 2 different statistical algorithms 
were used depending on the nature of the statistical problem. For a two-sided problem, 
we employed the SAM (Significance Analysis of Microarray) algorithm to identify genes 
differentially expressed between two groups of genes. (Tibshirani et al, PNAS 2001) 
Multiple testing correction has been built into the SAM algorithm based on the false 
discovery rate (FDR) and Q-value algorithm (Storey et al, 2002). The FDR rate for every 
gene list derived in this analysis was standardized to FDR ≤ 0.1.  
For a multi-parametric time series analysis we employed a mixed-effects analysis 
of variance model (ANOVA). The random effect in this analysis was classified as the 
technical replicates for each treatment group and time point. The nested linear mixed-
effect ANOVA model follows this format.  
)(Re/)( 210 pErrorTimebTreatmentTypebbxy  
The p values of the ANOVA model were adjusted for multiple testing using the 
false discovery rate (326).  The adjusted P values, or the false discovery rates (FDR), are 
designated as Q values, where Q = P*n/i (n = total number of probe sets on the 
microarrays, i = sorted rank of P values).  The fold change was calculated as the ratio of 
the two group means based on the observed signal values from MAS5 and the gene 
expression signal change was calculated as the difference of the two group means. 
Differential gene lists were generated for time series analysis using a FDR FDR ≤ 0.1 for 
all factors. 
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2.4.1  Hierarchical Clustering, Correlation Analysis and Principal Component 
Analysis (PCA)  
In addition to generating gene lists using SAM or ANOVA, we also applied a 
number of unbiased, unsupervised clustering techniques to assess natural groupings 
found within the data. For hierarchical clustering we used complete linkage with a 
Euclidean distance, similarity metric to measure distance between groups of genes. For 
my correlation analysis, we used a boot-strapped adjusted (permutation based) pearson 







 principal components of all expressed genes to understand if 
treatment conditions naturally separated in dimensionally reduced projections.  
 
Chapter 2: Materials and Methods 
 
Author: Mark Phong   Page 101 of 291 
 
2.4.2  Pathway Analysis and Functional Annotation Clustering 
For all gene lists generated in the microarray experiment, we performed 
functional annotation clustering and canonical pathway analysis using two computational 
tools. We used the NIH DAVID tool (Lempicki et al, Genome Biology 2003) for 
functional clustering of gene lists. We used the Ingenuity pathway analysis tool 
(www.ingenuity.com) for canonical pathway over-lay and for canonical pathway network 
construction. Functional analysis and pathway analysis gives context to gene lists 
produced from statistical analysis of microarray data.  
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Chapter 3: The role of p38 MAPK in regulation of DNA damage G2 cell 
cycle checkpoint control 
3.1  Background 
 The p38 MAPK is one of the main stress induced kinases that is critical for 
response to many types of environmental stress including bacterial infection, osmotic 
stress and UV damage (41). The response of p38 to different types of stress has been 
detailed concisely in chapter 1. This chapter will focus on my studies addressing p38’s 
role in the control of the cell cycle specifically at the G2 to M transition point and in 
other aspects of p38’s role in DNA damage response. Our interest with p38 stems 
primarily from reports that p38 was activated in response to DNA damage and 
suggestions that inhibition of p38 signaling would provide an ideal new mechanism to 
effectively target cancer cells. Prior publications as detailed in chapter 1 have suggested a 
link between p38 activity and DNA damage checkpoint response at the G2 to M phase of 
the cell cycle. As many of these published studies were conducted in mouse cells and in 
untransformed cells, we were interested in definitively exploring p38’s role in the control 
of cell cycle progression specifically in the response to DNA damage and in the context 
of cancer cells. Our goal was to the gain a deeper mechanistic understanding of p38 
function at the G2 checkpoint, and to test that inhibition of p38 was an effective anti-
cancer strategy that should be developed further for clinical testing. 
 
3.2  p38 MAPK is activated during DNA damage at all stages of the cell cycle 
 Since p38 is known to be activated in response to DNA damage, we asked if the 
extent of p38 activation is correlated with the sources of DNA damage and the underlying 
cell cycle states. Prior publications have shown that p38 MAPK is activated during events 
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leading to DNA damage (181,316,332). These events include genotoxic damage caused 
by Topo-isomerase II inhibitors such as Doxyrubicin-HCL (Adriamycin), and radiation 
damage by UV and IR radiation. To test the effect of different sources of DNA damage 
on p38 pathway and cell cycle checkpoint response, unsynchronized and synchronized 
HeLa cells were treated with 160nM Adriamycin (Figure 3.1A), increasing doses of UV 
irradiation (Figure 3.1B), and 0.01% MMS (Figure 3.1C). Based on multi-parametric 
Acumen & FACS cytometry data, treatment with Adriamycin, UV and MMS damage all 
led to a G2 checkpoint arrest in p53 functionally null HeLa cells (Top panels of figure 
3.1A, B&C). Western blot assays of p38 and DNA damage response pathways to the 
different sources of DNA damage also showed strong induction of p38 pathways, 
corresponding to the G2 checkpoint arrest observed in multi-parametric cytometry data 
(Bottom panel Figure 3.1A, B&C).  
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Figure 3.1: p38 MAPK is activated by various DNA damaging stresses. (A) 
Activation of p38 by Topo-II inhibitors. (B) p38 MAPK is activated by UV-B 
irradiation. (C)  p38 pathway activated by 0.01% MMS damage 
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 Having demonstrated that p38 is activated strongly by different genotoxic agents 
and by environmental UV damage. We next asked if p38 could be activated equally well 
at different stages of the cell cycle. For this, HeLa cells were synchronized in G1 by 
48hrs serum-starvation (Figure 3.2A) or in early S phase by double thymidine 
block/release (Figure 3.2B) or in G2 by CDK1 inhibitor (RO-3306) block for 21hrs 
(Figure 3.2C) and then released in fresh growth medium containing 0.01% MMS.   
DNA damage following the different cell synchronization techniques all showed 
rapid induction of p38 and Chk1 pathway activity (Figure 3.2).  
This shows that p38 is activated by DNA damage at all stages of the cell cycle.  
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Figure 3.2: p38 MAPK is activated at all stages of the cell cycle. (A) p38 is activated 
by MMS damage after 48hours serum starvation, cells in G1 phase. (B) p38 is 
activated by MMS damage after double thymidine block/release protocol, cells are 
in S phase. (C) p38 is activated by MMS following release from CDK1i (RO-3306) 
, cells in G2. 
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3.3  LY479754 and SB203580 are effective inhibitors of p38 pathway  
 To probe the effect of p38 in the DNA damage response pathway, we used 
multiple in-vitro biochemical tools including a potent p38 inhibitor LY479754 (referred 
to subsequently as p38 inhibitor) (106). We showed using anisomycin, a potent anti-
microbial agent, that a dose in the range of 80nM to 160nM of LY479754 can effectively 
suppress MAPKAPK2 (MK2) phosphorylation in HeLa cells (Figure 3.3). Concurrent 
analysis of phospho-Chk1 and phospho-JNK status showed that doses of up to 1 M of 
LY479754 had no effect on the expression of these proteins.  
 
 
Figure 3.3: In-vitro kinase assay for LY479754 in HeLa cells. HeLa cells 
were treated for 1hr with 5 g/ml of anisomycin and co-incubated with stated 
concentration of p38 inhibitor (LY479754). MAPKAPK2 phosphorylation at 
serine 334 was used as a marker of p38 pathway activity.  
 
Chapter 3: Role of p38 MAPK in DNA damage G2 cell cycle control 
 
Author: Mark Phong   Page 108 of 291 
 
 As the majority of prior publications have used SB203580 to biochemically 
inhibit p38 pathway. We conducted a dose response experiment to determine the 
effectiveness of the inhibitor.  
 
 
Figure 3.4: In-vitro kinase assay for SB203580 in HeLa cells. HeLa cells were 
treated for 1hr with 5 g of anisomycin and co-incubated with stated concentration 
of p38 inhibitor (SB203580). MAPKAPK2 phosphorylation at serine 334 was used 
as a marker of p38 pathway activity.  
 
SB203580 is an effective inhibitor of p38 pathway activity. In the dose response 
study conducted in HeLa cells, SB203580 dramatically inhibits p38 pathway activity in 
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the range of 312nM, with complete suppression of phospho-MAPKAPK2 observed at 
625nM (Figure 3.4). It should be noted that most prior publications use dose 
concentrations of SB203580 of around 10 M to 40 M to suppress p38 activity, many 
times over what we observe to be the effective dose for SB203580.  
3.4  Adriamycin dose titration to find optimal dose for cell-cycle experiments 
 The reports of the p38 pathway acting as a key regulator of G2 checkpoint activity 
and fidelity have stirred considerable interest in the area of oncology treatment. 
Activation of DNA damage checkpoint at the G2 to M transition in response to 
chemotherapeutic treatment has been implicated as a mechanism that allows some cancer 
cells to escape apoptosis and cell death. We began this exercise with the hypothesis that 
the combination of a potent p38 inhibitor with a genotoxic chemotherapeutic agent would 
increase the efficacy of treatment by abrogating the DNA damage G2 checkpoint, forcing 
cells pre-maturely into mitosis. Forcing cells pre-maturely into mitosis has been known to 
lead to a phenomenon known as mitotic catastrophe, leading to increased cell death.  
To begin this experimental series, Adriamycin, a Topo-isomerase II inhibitor 
(Doxurubicin HCL) was selected as a genotoxic agent to explore the role of p38 activity 
in G2 DNA damage checkpoint function. Before undertaking a study of p38 function in 
G2 checkpoint function, an optimal dose of Adriamycin that induced a strong G2 
checkpoint without excessive cytotoxicity had to be determined. To address this, a dose 
titration experiment of Adriamycin in HeLa cells was conducted using a multi-parametric 
Acumen HCA assay (Figure 3.5). In this assay, the 3 primary parameters under 
consideration were the DNA content (propidium iodide), mitotic index (phospho-Histone 
H3) and cell viability (cell count). From these 3 parameters, the ideal dose of Adriamycin 
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Figure 3.5:  Adriamycin Dose Response in HeLa cells at 20hrs. (A) Distribution of 
Cell Cycle States at 20hrs post Adriamycin, in an Adriamycin Dose response 
experiment (B) Mitotic Index in HeLa cells in a dose response to Adriamycin.  (C) 
Cell viability assay: Cells were stained with PI and counted. 
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Cells with the highest 4N DNA content population could be achieved in the dose 
range of 80nM to 320nM (Figure 3.5A). At doses higher than 1.2 M, cells tend to arrest 
in S-phase instead of G2. A dose of Adriamycin below 80nM led to leaky G2 checkpoint 
arrest with significant positive phospho-Histone H3 signal (Figure 3.5B). Lastly, high 
doses of Adriamycin led to significant cell death, with doses of Adriamycin above 
320nM leading to significant loss of cells (>50% loss) (Figure 3.5C).  The results of the 
dose response studies with Adriamycin showed that a dose of around 160nM was 
optimal, as a strong G2 cell cycle arrest was induced with acceptable levels of cellular 
toxicity based on cell viability (Figure 3.5).  
 
3.5  Biochemical inhibition of p38 MAPK cannot abrogate Adriamycin induced 
G2 checkpoint arrest in HeLa Cells. 
As p38 is strongly activated in response to DNA damage resulting in a G2 
checkpoint arrest, its activity is implicated as critical for proper checkpoint establishment 
and function. If so, then inhibition of p38 activity during G2 would be expected to 
abrogate the checkpoint -mediated arrest in response to DNA damage. To test this, 
unsynchronized HeLa cells were dosed with 160nM of Adriamycin for 20hrs to allow for 
the establishment of a robust G2 checkpoint arrest. Following 20hrs, original Adriamycin 
only media was replaced with growth media containing 320nM of LY479754 or 1.5 M 
of the reference Chk1 inhibitor and 160nM Adriamycin. An additional nocodazole trap 
consisting of 120nM of nocodazole was added to trap in mitosis, any cells that escape the 
G2 checkpoint arrest. Cells were fixed and analyzed for mitotic index (phospho-Histone 
H3) and for cell cycle state (propidium iodide) using multi-parametric Acumen high 
content cytometry or by multi-parametric FACS (Figure 3.6A &B).  
Chapter 3: Role of p38 MAPK in DNA damage G2 cell cycle control 
 






Chapter 3: Role of p38 MAPK in DNA damage G2 cell cycle control 
 
Author: Mark Phong   Page 113 of 291 
 
 
Figure 3.6:  Inhibition of Chk1 but not p38 abrogates Adriamycin induced G2 
checkpoint Arrest:  (A) Summary line graph of mitotic index across time for 
different treatment conditions. (B) Representative multi-parametric plots of mitotic 
index (ph-Histone H3) and DNA content (PI) at 15hrs post p38 
inhibitor+nocodazole or Chk1 inhibitor+Nocodazole addition. (C) Western Blots 
of synchronized HeLa cells (thymidine block/release) treated with Adriamycin and 
chemical inhibitors (160nM p38i, 2uM MK2i, 1.5uM Chk1i) 
 
 HeLa cells treated with 160nM of Adriamycin arrest with a majority 4N 
population after 20 hours of treatment. Our expectation that p38 activity is necessary for 
proper G2 checkpoint activation implies that inhibition of p38 activity should release 
cells from G2 checkpoint arrest. HeLa cells treated with 320nM of LY479754 do not 
exhibit any significant increase in mitotic index in the 20 hours after inclusion of p38 
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inhibitor with a nocodazole mitotic trap (Figure 3.6A). This result contrasts strongly with 
the effect of a Chk1 inhibitor (LY2494516), where we saw a dramatic increase in mitotic 
index in the same time period with a nocodazole mitotic trap (Figure 3.6A &B).  
Multi-parametric Acumen cytometry data was further supported by data produced 
from synchronized HeLa cells in a western blot assay. In this experimental regime, HeLa 
cells were synchronized using 3mM thymidine block/release protocol. In this 
experimental regime with synchronized HeLa cells, Adriamycin induced a strong G2 
checkpoint arrest, which was relieved by specific inhibition of Chk1 with a Chk1 
inhibitor or by inhibition of the ATM/ATR response with 6mM caffeine, but not by 
inhibition of p38 or its downstream substrate MK2 by measuring levels of phospho-
Histone H3. (Figure 3.6C) To better understand the effect of biochemical inhibition on 
the G2 DNA damage checkpoint, we probed for additional cell-cycle related checkpoint 
kinases that were known to play a role at this checkpoint. These included phosphorylated 
CDC2 (CDK1) at tyr15, and the levels of Wee1 kinase. Co-analysis of phospho-CDC2 
and Wee1 levels show that inhibition of the ATM/ATR pathway with either a specific 
Chk1 inhibitor (1.5uM) or the generic ATM/ATR inhibitor caffeine (6mM) led to 
dramatic decreases in expression of both these proteins, corroborating with an increase in 
phospho-Histone H3, indicating the effective abrogation of the G2 checkpoint (Figure 
3.6C). Inhibition of p38 with LY479754 or a specific MK2 inhibitor (LY2441693) had 
no such effect on these mitotic entry markers. (Figure 3.6C) Additionally, we noticed that 
abrogation of G2 checkpoint with either the Chk1 inhibitor or caffeine still occurs with 
high levels of phospho-p38 and phospho-MK2 still present.  
Taken together this data suggests that inhibition of the ATM/ATR pathway with 
either a specific Chk1 inhibitor or with caffeine was able to abrogate the G2 DNA 
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damage checkpoint induced by Adriamycin whereas inhibition of p38 was unable to 
abrogate the G2 DNA damage checkpoint.  
 Additional experiments involving various doses of p38 inhibitor (5nM to 2.5 M) 
and multiple concentrations of Adriamycin (9nM to 160nM) demonstrate that these 
results were not specific for a particular dose range of LY479754 or Adriamycin (Figure 
3.7). 
 
Figure 3.7:  Dose titration of Adriamycin and p38-inhibitor (LY479754) in 
thymidine synchronized HeLa cells.  
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Confocal Immunofluorescence Microscopy 
To further substantiate the results in HeLa cells beyond biochemical assays, a 
series of confocal microscopy experiments were performed to image cells damaged by 
Adriamycin and treated with either the p38-inhibitor or the Chk1-inhibitor. HeLa cells 
were synchronized with double thymidine block and upon release subsequently damaged 
with 160nM Adriamycin in combination with either 320nM p38-inhibitor or 2uM Chk1-
inhibitor. Cells were fixed 10 hours after treatment with Adriamycin and inhibitors and 
imaged according to the confocal microscopy methodology described in the methods and 
materials section (Figure 3.8). 
 In concordance with the results of other assays, the confocal microscopy imaging 
shows that Adriamycin induced a strong G2 checkpoint arrest in synchronized HeLa 
cells. 10 hours post inhibitor treatment, cells treated with Adriamycin showed a “spread-
out” and flat morphology characteristic of cells in interphase. Hoerscht stained DNA 
revealed un-condensed DNA and no Histone-H3 phosphorylation (ser10) was detectable 
(Figure 3.8 left panel). Combining the lack of ph-Histone-H3 staining with CyclinB1 
primary co-localization within the cytoplasm and the lack of condensed DNA, imaging 
data presents the case from multiple markers that Adriamycin induces a strong G2 
checkpoint arrest.  Imaging of HeLa cells treated with 320nM p38-inhibitor and 160nM 
Adriamycin showed very little differences in terms of morphology or immunofluorescent 
staining patterns with cells treated with only Adriamycin. As similar patterns of no 
phospho-Histone-H3, primarily cytoplasmic CyclinB1, the lack of cells with a mitotic 
spindles and uncondensed DNA were seen in cells treated with the p38 inhibitor (Figure 
3.8, middle panel).  
Significant differences however, were observed in HeLa cells treated with 2 M 
Chk1-inhibitor and adriamcyin. Treatment with a Chk1 inhibitor led to cells with distinct 
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bipolar mitotic spindles, condensed DNA, nuclear cyclin B1 and strong phospho-Histone 
H3 levels (Figure 3.8 right panel). Taken together this imaging data shows that inhibition 
of Chk1 but not p38 was able to induce cells to bypass an Adriamycin induced G2 
checkpoint arrest.  
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Figure 3.8:  Confocal Microscopy images of thymidine synchronized HeLa cells 
damaged with 160nM Adriamycin (Left) and dosed with either 320nM p38 
inhibitor (Middle) or 2uM Chk1-inhibitor (Right). Red Dye: Alexa 555, Green 
Dye: Alexa 488, Blue Dye: Hoerscht Stain.  
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3.5.1  Biochemical inhibition of p38 cannot abrogate Adriamycin induced G2 
checkpoint arrest in other cancer cell-lines 
  While a large part of this study was conducted using HeLa cells as the primary 
cell-line model, we were interested to investigate if these results could be reproduced in 
other commonly used cancer cell-line models. To address this issue, we studied the effect 
of p38 inhibition in combination with Adriamycin stress in Calu6 (Lung 
Adenocarcinoma), A549 cells (Lung non-small cell carcinoma) and in U2OS cells 
(Osteosarcoma cells).  
 There were some complications involved in switching cell-line models between 
HeLa cells and other cancer cell-line models. The vastly varying genetic background 
between the different cancer cell-lines resulted in varying degrees of sensitivity to both 
Adriamycin damage and to the p38 inhibitor LY479754. For each cell-line model, we 
conducted a small pilot experiment to determine optimal cell treatment conditions. We 
found that a dose range between 160nM and 320nM of Adriamycin produced a very 
strong G2 checkpoint arrest in all three cell-lines. For the p38 inhibitor we found that a 
dose in the range of between 320nM-500nM and above effectively inhibited phospho-
MK2,T334 expression in all cell-lines. 
 In Calu6, lung adenocarcinoma cell-lines, we were able to reproduce the results 
observed in HeLa cells well. We found that strong biochemical inhibition of p38 kinase 
activity had no effect on the ability of Calu6 cells to mount a G2 checkpoint arrest in 
response to adriamcyin damage. Similar to our observations in HeLa cells, inhibition of 
Chk1 via a biochemical inhibitor led to a dramatic increase in mitotic index within a 20 
hour timeframe, while cells were trapped with a nocodazole metaphase trap (Figure 3.9). 
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Figure 3.9: Biochemical inhibition of p38 is unable to abrogate Adriamycin induced 
G2 checkpoint arrest in Calu6 cells. (A) Mitotic index plot (ph-Histone H3,s10) 
based on an Acumen Explorer HCA scan across time of Calu6 cells treated with 
320nM of Adriamycin and p38 or Chk1 inhibitors. (B) Western blot assay of 
Adriamycin treated Calu6 cells with p38 inhibitor (LY479754) 
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In addition to Calu6 cell-lines, the effect of p38 inhibition on Adriamycin induced G2 
checkpoint arrest was tested on A549 and U2OS cancer cell lines. Inhibition of p38 in 
A549 and U2OS cells was again unable to abrogate a G2 checkpoint arrest mounted in 
response to Adriamycin damage (Figure 3.10).  
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Figure 3.10: Biochemical inhibition of p38 and Chk1 was unable to abrogate 
Adriamycin induced G2 checkpoint arrest in A549 & U2OS cells. (A) Mitotic 
index plot (ph-Histone H3,s10) based on an Acumen Explorer HCA scan across 
time of A549 cells treated with 160nM of Adriamycin and 120nM nocodazole with 
p38 or Chk1 inhibitors. (B) Mitotic index plot (ph-Histone H3,s10) based on an 
Acumen Explorer HCA scan across time of U2OS cells treated with 320nM of 
Adriamycin and 120nM Nocodazole with p38 or Chk1 inhibitors 
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However in both A549 and U2OS cells, inhibition of Chk1 did not lead to a 
significant increase in mitotic index within a 24 hour time frame. This result in A549 and 
U2OS cells differed significantly from the results observed in HeLa and Calu6 cells. One 
possible explanation in this discrepancy could be the p53 status in these cells-lines. Both 
HeLa and Calu6 have a non-functional p53 pathway, whereas A549 and U2OS are 
regarded to have an intact p53 signaling pathway. A search of literature revealed prior 
publications that suggested that inhibition of Chk1 alone in a p53 functional environment 
was not sufficient to overcome a DNA damage G2 checkpoint arrest (59,217,232). 
 As Chk1 kinase was not the primary target of this study, we did not pursue further 
investigations into this phenomena, however future studies may delve into dissecting the 
Chk1, p53 pathway interaction in response to Adriamycin induced cell cycle arrest.  
 
3.6  Transient and stable knock-out of p38 or its down-stream substrate MK2 has 
no effect on Adriamycin induced G2 DNA damage checkpoint. 
 As chemical inhibitors are often reported to have off-target or dose dependent 
effects, we wanted to test the effect of p38 pathway suppression through a separate 
mechanism. To address this problem, we tested the effect of both transient siRNA knock-
down and stable-line shRNA knock down of p38. For the transient knock-down 
experiments we used validated Qiagen
TM
 oligonucleotides designed against the p38alpha, 
MK2 and Chk1 transcripts. In this experimental regime, unsynchronized HeLa cells were 
transfected with siRNA oligonucleotides using Lipofectamine-RNAiMax (Invitrogen) for 
48hrs in low serum media for 48 hours. Following 48 hours, siRNA transfection media 
was replaced with fresh growth media containing 160nM Adriamycin and 120nM 
nocodazole acting as a mitotic trap.  
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In HeLa cells, transient knock-down of p38 after 48hrs treatment with Qiagen siRNAs 
was unable to abrogate the G2 DNA damage checkpoint induced by Adriamycin (Figure 
3.11A). Over a 24 hour time period, cells transfected with siRNA oligonucleotides 
targeting p38 showed no significant increase in phospho-Histone H3 levels, while in a 
nocodazole mitotic trap. Cells transfected with siRNA oligonucleotides targeting Chk1, 
in contrast registered a significant increase in phospho-Histone H3 levels over a 24 hour 
period, indicating abrogation of the G2 checkpoint and mitotic entry (Figure 3.11A).  
 Additional experiments using western blots showed that despite effective siRNA 
knock-down of p38 and MK2 protein levels, no corresponding increase in phospho-
histone H3 levels were detected. (Figure 3.11B) These assays showed that effective 
siRNA knock-down of Chk1 protein, led to an increase in phospho-Histone H3 and a 
concordant decrease in phospho-CDC2 (CDK1), Y15 levels. (Figure 3.11B) 
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Figure 3.11:  Effect of siRNA KD of p38, MK2 and Chk1 transcript on establishment 
of Adriamcyin induced G2 DNA damage checkpoint. (A) Mitotic index derived 
from Acumen HCA assay in HeLa cells following reverse transfection of siRNA 
vectors with Lipofectamine RNAi-Max and 24hrs 160nM Adriamycin treatment. 
(B) Western Blot assay of effect of siRNA KD of p38, MK2 and Chk1 on 
Adriamycin induced G2 checkpoint arrest, 24hrs post Adriamycin & nocodazole. 
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 Together this data shows that in a p53 functional null system that knock-down of 
Chk1 can effectively abrogate the G2 checkpoint induced by Adriamycin. In addition to 
p38 knock-down, siRNA knock-down of MK2 was explored as a secondary hypothesis 
within this experimental context. While siRNA knock-down of MK2 could be achieved 
successfully (Figure 3.11B), it had no impact on the ability of cancer cells to mount a G2 
checkpoint arrest in response to Adriamycin (Figure 3.11A). These results show that 
siRNA knock-down of either p38 or MK2 had no significant impact on the proper 
function of the DNA damage G2 cell cycle checkpoint. 
 As a follow-up to studies involving transient siRNA knock-down of p38 and 
MK2, stable-lines incorporating a lentiviral vector against MK2 were made in HeLa cells. 
As MK2 has been implicated as both a downstream component of p38 pathway signaling 
as well as a direct substrate of CDC25B binding, we wanted to further investigate if 
stable-line knock-down of MK2 would produce any difference in the ability of cells to 
mount a successful G2 checkpoint in response to Adriamycin DNA damage. HeLa
MK2-/-
 
and their respective control cells HeLa
Vect
 (empty vector) were synchronized with double 
thymidine block/release and treated with 160nM Adriamycin.  
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Figure 3.12:  Effect of Adriamycin damage on Helamk2-/- cells. A. Western blots of 
HeLa cells incorporating an shMK2 vector or an empty vector control treated with 
anisomycin (1hour) and Adriamycin (24hrs). B. Mitotic index of synchronized 
HeLa MK2-null cells and synchronized MK2-null cells treated with Adriamycin.  
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 HeLa cells transfected with a lentiviral shRNA vector targeting MK2, and grown 
under constant selection pressure using puromycin results in a stably incorporated cell-
line with MK2 knocked down. Using anisomycin to test the effect of MK2 knock-down, 
showed that the MK2 pathway in HeLa
MK2-/-
 cells was effectively silenced (Figure 
3.12A). Having shown that the HeLa
MK2-/-
 cells do not have a functioning MK2 pathway, 
these cells and their respective empty vector controls were synchronized with double 
thymidine block release with 3mM thymidine in growth media. Following release from 
thymidine block, these cells were treated with 160nM of Adriamycin and with 
biochemical inhibitors against p38 and Chk1 kinase as additional controls.  
To show that these cells do not possess unusual cell cycle properties, HeLa
MK2-/-
 
cells were demonstrated to be able to enter and exit mitosis as normal in an unstressed 
environment (Figure 3.12B). Following treatment with Adriamycin, Hela
MK2-/-
 cells were 
able to mount a successful G2 checkpoint arrest, as measured by low levels of phospho-
Histone H3 (Figure 3.12C). The addition of LY479754 to these cells treated with 
Adriamycin was unable to abrogate the checkpoint arrest, whereas Hela
MK2-/-
 and the 
corresponding empty-vector incorporated HeLa cells that were treated with 1.5uM of 
Chk1i were found to enter mitosis in a slight delayed fashion versus un-perturbed cells 
(Figure 3.12C).  
This data shows that despite stable knock-down of MK2 and treatment with a 
potent biochemical inhibitor of p38, loss of p38/MK2 pathway activity did not impact the 
establishment of a G2 checkpoint arrest in response to Adriamycin.  
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3.7  Biochemical Inhibition of p38 cannot abrogate UV induced DNA damage G2 
checkpoint response in HeLa cells. 
Previous reports implicating p38 as a critical kinase in G2 checkpoint function 
had utilized UV irradiation as a source of DNA damage.  Earlier reports by Bulavin et al 
(38) and others had suggested that inhibition of p38 sensitizes cells to UV damage 
through abrogation of the G2 DNA damage checkpoint. Since p38 activity does not 
appear to be necessary for G2 checkpoint arrest in Adriamycin induced G2 checkpoint 
arrest, we wanted to investigate the role of p38 activity in response to UV damage. 
 UV damage is known to induce single strand breaks as well as bulky adjuncts to 
DNA through dimmer cross-linking (67). Such damage to DNA is known to halt the cell 
cycle through induction of single strand DNA response signals as detailed in preceding 
chapters. In this series of experiments we seek to understand the role of p38 MAPK 
activity on cellular response to UV induced DNA damage. We believe that if p38 plays a 
key role in G2 DNA damage in response to UV, both biochemical inhibition of p38 
activity as well as RNAi knock-out of p38 should have phenotypic differences.  
We first investigated if inhibition of p38 affected the ability of cancer cells to 
enter mitosis following UV damage. Similar to the experiments involving Adriamycin as 
a DNA damaging agent, a selective Chk1-inhibitor was used as a suitable counter-point 
to selective p38 pathway inhibition 
To test the effect of p38 inhibition on response to UV damage, unsynchronized 
HeLa cells were treated with 50mJ/cm
2
 of UV irradiation, followed by the immediate 
addition of fresh media containing 320nM p38 inhibitor or 2 M Chk1 inhibitor. In 
addition, 120nM of nocodazole was added to the media to trap in mitosis, cells that may 
escape the G2 checkpoint arrest. Measuring phospho-Histone H3 as a marker for mitotic 
entry, HeLa cells treated with a Chk1 inhibitor had a dramatic increase in mitotic index, 
Chapter 3: Role of p38 MAPK in DNA damage G2 cell cycle control 
 
Author: Mark Phong   Page 130 of 291 
 
while cells treated with a p38 inhibitor had no significant increase in mitotic index over 
time (Figure 3.13A). 
In addition, the effect of UV irradiation and p38 inhibition was tested on 
synchronized HeLa cells. HeLa cells were synchronized by double thymidine block and 
upon release, dosed with 100mJ/cm
2
 UV irradiation. Following irradiation cells were 
incubated with fresh media containing p38 inhibitor or MK2 inhibitor or Chk1 inhibitor. 
Cells were harvested 10 hours after release from thymidine block, as by this time the 
majority of control (un-irradiated) cells were observed to be in mitosis (Figure 3.13B 
lane1). Effective inhibition of p38 and MK2, as measured by decreased levels of 
phospho-MK2 and phospho-HSP27 had no measurable increase in phospho-Histone H3 
levels, contrasting with the effect of Chk1 inhibition which had a significant increase in 
the mitotic marker (Figure 3.13B).  
This data showed that despite effective inhibition of p38 pathway activity, HeLa 
cells were still able to mount an effective checkpoint arrest to UV damage. Inhibition of 
Chk1 activity however, led to an abrogation of the UV damage induced G2 checkpoint 
arrest.  
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Figure 3.13:  Effect of biochemical inhibition of p38, MK2 and Chk1 on UV damage 
in thymidine synchronized HeLa cells. (A) Plot of mitotic index (%ph-Histone H3) 
at select time points of unsynchronized HeLa cells treated with either 320nM p38 
inhibitor or 2 M Chk1 inhibitor and 120nM Nocodazole. (B) Western blot assay of 
3mM thymidine synchronized HeLa cells, 10hrs post release from UV and treated 
with respective levels of biochemical inhibitors.  
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3.7.1  Transient KD of p38 was unable to abrogate UV DNA damage checkpoint in 
HeLa or U2OS cells 
 Similar to experiments involving Adriamycin, we were interested in examining if 
the effects observed with the use of biochemical inhibitors could be reproduced using an 
alternate mechanism of silencing p38 pathway such as RNAi. For this experimental 
series, commercially validated Qiagen siRNA oligonucleotides were used to transiently 
silence the p38 and Chk1 pathways. HeLa cells were transfected with siRNA 
oligonucleotides targeting p38 and Chk1 for 48 hours. Following 48hour transfection, 
cells were exposed to 50mJ/cm
2
 of UV irradiation, and incubated in fresh growth media 
with 120nM nocodazole which will trap in mitosis any cells that escape the G2 
checkpoint arrest (Figure 3.14).  
 
 
Figure 3.14:  Effect of siRNA KD of p38 and Chk1 on UV damage induced G2 
checkpoint arrest 
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 Transient siRNA knock-down of p38 in HeLa cells had no significant effect on 
the mitotic index, measured by phospho-Histone H3 levels over time. SiRNA knock-
down of Chk1 in contrast, led to an increase in phospho-Histone H3 levels, similar to 
what was observed by biochemical inhibition (Figure 3.14). Previous western blot data as 
shown in figure 3.11B, demonstrated that the siRNA oligonucleotides targeting both p38 
and Chk1 effectively reduced their protein expression. This data supports the 
observations made with LY479754, that inhibition or knock-down of p38 is unable to 
abrogate a UV DNA damage G2 checkpoint in HeLa cells. 
 
 In addition to experiments conducted in HeLa cells, work was done to reproduce 
the Manke et al, publication on UV-C damage in U2OS cells.  
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Figure 3.15: Effect of siRNA KD of MK2 with UV-C irradiation in U2OS cells. (A) 
FACS scatter plot of phospho-Histone H3 and DNA content of siMK2 or siGFP 
transfected cells +/- 20J/m
2
 UV-C irradiation and 165nM nocodazole. (B) Western 
blot assay of siMK2 or siGFP transfected cells +/- 20J/m
2
 UV-C irradiation and 
165nM nocodazole.  
 
Despite repeated attempts to reproduce the Manke et al results with siRNA knock-
down of MK2 and response to UV-C irradiation, we found that siRNA knock-down of 
MK2 did not compromise the ability of U2OS cells to mount an effective G2 DNA 
damage checkpoint arrest.  
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3.7.2 Biochemical Inhibition of p38 and Chk1 have no effect on UV induced G2 
checkpoint Arrest in A549 cells 
 Similar to the experimental regime for the study of Adriamycin induced G2 
checkpoint arrest, for UV damage we were interested to test if the the results were 
specific to the HeLa cell-line model system. To address this, A549 lung cancer cell-lines 
were synchronized by double thymidine block and upon release irradiated with 50mJ/cm
2
 
of UV irradiation.  Immediately following UV irradiation, fresh growth media containing 
500nM p38 inhibitor or 1.5 M Chk1 inhibitor were added. Cells were tracked for a 24 
hour time period post irradiation.  
In A549 lung NSCLC cell-lines, biochemical inhibition of p38 did not have any 
significant effects on the mitotic index of thymidine synchronized A549 cells (Figure 
3.16). We noted that control A549 cells released from thymidine block begin to enter 
mitosis around 12 hours after release from 2
nd
 thymidine block, and that nocodozole 
treated cells show steady accumulation in mitosis across a 24hour period. Within the 
same time period, biochemical inhibition of p38 and Chk1 kinase in a p53 functional 
background, were unable to abrogate the G2 checkpoint in response to UV damage 
(Figure 3.16). The results of A549 cells in response to UV damage are similar to results 
previously reported for Adriamycin DNA damage. The data presented in this section also 
supports the hypothesis that Chk1 kinase inhibition is not sufficient to over-come a G2 
DNA damage arrest in p53 wild-type cells. 
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Figure 3.16:  Effect of biochemical inhibition of p38,and Chk1 on UV damage in 
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 3.8  Activation of p38 at G2 without DNA damage does not inhibit entry into 
mitosis 
If p38 activity is indeed important in execution and maintenance of DNA damage 
checkpoint induced G2 arrest, activation of p38 outside of the checkpoint context may be 
expected to impede progression into mitosis by untimely activation of the G2 checkpoint.  
Therefore, we investigated the effect of non-genotoxic activation of p38 by anisomycin, a 
potent antimicrobial agent, on the onset of mitosis.  
In HeLa cells, we first synchronized cells using the CDK1-inhibitor (RO-3306) 
block/release protocol as discussed previously. As CDK1 inhibitor treatment effectively 
blocks cells at the G2 to M boundary, CDK1 inhibition was an appropriate 
synchronization agent to use for this experiment. Anisomycin is an antimicrobial agent 
that functions through inhibition of protein synthesis. Short term exposure of anisomycin 
has been shown to strongly induce p38 in cancer cells, without inducing DNA damage. 
We performed a series of experiments in HeLa cells to understand if strong stimulation of 
p38, with an anti-microbial agent was able to prevent or impede cells from entering 
mitosis following release from CDK1 block. Briefly, HeLa cells were synchronized with 
9uM CDK1 inhibitor (RO-3306) for 21 hours, and 1 hour prior to release from CDK1 
inhibitor block 2ug/ml anisomycin was added. Cells were subsequently released from 
CDK1 block by 3x fresh media wash out and tracked across time for entry into mitosis. 
HeLa cells released from CDK1 inhibitor block, entered mitosis within 1hour of 
release marked by high levels of phospho-Histone H3, as previously described (423). 
HeLa cells treated with anisomycin also entered mitosis in the same time frame as 
untreated control cells, despite anisomycin treatment inducing strong activation of p38 
(Figure 3.17).  
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Strong activation of p38 by anisomycin was unable to block cells from 
progressing into mitosis. Based on an Acumen multi-parametric high content imaging 
assay, HeLa cells treated with anisomycin were not impeded in their entry into mitosis 
following release from CDK1 inhibition (Figure 3.17A). Protein assays conducted at 
matching time points to identically treated HeLa cells show a strong activation of p38 by 
anisomcyin prior to CDK1 release and subsequently post release (Figure 3.17 lower 
panel). In addition, both untreated control and anisomycin treated cells displayed a steady 
decrease in ph-Histone H3 levels as time progressed, suggesting that cells were not being 
trapped in mitosis. This data suggests that despite high levels of p38 activity, cells were 
able to enter and exit mitosis normally. This implies that p38 activity alone was not 
sufficient to activate a cell cycle arrest at the G2 to M transition point.  
Taken together with data produced with the p38 inhibitor and siRNA experiments, 
it suggests that p38 does not have a role in the regulation of cells transiting through the 
G2 checkpoint into mitosis.  
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Figure 3.17:  Effect of non-genotoxic stimulation of p38 on ability of cancer cells to 
enter mitosis. (A) Acumen High content assay of mitotic index (ph-Histone H3) of 
HeLa cells first synchronized with 9uM RO-3306 (CDK1 inhibitor) and treated 
with 2ug/ml anisomycin, a 6 hour time series. (B) Western Blots of HeLa cells 
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3.13  Summary 
 In this study we explored p38’s role in the control of the G2 DNA damage 
checkpoint. Using a combination of chemical biology as well as RNAi technology, we 
explored if there was a strong causal link between p38 activity and the establishment and 
maintenance of the DNA damage G2 cell cycle checkpoint. To our surprise and contrary 
to some earlier publications, we found that in various cancer cell line models there was 
no strong link between p38 activity, and the establishment or maintenance of the G2 
DNA damage checkpoint. This was shown via biochemical inhibition of p38 with a 
potent and specific inhibitor to p38 having no effect on the establishment and 
maintenance of the G2 DNA damage checkpoint in multiple tumor cell-line models in 
response to Adriamycin, UV and MMS damage. In addition, effective siRNA knock-
down of p38 was also unable to relieve the G2 checkpoint in response to Adriamycin and 
UV in these cancer cell line models. We also investigated the effect of non-genotoxic 
activation of p38 through the use of the anti-bacterial agent anisomycin, and found that 
untimely activation of p38 was unable to prevent cells from entering mitosis.  
Taken together this shows that inhibition of p38 through both biochemical and 
siRNA approaches as well as non-genotoxic activation of p38 had no effect on the G2 
DNA damage checkpoint function in cancer cell-lines. Instead inhibition of Chk1 in a 
p53 functionally null environment led to deactivation of the DNA damage G2 cell cycle 
checkpoint. Our data corroborates previously published data suggesting that Chk1 kinase 
activity is critical for the proper function of the G2 checkpoint in a p53 functionally null 
environment (440). As the majority of cancers have dysfunctional p53 pathways, this data 
suggests that inhibition of Chk1 may be a promising therapeutic strategy for increasing 
sensitivity to chemotherapeutic agents.  
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In summary, Chk1 activity but not p38 activity is required for the proper 
activation and maintenance of the DNA damage G2 cell cycle checkpoint in p53 null, 
transformed cancer cell lines.    
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Chapter 4: Effect of p38 inhibition on TNF-α induced inflammatory 
response and apoptosis 
 
4.1  Background 
As p38 is activated in response to DNA damage, but its activity is not associated 
with the execution or maintenance of the G2 checkpoint (Chapter 3), it is possible that its 
activity is related to another critical cellular function that may be beneficial to cells 
exposed to physiological stress. To explore this possibility, we decided to return to the 
original context of p38 activation: response to inflammatory cytokines. The p38 MAPK 
was originally discovered as a 38 kDa protein that underwent rapid tyrosine 
phosphorylation in response to lipopolysacchride (LPS) stress (225). The role of p38 in 
inflammatory response is well studied and its involvement in the initiation of 
angiogenesis (399,472), contributing to the establishment of the tumor microenvironment 
has made it an attractive target for therapeutic intervention.  
 The tumor microenvironment consists of the cells surrounding and supporting the 
ability of a tumor mass to proliferate, grow and escape death. The tumor 
microenvironment or stroma is believed to be a key factor relating to the ability of tumor 
cells to initiate, grow and ultimately metastasize to secondary locations. The stroma 
consists of a mixture of extracellular matrix components, cells and extracellular matrix 
molecules such as growth factors and cytokines (229,298). 
 Activities associated with the establishment of a tumor microenvironment include 
angiogenesis, or the ability to stimulate and grow blood vessels to promote tumor growth 
have been linked to the plethora of growth factors and cytokines that are produced by the 
stroma tissue and from the tumor itself. (354) Over-expression and dysregulation of 
cytokines such as TNF-α and FGF-1 are believed to play key roles in the establishment of 
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a persistent inflammatory response that contributes to the growth of a tumor. The 
interaction between the stroma and the tumor cell is believed to be dynamic and changes 
throughout the different stages of tumor growth (417). In the initial stages of tumor 
development the surrounding stroma sets the ground for successful tumor establishment 
by increased production of cytokines, neutrophils and growth factors. The increased 
production of cytokines and growth factors leads to sustained inflammation at the site of 
tumor growth (353,428). 
 The link between the need to sustain an inflammatory microenvironment and 
tumor progression has led to research on the molecular pathways involved in 
inflammatory response. TNF-α is one of the cytokines that is believed to be highly 
dysregulated during tumor formation. While TNF-α has a role in normal immune 
response including the induction of extrinsic apoptosis pathway, high levels of TNF-α 
have been associated with increased tumorigenesis. (275,329,436). It is reported that high 
TNF-α levels contributes to the establishment and maintenance of the tumor 
microenvironment as well as aids in up-regulation of cell survival pathways. A key 
pathway in the response to mitogenic growth signals and a key player in sustained 
response to inflammation is the p38 MAPK pathway.  
 In this experiment, we explored the molecular pathways regulated by TNF-α 
induction in Calu6 cells through whole genome transcriptome analysis. As the p38 
MAPK pathway plays a critical role in the response to inflammatory cytokine induction, 
we wanted to explore the effect of p38 inhibition on the response to TNF-α treatment. 
The use of DNA micro-arrays (gene chip) creates a new unbiased paradigm in 
understanding gene regulation induced by TNF-α in Calu6 lung carcinoma cells. In the 
upcoming analysis, we investigated the global function of p38 MAPK in response to 
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TNF-α induction, through DNA gene chip technology. The study design for this 
experiment is detailed further in section 4.3 of this chapter.  
  
4.2  TNFα induces p38 MAPK activity in Calu6 Cells 
 While p38 is reported to be strongly activated by TNF-α treatment in both 
untransformed and transformed cells, the aberrant genetic nature of cancer cells requires 
that we check the degree of p38 induction in Calu6 cells prior to beginning a gene 
expression study. To test the effect of TNF-α, Calu6 cells are treated with 25ng/ml of 
TNF-α for a 7 hour time series (Figure 4.1).  
 
 
Figure 4.1: MAPK pathway is strongly induced by TNF-α treatment in Calu6 cells 
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Treatment with 25ng/ml TNF-α strongly and rapidly activates p38 MAPK in 
Calu6 lung carcinomas (Figure 4.1). TNF-α treatment also strongly activates other 
members of the MAPK family, as p44/42 (ERK1/2) and JNK (SAPK) also show 
concordant activation in the same timescale as p38 MAPK.  
 The rapid and sustained activation of p38 by TNF-α makes this an ideal stress for 
the study of p38 MAPK activity in response to inflammatory cytokines.  
 
4.2.1  LY479754 effectively inhibits TNF-α induced p38 activity 
 Similar to experimental assays discussed in chapter 3 of this thesis, we use 
LY479754 as a biochemical inhibitor of p38 MAPK activity. We show that in response to 
TNF-α induced activity, LY479754 effectively suppresses p38 MAPK activity.  
 
 
Figure 4.2:  Phospho-MAPKAPK2 levels as marker of p38 MAPK activity, post 
TNF-α treatment. 320nM LY479754 effectively inhibits p38 activity in 
response to TNF-α 
 
 As shown in figure 4.2, LY479754 effectively suppresses ph-MK2 levels post 
TNF-α treatment. LY479754 is thus an effective inhibitor of p38 MAPK activity induced 
by TNF-α treatment. 
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4.3  Gene-Chip Experimental Design 
 
Figure 4.3: Experimental design for Gene-Chip experiment involving p38 inhibitor 
(LY479754) and TNF-α in Calu6 Cells  
 
We tested 4 treatment conditions during this experiment: 1. DMSO only, as the 
control condition, 2. LY479754 only, as a control for single agent effects of the p38 
inhibitor, 3. TNF-α (25ng/ml) only, to understand the effect of TNF-α, and 4. TNF-
α+LY479754 to understand the combinatorial effect of p38 inhibition with TNF-α 
treatment.  
 All conditions were run in 3 independent biological replicates and 2 technical 
replicates each for a total of 6 affymetrix U133plus2 chips per condition.  
 
4.4  TNF-α induces inflammatory response genes in a time dependent manner 
 We first analyzed the gene expression data generated on the Affymetrix HG-
U133A chip, by examining the effect of TNF-α on Calu6 cells. As described in the 
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methods and materials chapter, significant genes were identified using the Significance 
Analysis of Microarray (SAM) algorithm developed by Tibshirani et al. (385,416) we 
used a local false discovery rate (FDR) of 0.1 and a pair-wise fold change of 1.5, as the 
cut-off for significance across each condition.  
 
 
Figure 4.4: Count of number of significant probesets at each timepoint for TNF vs 
DMSO comparison. 
 
 As can be observed in figure 4.3, upon TNF-α treatment, the number of 
significant genes (probesets) increases steadily across time, suggesting that TNF-α 
induces a strong transcriptional response with positive feedback loops leading to more 
significantly expressed genes at later time points. The number of genes induced by TNF-
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α and significantly modulated by a p38 inhibitor (LY479754), shows very strong activity 
in the early time points, but significantly reduced activity at the later time points. This 
suggests that inhibition of p38 may have strong effects on the early transcriptional 
response to TNF-α, but may not play as significant a role in the later time points.  
 The analysis of TNF-α effects on the Calu6 cells will be divided into three major 
time categories, mainly early, mid and late. The early timepoints will cover the 30min 
and 60min time point. The mid time period will cover the 2hour time point and the period 
of late will cover the 4 hour and 7 hour timepoint.  
 
4.5  Early transcriptome effects of TNF-α treatment on Calu6 cells 
 The early transcriptional response to TNF-α mainly consists of the activation of 
immediate early response genes. The immediate response of cancer cells to TNF-α 
induction is indicative of the key pathways that are induced to sustain the inflammatory 
response, a key factor to maintaining a suitable microenvironment for tumor growth. As 
seen in figure 4.4, we observed that 24 genes and 133 genes were significantly modulated 
by TNF-α at the 30min and 60min time points respectively.  An overlap of the genes 
modulated at the early time points by TNF-α showed that 90% of the genes modulated 
significantly at 30mins were also modulated at 60mins (Figure 4.5). Subsequent down-
stream analysis of genes for early transcriptional response to TNF-α, will be based on the 
60min gene list.  
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Figure 4.6: Compacted Heatmap of genes significantly modulated by TNF-α at 
60mins, with FC(log2)>1.5 filter & FDR<0.1 
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 As can be observed in figure 4.6, a significant number of genes are strongly 
modulated by TNF at the 60min time point. Genes strongly modulated by TNF-α at 
30min were also significantly modulated at 60min, representing a strong overlap in 
signaling pathways. The genes that are regulated by TNF-α include early response genes 
such as EGR2, IER3 and the cytokines IL8, CXCL3, the Jun kinase and members of the 
NFkB family. These genes have been characterized to play a role in stress response, 
mitogen response and inflammation 
 Due to the high dimensionality of gene expression data, we will highlight 
functional pathways of significance that are modulated by TNF-α treatment. Functional 
pathway analysis for the following sub-sections was conducted using two pathway 
analysis tools. The first is the DAVID tool published by the NIH for functional 
annotation and clustering of gene expression data (164,165). The second tool used in this 
analysis is the Ingenuity Pathway Analysis Tool (324,337). The DAVID tool relies 
primarily on Gene Ontology, protein domain (e.g. Interpro & PdB), and public pathway 
and interaction databases such as KEGG and Bind to functionally annotate gene lists. The 
Ingenuity pathway analysis tool relies on manual curation of literature, and a combination 
of public and proprietary protein-protein, protein-DNA databases to find networks and 
associations between expressed genes.  
In the following analysis we will also integrate the effects of the p38 inhibitor, as the 
primary purpose of this study to gain a mechanistic understanding of the effects of 
inhibition of p38 in response to TNF-α stress.  This will allow the highlighting of genes 
and pathways that are modulated by TNF-α and are also the target of a specific p38 
MAPK inhibitor.  
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I. TNF-α induces Immediate Early Response Genes that is blocked by p38 
inhibitor 
Among the groups of genes that were strongly modulated by TNF-α in the early time 
points, immediate early response genes such as IER2& IER3 as well as the EGR1 genes 
prominently stood out. In addition to the genes which are named to correspond with their 
function in early response to stress, the Jun transcription factor is also induced strongly, 
early in response to TNF-α treatment. These genes are associated with immediate early 
response to stress, and upon TNF-α treatment are strongly induced.  
To illustrate that p38 MAPK plays a key role in the propagation of early stress 
signals, we showed that addition of 320nM of p38 MAPK inhibitor LY479754 is capable 
of modulating the gene expression response of some of these early response genes. The 
normalized gene expression signals for this class of genes are illustrated in figure 4.7. 
The boxplots (plotted in log2 scale), illustrate a significant up-regulation of expression in 
the immediate aftermath of treatment with 25ng/ml of TNF-α. These plots show that p38 
plays a role in early response to stress by observing a statistically significant decrease in 
expression upon p38 inhibitor treatment (Figure 4.7).  
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Figure 4.7: Boxplot of selected immediate early response genes. Boxplot plot 




Table 4.1: Gene table of early response genes induced by TNF-α and modulated by 
LY479754 treatment 
 









201694_s_at EGR1 1.31170662 -0.856174
Early growth response protein 1 (EGR-1) (Krox-24 protein) 
(Transcription factor Zif268) (Nerve growth factor-induced 
protein A) (NGFI-A) (Transcription factor ETR103) (Zinc finger 
protein 225) (AT225). 
[Source:Uniprot/SWISSPROT;Acc:P18146]
205249_at EGR2 1.50800623 -0.750126
Early growth response protein 2 (EGR-2) (Krox-20 protein) 
(AT591). [Source:Uniprot/SWISSPROT;Acc:P11161]
201473_at JUNB 1.73309883 -0.727426
Transcription factor jun-B. 
[Source:Uniprot/SWISSPROT;Acc:P17275]
202081_at IER2 1.06134708 -0.311251
Immediate early response gene 2 protein (Protein ETR101). 
[Source:Uniprot/SWISSPROT;Acc:Q9BTL4]
Chapter 4: Effect of p38 inhibition on TNF-α induced inflammatory response and apoptosis 
 
Author: Mark Phong   Page 153 of 291 
 
II. TNF-α treatment activates death receptor signaling pathways, and anti-
apoptotic genes 
In normal physiological contexts, TNF-α treatment is known to induce cell death 
through the induction of the programmed cell death pathway. In the immediate aftermath 
of TNF-α treatment, genes and pathways related to the programmed cell death pathway 
as determined by the DAVID bioinformatics tool, were strongly induced by TNF-α 
treatment (Figure 4.8). The genes related to programmed cell death induced early by 
TNF-α treatment are plotted as a heatmap below.  
 
 
Figure 4.8: Genes belonging to death receptor and programmed cell death pathway, 
induced by TNF-α treatment in the early timepoints. 
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In cancer cells, normal extra-cellular signaling networks for cytokine and chemokine 
production have been subverted for the promotion and establishment of a tumor micro-
environment (175). As we explored the transcriptional response of cancer cells to TNF-α 
treatment, we focused on the effect of TNF-α on the activation of the extrinsic apoptosis 
pathway. A key hallmark of cancer highlighted by Weinberg et al (138), is the ability of 
cancer cells to evade apoptosis inducing signals. Among the many genes significantly 
modulated by TNF-α treatment, a number of them belonged to the negative regulation of 
apoptosis sub-cluster (as defined by functional cluster by DAVID tool). Specifically 
members of the IAP family of proteins (BIRC2 & BIRC3) as well as the BCL2 family of 
anti-apoptotic proteins were strongly induced in the early response to TNF-α (Figure 4.9).  
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Figure 4.9: Anti-apoptosis genes induced by TNF-α and modulated by p38-inhibitor 
(LY479754) at 60mins 
 
From the heatmap plotted as figure 4.9, it is clear that treatment with a potent p38 
inhibitor is able to alter the transcriptional profile of a number of anti-apoptotic genes 
induced by TNF-α treatment. In the immediate aftermath of TNF-α treatment, cancer 
cells respond to pro-apoptotic stimulus by inducing strong anti-apoptotic signals to 
counteract the effect of TNF-α. The p38 MAPK is implicated as a central responder to 
stress and in this context may play a cyto-protective role.  
In addition to genes modulated by both TNF-α and a p38 inhibitor we find that some 
members of the BCL2 family of genes are strongly modulated by the p38 inhibitor. These 
genes include the anti-apoptosis gene BCL2L1 (BCL-XL) and BCL2. We plot these two 
genes as separate box plots below.  
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Figure 4.10: Boxplots of log2 normalized MAS5 signal: Inhibition of p38 with TNF-α 
modulates BCL2 anti-apoptosis proteins BCL2 & BCL-xl 
 
This data suggests that in an early response to stress and to extrinsic pro-apoptotic 
stimuli, cancer cells activate strongly an anti-apoptotic mechanism. This is evident in the 
strong induction of inhibitor of apoptosis proteins (BIRC family) as well as the anti-
apoptotic members of the BCL2 family of protein (BCL2& BCL-xl). The p38 MAPK 
may play a role in the transduction of this cell survival signaling pathway as inhibition of 
p38 with a potent p38 inhibitor significantly impinges on the ability of Calu6 cells from 
mounting a fast anti-apoptotic response to TNF-α. This microarray data provides some 
potential mechanistic insight into the multi-faceted role of p38 MAPK in stress response. 
It may suggest that p38 plays a pro-cell survival role in the early response to stress or 
extrinsic pro-apoptotic stimuli. A table of genes functionally annotated to have a role in 
negative regulation of apoptosis (by NIH DAVID tool) is given below as table 4.2.  
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Table 4.2: Anti-Apoptotic Genes induced by TNF-α in early time points, all genes 
FDR<0.1 
 
Inhibition of p38 restores FAS death domain signaling in Calu6 cells 
In addition to the fast up-regulation of anti-apoptotic pathway components, we 
observed that Calu6 lung carcinoma cells also attempted to escape apoptosis through 
direct down-regulation of key intracellular components of the FAS, or death domain 
receptor signaling pathway. These components include FADD, the key intra-cellular 
signaling component of the FAS signaling pathway. In addition to FADD a number of 
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other signaling kinases connected to the death receptor pathway were down-regulated 
upon TNF-α treatment.  
 
 
Figure 4.11: Boxplots of log2 normalized MAS5 signal: Members of FAS signaling 
pathway are modulated by p38 inhibition in the early time points. 
 
Similar to observations that p38 inhibition affected certain components of the 
inhibitor of apoptosis pathway, inhibition of p38 led to the recovery or increased the 
expression of these FAS pathway components. This data again suggests that the p38 
MAPK pathway is linked to the pro-cell survival response to TNF-α induced stress.  
In summary, we observed that genes associated with anti-apoptotic function are 
induced strongly in early response to TNF-α. These genes include members of the IAP 
family and the BCL2 family of anti-apoptotic proteins. Inhibition of p38 with a potent 
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p38 inhibitor shows some effects on modulating some members of this gene list 
associated with the negative regulation of apoptosis. In addition we found that members 
of the FASR signaling pathway were down-regulated in response to TNF-α treatment, 
p38 inhibition reversed this down-regulation. Combining the observations from this gene 
expression study with the work discussed in chapter 3 of this thesis, we there is 
mechanistic evidence that p38 may play a role in regulating a cellular response to 
apoptosis. Specifically p38 MAPK may in a stress context play a role in the early 
induction of cell survival pathways to prevent the early onset of apoptosis. 
 
III. Inhibition of p38 modulates TNF-α induced cell proliferation 
TNF-α induction has been shown to increase cytokine and growth factor 
production in both cancer and untransformed cells (406). The over-expression of 
cytokines including TNF-α has been linked to the increased proliferation potential of 
tumor cells and the establishment of a suitable tumor microenvironment for tumor 
growth. We find that in the early time points post treatment with TNF-α, genes linked to 
increased cell-proliferation are strongly induced by TNF-α treatment.  
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Figure 4.12: Genes associated with increased proliferation, induced by TNF-α and 
modulated by p38i treatment 
 
In total, 31 genes associated with cell proliferation were strongly induced by TNF-α 
treatment at 60mins. Among the genes induced strongly in the early time points include 
pro-inflammatory cytokines such as IL6 & IL8 as well as TNF-α. As can be observed in 
the heatmap plotted as figure 4.12, treatment with a potent p38 inhibitor led to a 
significant decrease in a large number of genes associated with cell proliferation. A more 
detailed plot of some of these genes is given as boxplots (Figure 4.13).  
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Figure 4.13: Boxplot of selected cell proliferation genes induced strongly by TNF-α 
and modulated by p38 inhibition 
 
Genes such as PTGS2 (alias: Cox-2) and IL6 and IL8 are strongly associated with 
induction of pro-inflammatory response and are observed to increase dramatically almost 
immediately upon treatment with TNF-α. BMP2 is a morphogenic protein strongly 
associated with bone and osteoclast formation. BMP2 has primarily been linked to TGF-
 signaling, but is also observed to increase in expression levels upon cytokine 
stimulation. BMP2 is strongly induced by TNF-α treatment and is also observed to be 
inhibited significantly by p38 inhibition. The significant inhibition of cell proliferation 
signaling through inhibition of p38, confirms in this study the link between p38 signaling 
and cell proliferation. Inhibition of p38 strongly modulated a significant number of genes 
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associated with proliferation in the early time points, where 19/41 (45%) of genes 
(probesets) associated with cell proliferation were significantly modulated by p38 
inhibition. The gene table associated with early TNF-α induced cell-proliferation is 
displayed as table 4.3.  
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Table 4.3: Genes induced early by TNF-α associated with cell proliferation. A 
significant portion of these genes are strongly modulated by p38 inhibition 
(LY479754), all genes FDR<0.1 
 
Summary of Early Time Points (30mins & 60mins) 
 In the immediate aftermath of TNF-α treatment, a strong induction of a number of 
physiological pathways and functional clusters including the immediate early response 
stress pathway, the regulation of apoptosis pathway and the cell proliferation pathway. 
Within these functional clusters, genes and pathways associated with pro-inflammatory 
signaling were strongly induced by TNF-α, and were attenuated by a p38 inhibitor. In 
addition to inflammation, a significant number of genes related to apoptosis and 
proliferation pathways were significantly modulated by inhibition of p38. Modulation of 
these pathways provides some mechanistic insight into the potential roles of p38 in the 
immediate response to stress, and to pro-apoptotic extrinsic death induction by TNF-α.  
 
4.6 Effect of TNF-α and p38 inhibition at the mid time point (2hrs) 
 As can be observed in the summary plot of the number of genes modulated by 
TNF-α and the p38 inhibitor in figure 4.4, the mid time point of this study has an 
increasing number of genes induced by TNF-α treatment and has the largest number of 
genes also modulated by p38 inhibition. The 2 hour time point in this study could be the 
“cross-over” point, where the effect of TNF-α triggers a host of secondary signaling 
pathways and the effect of the p38 inhibitor has potential maximum transcriptional effect.  
 A summary of the top 10 functional pathways/networks as determined by the 
Ingenuity Pathway Analysis (IPA) tool is provided below (Table 4.4).  
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Table 4.4: Top functional pathways for TNF-α+LY479754 at 2hour time point  
 
I. TNF-α induces cell developmental and differentiation pathways 
We found that after 2hours of TNF-α treatment, approximately 600 genes (probesets) 
were significantly modulated by TNF-α. Of these genes, approximately 30% were 
modulated by a p38 inhibitor. The largest functional category according to both DAVID 
and Ingenuity pathway analysis tools was related to cell development and differentiation 
pathways.  
 
Top Functions Score Focus Molecules
Protein Synthesis, Cellular Compromise, Cellular Growth 
and Proliferation 52 31
Cancer, Hematological Disease, Cellular Development 47 29
Gene Expression, Cellular Development, Nervous 
System Development and Function 44 28
Cancer, Cell Death, Connective Tissue Disorders 42 27
Gene Expression, Carbohydrate Metabolism, Small 
Molecule Biochemistry 35 24
Cellular Development, Organ Morphology, Organismal 
Functions 34 24
Embryonic Development, Tissue Development, Cellular 
Development 29 21
Infection Mechanism, Cellular Development, Gene 
Expression 27 20
Cancer, Hematological Disease, Ophthalmic Disease 25 19
Cellular Assembly and Organization, Developmental 
Disorder, Cellular Growth and Proliferation 23 18
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Figure 4.14: Heatmap of genes classified as developmental genes, significantly 
changed by TNF-α. A large sub cluster of genes are also modulated by p38i 
(LY479754) treatment. 
 
Within the functional cluster of genes related to growth, development and cell 
differentiation, we found members of a number of key signaling pathways whose 
deregulation leads to oncogenesis. These pathways include the TGF-  signaling 
pathway, the MMP pathway and the Hedgehog/Notch signaling pathway. The 
components of these pathways are plotted as boxplots below. Besides the genes plotted 
for illustration in figure 4.15 below, other components of the TGF-  and the 
Hedgehog/Notch signaling pathway can be observed being modulated by TNF-α in this 
mid-time point.  
Chapter 4: Effect of p38 inhibition on TNF-α induced inflammatory response and apoptosis 
 
Author: Mark Phong   Page 166 of 291 
 
 
Figure 4.15: Boxplot of selected development and cell differentiation genes, induced 
by TNF-α and modulated by p38-inhibition. 
 
To give some context to the regulation of cellular development genes by p38 
inhibition, genes modulated in this section were analyzed through network analysis in 
IPA. The nearest neighbor linkage analysis in IPA produces a network of putative 
relationships among genes in a gene list and is presented as an acyclical directed graph. 
The sub-network for developmental genes modulated by p38 inhibition is presented in 
figure 4.16.  
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Figure 4.16:  IPA network analysis of cellular development genes modulated by p38i (LY479754) at 
2hours 
 
A potent p38 inhibitor is able to influence the transcriptional response of a 
number of key developmental signaling pathways including components of the TGF-  
and Hedgehog/Notch signaling pathway (Figure 4.16). While TNF-α has been studied 
extensively as one of the key components of immune system stimulated death receptor 
signaling, its dysregulation and over-expression could promote sustained inflammatory 
signaling leading to induction of a host of growth and proliferation pathways. 
Mechanistically we have identified that p38 MAPK signaling may be critical to the early 
induction of a number of these pathways, suggesting that a p38 MAPK inhibitor may be 
a useful therapeutic agent targeting the formation and establishment of a successful 
tumor microenvironment.  
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II. TNF-α induces both pro and anti-apoptotic signaling pathways that are marginally 
counteracted by inhibition of p38.  
 Following 2hours of TNF-α treatment, the immediate early response to the stress 
has activated a host of secondary signaling pathways that in turn activate their own 
respective down-stream signaling pathways. In the early time points, we observed a 
strong up-regulation of some pro and anti-apoptotic factors, many of which were also 
modulated partly by p38 inhibition. At this time point, many more components of the 
apoptosis signaling machinery have been activated. Some components of this machinery 
show some dependence on p38 signaling, other components behave in a p38 independent 
manner. At this time point we also observed within this functional cluster, a group of 
genes that were down-regulated by TNF-α treatment, but whose expression recovers 
upon p38 inhibition. We will separately dissect each of these groups of genes in order to 
gain a better mechanistic understanding of p38 activity in response to TNF-α stimulation 
in Calu6 lung cancer cells. 
 
 
Figure 4.17:  Venn Diagram of TNF-α and TNF-α+LY479754 modulated apoptosis 
genes at 2hrs time point 
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A large number of genes functionally related to apoptosis are affected by TNF-α, 
2 hours post treatment. A small but significant number of these genes are directly 
modulated by a p38 inhibitor in the same time-frame. Functional analysis of expressed 
genes suggests that there are two classes of genes modulated within this functional 
cluster, one that depends on p38 signaling and another class that does not. We will deal 
with each class of genes separately in the following sections.  
A heatmap plot of genes involved in apoptosis and modulated by the p38 inhibitor is 
plotted in figure 4.18. 
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Figure 4.18:  Heatmap of 22 genes related to apoptosis, modulated by p38 inhibitor in 
conjunction with TNF-α treatment at 2hrs.  
 
A number of the genes classified as being involved in apoptosis and modulated by 
the p38 inhibitor belong to cytokine, chemokine and growth factor families. These 
include IL6 & IL8 as well as TGF- . The transcription factor FOXO1A is also among 
the genes strongly induced by TNF-α and down-regulated by a p38 inhibitor. A table of 
genes classified by DAVID related to apoptosis and significantly modulated by TNF-α 
and the p38 inhibitor is presented in table 4.5.  
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Table 4.5: Genes functionally related to Apoptosis, induced by TNF-α and 
modulated by p38i (LY479754), all genes FDR<0.1. 
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A further network analysis of these genes puts into pathway context some of the 
potential relationships between the genes in the list (Figure 4.19). 
 
 
Figure 4.19:  A pathway/network diagram of the top network of genes significantly 
regulated by p38 inhibitor LY479754 and TNF-α at the 2hrs timepoint 
 
As can be observed in the pathway/network diagram (Figure 4.18), p38 inhibition 
modulates the expression of many anti-apoptotic and pro-cell survival genes, including 
CREB3 and BIRC2. It also increases the expression of FAS, death domain associated 
protein (FADD), suggesting that inhibition of p38 leads to the decrease in certain anti-
apoptosis genes and up-regulates other pro-apoptosis genes. 
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The second category of genes functionally related to apoptosis in the mid-time point 
is strongly modulated by TNF-α but are generally not significantly affected by a p38 
inhibitor. These genes are part of a transcriptional response that diverges away from 
direct p38 pathway control, beginning at this time point. 
We note that in the unsupervised clustering shown in Figure 4.20, the TNF-α 
condition and the TNF-α+LY479754 conditions are intermingled and undistinguishable 
from each other. These are genes whose transcriptional response at 2hrs are generally 
unaffected by inhibition of p38 signaling.   
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Figure 4.20:  Heatmap of 57 genes (probesets) functionally classified as apoptosis 
related, strongly induced by TNF-α but unaffected by p38 inhibition 
(LY479754). 
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Table 4.6: Apoptosis related genes induced strongly by TNF-α, but not modulated 
significantly by p38i (LY479754) at 2hr time point, all genes FDR<0.1 
 
At the two hour time point, it is observed that genes and pathways strongly 
regulated by TNF-α, are relatively unaffected by p38 inhibition. These genes and 
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pathways are activated and behave independently of p38 regulation. Some key genes that 
stick out strongly at this time point include anti-apoptotic genes relating to the IAP 
proteins BIRC2 and BIRC3. We had observed a slight down-regulation of both of these 
genes at earlier time points, with p38 inhibition, but this cyto-protective pathway seems 
to increase in intensity as time progresses on through this experiment. This data suggests 
that Calu6 cancer cells may escape death inducing TNF-α extrinsic apoptosis pathway 
activation by strong up-regulation of IAP proteins. We note that at earlier time points, 
p38 inhibition impinges upon this pathway, however at later time points, alternative 
signaling pathways seem to be able to over-come blockade of p38 signaling to enable 
these anti-apoptotic pathways to activate. In addition to anti-apoptosis pathways behaving 
independently of p38 activity, we observe that a number of transcription factors related to 
cell growth and proliferation are also activated at this time point. These transcription 
factors include the Creb1, RELB and Maff, which relate to diverse pathways such as 
NFkB (RELB), cell survival (Creb1) and transcription regulation (Maff). The strong 
induction of Creb1, may be suggestive of additional trans-activation of pro-survival genes 
to help in evasion of TNF-α induced apoptosis.  
 
II. TNF-α induces genes that regulate the Cell Cycle 
Another functional cluster identified in the genes significantly modulated by 
TNF-α at the 2hrs time point was the cell cycle related cluster. These genes have been 
functionally documented to play a role either in regulation of cell cycle or play a role in 
the progression of the mammalian cell cycle. As previous chapters of this thesis have 
focused extensively on gaining a mechanistic understanding of p38 MAPK’s role in cell 
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cycle progression and control, this cluster of genes is of particular interest to this study. 
The genes identified to belong to this cluster are plotted below. 
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Figure 4.21: Cell cycle genes are modulated by TNF-α, but relatively unaffected by 
p38-inhibitor: (A) Heatmap of 24 genes induced by TNF-α, related to cell cycle 
as determined by SP_PIR database (protein super-family database), all genes 
FDR<0.1 (B) 21 Cell cycle related genes down-regulated by TNF-α and 
unaffected by p38i (LY479754), all genes FDR<0.1 
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We observed that a significant number of genes related to the progression or 
regulation of the cell cycle were induced or repressed by TNF-α treatment at the 2hrs 
time point. It is very interesting to note that in this unsupervised clustering, the TNF-α 
conditions and the TNF-α+LY479754 conditions cluster together. This shows that these 
genes related to the progression or regulation of the cell cycle are relatively unaffected by 
inhibition of p38 at this time point. Certain genes worth highlighting from this functional 
cluster include PLK1 (down), PLK2 (up) and CDKN1A (up) genes. The exception to this 
general observation was the gene GADD45A, a gene related to DNA damage arrest 
response. However we find that inhibition of p38 does not down-regulate GADD45A, 
instead inhibition of p38 leads to even higher expression of GADD45A, when compared 
to both DMSO control and to TNF-α treatment alone. The normalized expression patterns 
of these highlighted genes are illustrated as boxplots below.  
 
Figure 4.22:  Boxplots of selected Cell cycle related genes, modulated by TNF-α at 
2hrs time point. 
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IV. TNF-α induces NFkB signaling that is not significantly modulated by p38 inhibition 
at 2hours 
The NFkB pathway is a central pathway involved in stress response, cytokine 
production and induction of apoptosis. It is one of the main pathways believed to be 
induced by extrinsic cytokine signaling, and is reported to be responsive to TNF-α 
induction. Among the genes found significantly modulated by TNF-α in the 2hrs time 
point, we found a significant functional cluster associated directly with NFkB signaling. 
The normalized gene expression of these genes is plotted below. 
 
 
Figure 4.23:  Heatmap of NFkB genes induced by TNF-α treatment at 2hrs time 
point, all genes FDR<0.1 
 
Chapter 4: Effect of p38 inhibition on TNF-α induced inflammatory response and apoptosis 
 
Author: Mark Phong   Page 181 of 291 
 
Genes and pathways associated directly or down-stream of NFkB signaling are 
induced by TNF-α treatment. In figure 4.23, we plotted genes that have the associated 
GO term: GO:0007249~I-kappaB kinase/NF-kappaB cascade. We find that the majority 
of these genes are strongly induced by TNF-α treatment, in concordance with previously 
reported studies linking the NFkB pathway with TNF-α response. We also find that the 
majority of the genes linked to the NFkB pathway do not have strong transcriptional 
response to a p38 inhibitor. While the genes can be segregated into two distinct clusters 
based on unsupervised clustering, the degree of modulation by the p38 inhibitor is very 
slight, with most being statistically insignificant (FDR, p-val >0.1) and fold-changes 
<0.5.  
This observation leads to the conclusion that at the mid-time point of this study, the 
p38 pathway and the NFkB pathway do not experience significant cross-talk in their 
signaling networks. High activity of the NFkB pathway at this time point, moving 
forward would suggest an alternative or parallel pathway from the p38 MAPK pathway 
for cancer cells to maintain a high expression of cytokine and chemokines. In addition, 
the induction and regulation of apoptosis pathways are closely tied to NFkB signaling, 
which may suggest a plausible explanation as to the lack of effect of a p38 inhibitor on 
modulating a large number of apoptosis related genes in this time point. From a signaling 
pathway standpoint, it is likely that the cell has transitioned from an immediate early 
response pathway like the p38 MAPK pathway to a more long term responder of stress in 
the NFkB pathway. This does not necessarily negate the role of p38 in the long term 
response to stress, it just illustrates that a cancer cells has multiple parallel pathways in 
which to respond to external stress or mitogenic signals. Genes directly related to the 
NFkB pathway are tabulated in table 4.7 below. 
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Table 4.7: NFkB related genes directly modulated by TNF-α treatment at 2hrs, all 
genes FDR<0.1 
 
Summary of Mid-Time point (2hrs) 
 In this time point we observed a very large increase in the number of genes 
positively and negatively regulated by TNF-α treatment. We also observed the largest 
number of genes that were modulated by a p38 inhibitor (LY479754) versus the TNF-α 
treatment condition. In this section we highlighted 4 major functional clusters that were 
modulated by TNF-α, of which 2 of these functional clusters were observed to not be 
sensitive to p38 inhibition. The two functional clusters that were observed to be sensitive 
to p38 inhibition were the cell proliferation, development and differentiation cluster and 
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the regulation of apoptosis cluster. In the cell proliferation/development/differentiation 
cluster, we found that a large number of induced genes including cytokines such as IL6, 
IL8 and TNF-α were inhibited by a p38 inhibitor. The transcriptional repression of this 
class of genes, suggests that p38 MAPK is required for these genes to effectively respond 
to TNF-α stimulation. In the apoptosis functional cluster we identified 2 groups of genes, 
the first group whose expression was observed to be sensitive to a p38 inhibitor, and a 
second group whose expression was insensitive to p38 inhibition. This data suggests that 
similar to the effects observed in the early time points, p38 plays a role in the regulation 
of apoptosis, however there is clear evidence that there are parallel signaling pathways 
that regulate apoptosis in addition to p38 signaling. One such pathway that has come up 
prominently in this time point is the NFkB pathway. NFkB response to TNF-α is well 
documented so it is no surprise to observe strong induction of NFkB signaling in 
response to TNF-α. We observed that the transcriptional response of the majority of 
genes belonging to the NFkB pathway were not responsive to a p38 inhibitor, suggesting 
that at this time point, we observe little cross talk between the p38 and NFkB pathway. 
Lastly, as a large proportion of this thesis is focused on gaining a mechanistic 
understanding of p38 MAPK in the context of control of the cell cycle. We observe that 
TNF-α, a non-genotoxic stress induces a fairly large transcriptional response in genes 
related to cell cycle progression or cell cycle regulation. We observe that inhibition of 
p38 in the most part has little effect on genes functionally related to the cell cycle. This 
lends some support to the observation that p38 activity at the G2 cell cycle arrest 
checkpoint may be associated with a stress response and not a cell cycle arrest phenotype. 
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4.7  Effect of TNF-α treatment and p38 inhibition at the late time points (4hrs & 
7hrs) 
 In the early (30min & 60mins) and mid (2hrs) time points, we observed 
significant induction of gene expression in response to TNF-α treatment. Many of the 
genes induced in the early and mid time points in this study belonged to early response 
signaling pathways. In the later time points, however we find that a lot of the signaling 
and response networks are likely due to sustained activation or longer term response 
pathways in response to stress. As observed in figure 4.3, the number of genes (probsets) 
significantly modulated by TNF-α at these two later time points is very large. We present 
the significant genes at this time point as a collection of functionally related pathways. 
We will highlight a number of key pathways that are of interest to this study. In table 4.8 
below, we present the top 15 (neighborhood) gene networks of relevance derived from 
the Ingenuity pathway analysis tool, for genes modulated by TNF-α at the late time 
points.  
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Table 4.8: Top networks for genes modulated by TNF-α at the late time points. 
 
 As detailed in table 4.8 above, TNF-α induces a host of physiological pathways 7 
hours post treatment. The functional pathways with the highest clustering score include 
the cell death, cell to cell signaling, cellular development and inflammatory response. As 
many of these functional pathways have been observed in the earlier time points, within 
each section we will also examine the pattern of gene expression across time for the 
group of genes that are highly expressed across time.  
 
I. TNF-α induces sustained pro and anti-apoptotic signaling  
As observed in other time points during this study, TNF-α treatment induces a strong 
apoptotic response in Calu6 cells. Genes related to the induction and the regulation of 
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apoptosis are among the top functionally related clusters in the large group of genes 
modulated by TNF-α treatment. We plot these genes as a heatmap below. 
 
 
Figure 4.24: Heatmap of Cell Death related genes induced by TNF-α at the late time 
points (4hrs & 7hrs), all genes FDR<0.1 
 
A large number of the cell death and apoptosis related genes induced strongly by 
TNF-α are not strongly modulated by p38 inhibition at this time point (Figure 4.24). This 
is likely due to the large number of feedback and parallel signaling pathways already 
induced by this time. There are a number of genes however whose transcriptional 
response is degraded by p38 inhibition even at this later time point. These genes whose 
expression is still affected by p38 inhibition, allow us to dissect the apoptosis and cell 
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death pathways to understand what genes and pathways still depend on p38 kinase 
activity.  
Genes specific to induction of apoptosis are plotted as a sub-network to illustrate 
relationships among genes. 
 
Figure 4.25: Ingenuity pathway analysis network diagram of apoptosis related genes 
strongly induced by TNF-α at late time points.  
 
The network diagram (Figure 4.25) shows a strong interconnected relationship 
between genes strongly induced by TNF-α and the NF B pathway, suggesting that by the 
late time points, early response signaling through the p38 pathway has been replaced by 
signaling through the NF B pathway.  
In addition to pro-apoptotic genes induced at the late time points, a few genes 
observed to be highly expressed in the late time points have been observed to be 
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significantly expressed in the earlier time points. Among the genes, whose activity is 
consistently up-regulated by TNF-α treatment across time is a small family of anti-
apoptosis genes, including the IAP (Inhibitor of Apoptosis) proteins. As the IAP proteins 
are strongly expressed across time in response to TNF-α treatment, we conclude that they 
play a major role in protecting Calu6 lung cancer cells from TNF-α induced apoptosis 
(Figure 4.26).  
 
 
Figure 4.26:  IAP and other pro-cell survival genes are strongly expressed across time 
in response to TNF-α treatment 
 
We find that while the number of genes modulated strongly by p38 inhibition at 
this time point is small, they still consist of a number of highly relevant genes for the 
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control of apoptosis. The gene CLU (Clusterin) has been implicated to interact and 
inactivate the pro-apoptosis BCL2 protein Bax. The gene TRADD is a central 
component of the TNF receptor death domain complex. The FOSL2 is one of 4 members 
of the FOS family that is known to play a role in cell proliferation and survival. Finally 
Casp6 is central component of the central caspase activation pathway. These genes and 
others all show a similar pattern in that TNF-α decreases apoptosis potential while 
inhibition of p38 restores the expression to levels consistent with a more pro-apoptotic 
setting. A subset of these genes is plotted as boxplots below (Figure 4.27).  
 
 
Figure 4.27:  Boxplot of apoptosis related genes, modulated by p38 inhibition at the 
late time points (4hrs & 7hrs) 
 
 Calu6 cells respond to TNF-α stress by strong activation of anti-apoptotic proteins 
or reduction of key components of the pro-apoptotic signaling cascade at late time 
points. At early and mid time points, p38 activity was found to play a role in supporting 
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a pro-survival response to TNF-α. The complication as time progresses in this study is 
the host of parallel signaling pathways that have been activated by this time point. Many 
of these signaling pathways (i.e. NF B) play a strong role in the control of apoptosis and 
genes that may have depended on p38 activity in the earlier time points may now be 
induced by parallel signaling pathways.  
 A table annotating the genes discussed in this section is displayed below as table 
4.9. 
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Table 4.9: Top 40 Apoptosis Genes modulated by TNF-α in the late time points 
 
II. TNF-α induces sustained Inflammatory response  
Among the many top functional clusters identified among the genes induced by TNF-
α treatment at the late time points is the cluster for inflammatory response. As TNF-α is 
known to play a key role in inflammatory cytokine production, this observation should 
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not be surprising. We observed throughout the different time points in this study, the 
onset, and continuous induction of pro-inflammatory pathways. We find that TNF-α 
triggers a strong transcriptional response to sustain an inflamed phenotype. This 
contributes to the ability of cancers cells to maintain an inflamed tumor 
microenvironment, which is ideal for increased cell proliferation and tumor growth. In 
this section we highlight the key signaling and pathway components that contribute to 
this sustained inflammation response. 
 
Figure 4.28: Heatmap of Genes associated with inflammatory response at late time 
points (7hrs), all genes FDR<0.1  
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Among the genes related to inflammation strongly induced at the late time point, 
include a number of inducible cytokines including IL8, IL6 and CXCL3 (Figure 4.28). In 
addition to evidence of positive feedback loops inducing addition cytokine production, 
we observed that TNF-α induced multiple components of the NF B pathway strongly. 
The expression of these genes shows that Calu6 cells increase pro-inflammatory 
molecules in response to TNF-α induction. When taken into context with increased anti-
apoptotic gene induction as described in preceding sections, it shows that TNF-α 
treatment in a cancer setting leads to an increased inflammatory response with a marked 
decrease in associated apoptosis induction.  
This data shows again that NF B plays a role in the induction of cytokine 
production in response to TNF-α treatment. As the p38 pathway was responsible for early 
induction of cytokine production, in the late time points, this role has been taken over by 
the NF B pathway, leading to sustained cytokine production. This switch from a p38 
dependent (early response) to an NF B dependent signaling network is a possible 
explanation as to why inhibition of p38 no longer significantly affects the transcriptional 
response rate of inflammatory cytokines at the later time points. This suggests that at the 
later time points, the NF B pathway plays a strong role in the induction of both cytokine 
production pathways as well as signaling pathways that regulate the induction of 
apoptosis. 
This provides a potential mechanistic understanding of how cancer cells are able to 
hijack dual functioning cytokines such as TNF-α to promote the rapid establishment of a 
tumor microenvironment without undergoing sustained cell death through apoptosis 
induction. In addition we find that by this time in the study, inhibition of p38 has only 
marginal effects on the components of the inflammation response. A plausible 
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explanation as stated earlier is the induction of a host of parallel or redundant signaling 
pathways that lead to the induction of inflammatory pathways despite p38 inhibition. A 
table describing the gene expression of the genes discussed in this section is presented 
below (Table 4.10).  
 
Table 4.10: Inflammatory genes induced by TNF-α at the late time points 
 
III. TNF-α induces genes linked to progression of cell cycle 
The last major category of genes that we explored in-depth in this analysis are the 
genes related to the progression of the cell cycle. Similar to observations at the mid-time 
point, we find a sizeable functional cluster of genes induced by TNF-α treatment related 
to the progression and control of the cell cycle. In general, sustained exposure to TNF-α 
seems to increase genes related to progression of the cell cycle and cellular proliferation.  
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Figure 4.29:  Heatmap of Genes associated with Cell cycle progression and 
regulation at late time points (7hrs), all genes FDR<0.1  
 
Similar to observations made at the 2hrs time point, TNF-α induces strong 
expression of genes linked to cell cycle progression or increased cell proliferation. For 
the majority of these genes, we find that inhibition of p38 had little impact on their 
transcriptional response. Genes within this differential list, linked specifically to 





NMN and CCNG2 (cyclin G2). Detailed boxplots of these genes are provided below.  
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Figure 4.30:  Boxplot of select cell cycle regulator genes, induced by TNF-α but 
unaffected by p38 inhibition at late time points (7hrs), all genes filtered by 
FDR< 0.1 
 
Many of the cell cycle regulatory proteins induced by TNF-α at the late time points 
were also observed to be induced at other time points. We observed that a large number 
of the genes linked to cell cycle regulation or progression were not significantly impacted 
by p38 inhibition. We illustrate this by plotting some of these cell cycle genes in line 
graphs across time. (Figure 4.27) we note that some of these genes have cyclical 
expression cycles. It is not clear if the cyclical nature of their gene expression is due to 
the nature of their activation pathway or if this is an aberration of the microarray 
platform.  
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Figure 4.31:  Line plots of select cell cycle regulator genes, induced by TNF-α but 
unaffected by p38 inhibition across time, all genes filtered by FDR< 0.1 
 
TNF-α in the context of Calu6 lung carcinoma cells, strongly induces proliferation 
through up-regulation of many genes associated with progression of the cell cycle as well 
as cellular proliferation. Similar to what was observed at the 2hrs time point, inhibition of 
p38 MAPK seemed to have little effect on the transcriptional expression of the majority 
of the genes associated with cell cycle progression. This suggests that at a transcriptional 
level, inhibition of p38 MAPK does not have any dramatic impact on genes related to the 
cell cycle, and hence may not have much impact on the ability of cells to progress 
through the cell cycle during a stress event.  
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Summary of Late Time Points (4hrs & 7hrs) 
 The 4hrs and 7hrs time points are the last time points for this microarray study on 
the effects of TNF-α and concurrent p38 MAPK inhibition of the Calu6 lung carcinoma 
cell line. As time progresses we find that the number of genes significantly induced or 
modulated by TNF-α increases dramatically. Post 7 hours of TNF-α treatment, we find a 
dramatic increase in gene expression versus the earlier time points. Integrating the 
statistics of genes modulated by p38 inhibition, we find that the over-all count of genes 
strongly modulated by p38 inhibition drops off considerably by 7hours post TNF-
α+LY479754 treatment.  
 In the late time points, we observed the largest functional cluster of genes relating 
to the induction of apoptosis/cell death and cellular development/differentiation. Other 
large functional clusters identified within the list of statistically significant genes 
included clusters for inflammation response and for cell cycle control. We found in 
detailed analysis of the apoptosis/cell death cluster that there was a consistent 
transcriptional pattern of up-regulation of anti-apoptosis components such as IAP 
proteins and anti-apoptotic members of the BCL2 family. In addition to direct up-
regulation of anti-apoptosis gene pathways, we also found a concerted effort in Calu6 
lung cancer cells to down-regulate key components of the death receptor signal 
transduction pathway. Among these genes included down-regulation of TRADD, a 
critical complex member of the TNF-α death receptor pathway and to a lesser extent 
FADD, a critical component of the FAS signaling pathway. Inhibition of p38 MAPK 
seems to be able to reverse this pro-survival trend through recovery in expression of pro-
apoptotic genes as well as down-regulation of pro-survival genes like BCL-xl.  
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 We note that at a transcriptional level, inhibition of p38 does not seem to have 
much impact on genes related to the regulation or progression of the cell cycle. Sustained 
treatment of TNF-α does seem to have sustained impact on cell cycle and proliferation 
genes. Sustained exposure to TNF-α seems to induce strong cellular proliferation 
signaling.  
 
4.8 In-Vitro Validation 
To confirm some of the observations and hypothesis generated from the analysis 
of the microarray data, a small series of in-vitro validation was carried out in Calu6 cells.  
Within the context of the original microarray experiment, p38’s role in immediate 
early response was validated through RT-PCR assays at LRL. 
However, we were interested to test the hypothesis that inhibition of p38 led to a 
degradation of anti-apoptosis response to TNF-α treatment. To test this hypothesis, 
unsynchronized Calu6 cells were treated in paired fashion with TNF-α or TNF-
α+LY479754 and tracked over a 48 hour period at the times indicated (Figure 4.32).  
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Figure 4.32:  Western blots of TNF-α and TNF-α+LY479754 treated Calu6 cells over 
a 48hour time series. 
 
In Calu6 cells, LY479754 effectively inhibits p38 pathway activity, in response to 
TNF-α treatment (Figure 4.32, phospho-MK2 blot). TNF-α induces apoptosis in Calu6 
cells over the 48 hour time periods with or without the p38 inhibitor. However, Calu6 
cells treated with a p38 inhibitor seem to have low levels of parp-cleavage much earlier 
than cells treated only with TNF-α (Figure 4.32). Levels of BCL2 and BCL-xl are also 
decreased at the later time points in cells treated with the p38 inhibitor. Lastly, expression 
of the FAS receptor death domain (FADD) decreases dramatically with TNF-α treatment, 
in line with what was observed in the transcriptional data. FADD protein levels remain 
strongly expressed in Calu6 cells treated with the p38 inhibitor.  
This data confirms some aspects of the hypothesis generated from the microarray 
data. We observed that in response to TNF-α, components of the BCL2 anti-apoptosis 
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family are strongly induced, while elements of the extrinsic apoptosis pathway are down-
regulated. The expression of these proteins is reversed with p38 inhibition, leading to the 




 In this chapter we explored the potential role of p38 MAPK in response to TNF-α 
treatment in the Calu6 lung carcinoma cell line. DNA microarrays allow the simultaneous 
measurement of tens of thousands of gene transcripts, giving an unbiased view of the 
effect of stress and damage response on the transcriptome. In this study we utilized DNA 
microarrays to gain a mechanistic insight into the role of p38 MAPK in the response of 
cells to TNF-α treatment. TNF-α is a secreted cytokine responsible for the induction of 
extrinsic apoptosis pathway as well as for inflammatory response. As solid tumors 
require the establishment of an appropriate tumor microenvironment for successful 
growth and proliferation, the dysregulation of inflammation pathways is considered one 
of the first steps in tumor formation. Our interest was to gain a mechanistic understanding 
of p38 MAPK in the context of inflammatory and non-genotoxic stress response.  
 We found that p38 MAPK played a significant role in a number of key 
physiological pathways in response to TNF-α induced inflammatory stress. In the early 
time points p38 activity was needed for the activation of immediate/early response 
pathways. We also observed that at multiple time points throughout the study, p38 
activity was needed for pro-survival signaling. As TNF-α elicits strong responses from 
multiple signaling pathways, cancer cells need to inactivate pro-apoptosis pathways. To 
counteract pro-apoptotic stimuli, Calu6 activate strongly the IAP pathway, and the anti-
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apoptotic members of the BCL2 family. BIRC2 and BIC3 were found to be activated by 
as much as 10-fold across the different time points in this study, while components of the 
BCL2 family were activated by a smaller extent, topping out at around 4-6 fold. 
Inhibition of p38 changed the transcriptional response of many of the anti-apoptosis 
proteins significantly. This hypothesis generated from the microarray data was validated 
in a series of in-vitro experiments that showed that p38 inhibition led to the modulation 
of anti-apoptotic pathway components such as FADD, BCL-xl and BCL2 (Figure 4.32).  
The most dramatic changes in transcriptional response due to p38 inhibition were 
observed at the earlier time points (30mins, 60mins and 2hrs). Early modulation of 
transcriptional events has been linked with significant changes in protein levels at later 
time a point, hence observing significant changes to transcriptional response at the early 
time points is believed to lead to significant physiological differences. 
 Inhibition of p38 also dramatically affected the regulation of proliferation and 
inflammation response genes especially at the early time points. These genes include 
known TNF-α targets including TGF- , BMP2 pathway and components of the NF B. 
Inflammation response modulated strongly by TNF-α treatment included cytokines such 
as IL6, IL8 and PTGS. We found that biochemical inhibition of p38 led to dramatic 
decrease in many up-regulated genes involved in proliferation and inflammatory 
response.  
 The gene expression data strongly supports the prior observations that p38 MAPK 
activity may be linked to cyto-protection in response to stress. This extends the work 
presented in chapter 3 of this thesis to support the idea that p38’s activity in response to 
DNA damage is related to protection from stress induced apoptosis pathways. This 
suggests that targeted inhibition of p38 may have therapeutic benefits in conjunction with 
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chemotherapeutic treatments. Inhibition of cell survival pathways with a potent p38 
inhibitor will have the potential to greatly enhance the cell killing potential of current 
genotoxic agents, increasing the efficacy of current treatment regimes.  
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Chapter 5: Alternative roles for p38 in response to DNA Damage 
outside G2 cell cycle checkpoint response 
 
5.1  Background 
 The p38 MAPK is activated strongly in response to stress including DNA 
damage. While the traditional role for p38 in stress response has been in the realm of 
response to inflammatory cytokines, numerous roles for p38 in other types of stress 
response have been suggested. In chapter 3, we explored the role of p38 activity in DNA 
damage induced G2 cell cycle checkpoint arrest. Our results showed that while p38 is 
strongly activated in response to DNA damage, its activity is not required for the 
activation or maintenance of the G2 cell cycle checkpoint arrest. As p38 activity is not 
required for G2 cell cycle checkpoint function, we reasoned that its activity may be 
associated with other physiological processes related to DNA damage. In this chapter, we 
explore a number of alternative hypotheses that connect p38 activity in response to DNA 
damage to non G2 cell-cycle checkpoint function. The goal is to attempt to elucidate 
other possible roles for p38 activity beyond the original hypothesized role in G2 cell 
cycle checkpoint function. 
 
5.2  A role for p38 MAPK activity during mitotic progression 
 Beyond the role of p38 in G2 DNA damage cell cycle checkpoint function, 
numerous publications have suggested some alternative roles for p38 activity in cell cycle 
progression. A publication by Fornace et al (48), showed that p38 was activated during 
normal transition from G2 to M phase of the cell cycle in the absence of stress, and 
remained activated and localized to the centrosomes during metaphase. This suggests a 
potential non-DNA damage role for p38 activation during mitotic transition.  
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 To confirm the observations made in the paper, a part of the results from this 
publication was reproduced. HeLa cells were synchronized by double thymidine block 
and released into fresh growth media. Cells were tracked for 12 hours after release for 
thymidine block and harvested according to the time points presented in Figure 5.1. 
 
 
Figure 5.1: p38 MAPK was activated during normal mitosis, without any DNA 
Damage. Western blot of hela cells, synchronized with double thymidine block/release 
technique. % cells with 4N DNA determined by flow cytometry. 
 
 As can be observed in figure 5.1, phosphorylation of p38 can be observed starting 
at 7 hours post release from thymidine block. Based on levels of ph-CDC2,tyr15 and 
phospho-Histone H3 at the same time points, it was clear that p38 was activated just prior 
to entry into mitosis. Based on other mitotic markers at the same time points, p38 seems 
to be active in early mitosis when cyclin B1 was still present. Loss of p38 activity seems 
to correlate with loss of cyclin B1, suggesting that p38’s activity decays at the end of 
mitosis or as cells exit mitosis. This data reproduces the observations made in the 
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Fornace et al paper, showing that p38 activation occurs during mitotic progression 
without exogenous stress.  
5.2.1  Inhibition of p38 during regular mitosis has no impact on completion of 
mitosis 
 As high p38 activity is correlated with the onset of mitosis in unperturbed cells, it 
was natural to assume that p38 plays a critical role in some context within mitosis.  
To understand if p38 kinase activity plays a critical role in mitosis, we first tried to inhibit 
p38 activity without any exogenous stress to the system. As p38 activity was high in the 
early phases of mitosis, and was known to co-localize to the centrosomes, inhibition of 
p38 may have some impact on the kinetics of mitosis. To test this hypothesis, we 
synchronized Hela cells with a CDK1 inhibitor (RO-3306) as described previously. Upon 
release from CDK1 inhibitor, cells were dosed with 500nM p38 inhibitor (LY479754) or 
1 M Chk1 inhibitor or 120nM Nocodazole and tracked for 6hours post release (Figure 
5.2A&B).  
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Figure 5.2: Effect of inhibition of p38, and Chk1 on mitotic progression in Hela 
cells. (A) Hela cells synchronized with 9uM RO-3306 were released into 160nM p38i or 
1.5uM Chk1i (B) Cell cycle profile (3mM PI) of cells treated with p38i or Chk1i or 
control cells  (C) Confocal Microscopy of Hela cells synchronized with CDK1 inhibitor 
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Block/Release, with or without 500nM p38-inhibitor. Color Code: Red: ph-p38 
(thr180/tyr182), Green: α/  Tubulin, Blue: DNA 
 
 CDK1-inhibitor (RO-3306) block/release treatment was able to synchronize hela 
cells at the G2 to M boundary after dosing for 21 hours. Using both the mitotic index and 
the cell cycle profile as readouts for the state of cells, we see that untreated cells enter 
mitosis within 1 hour of release and begin exiting mitosis within 3 hours of release from 
CDK1 inhibition (Figure 5.2A & B). Treatment with a potent p38 inhibitor and a Chk1 
inhibitor did not seem to have a significant effect on the ability of cells to progress 
through mitosis, whereas treatment with 120nM nocodazole traps cells in mitosis (Figure 
5.2A).  
 Additional confocal immunofluorescence microscopy shows that CDK1 inhibitor 
block effectively synchronizes cells at the G2 to M boundary, with cells rapidly entering 
mitosis 1hour post release (Figure 5.2C, left panel). Treatment of CDK1 inhibitor 
synchronized HeLa cells with 500nM LY479754 also does not seem to impede cells 
progressing through mitosis, as cells treated with p38 inhibitor are captured under going 
metaphase and telophase (Figure 5.2C, right panel).  
 These results imply that while p38 was active in unperturbed cells during mitosis, 
inhibition of p38’s kinase activity does not have any discernable effect at the phenotypic 
level. Cells seem to transition through mitosis in the same kinetics as untreated and there 
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5.2.2  Adriamycin damage has no effect on mitotic progression 
 Having tested the effect of inhibition of p38 on the ability of cells to complete 
mitosis in the absence of genotoxic stress, the next question was what effect DNA 
damage during mitosis may have. We sought to understand if genotoxic agents that 
induce cell cycle arrest during interphase had an effect in mitosis, the final stage of the 
cell cycle. As p38 was induced in mitosis, we asked whether p38 activity plays a role in 
any response to DNA damage during mitosis.  
 To test this, cells were synchronized using the CDK1-inhibitor block/release 
protocol described previously. Post release from CDK1i block cells were tracked for 
mitotic entry visually by looking for a “round-up” phenotype in a standard light 
microscope. Unstressed cells released from CDK1 inhibitor block can be observed 
entering mitosis with a large percentage of cells achieving this “round-up” phenotype 
within 30mins of release. At this point, mitotic cells were harvested using a “tap-off” 
protocol and seeded onto 96well micro-titer plates in fresh growth media containing 
160nM Adriamycin and p38 inhibitor or Chk1 inhibitor. A subset of the mitotic cells 
were treated with 120nM nocodazole to trap them in mitosis while another subset were 
left untreated to act as untreated control. Cells were tracked for 24 hours post damage 
with Adriamycin (Figure 5.3). 
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Figure 5.3: Effect of Adriamycin on cells in Mitosis: (A) Mitotic index of hela cells 
synchronized by CDK1i block/release treated with Adriamycin during mitosis. (B) DNA 
damage index ( -H2AX) of cells of hela cells synchronized with CDK1i block/release. 
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 Adriamycin treatment does not seem to have any effect on the ability of cells 
already in mitosis from completing mitosis based on mitotic index (Figure 5.3).  The 24 
hour time course Acumen multi-parametric cytometry data shows that Adriamycin only 
seems to have an effect on cells during the interphase component of the next subsequent 
cell cycle and does not exhibit any effect on mitotic cells. Considering that Adriamycin is 
a Topo-II inhibitor, this result is not surprising. As DNA was fully condensed during 
mitosis, it was likely that the topo-isomerase enzymes do not have a role during mitosis, 
hence a topo-isomerase inhibitor like Adriamycin only has the opportunity to impinge on 
the cell cycle at the next subsequent cell cycle, through disruption of DNA replication.  
 Addition of a p38 inhibitor to Adriamycin damage also did not appear to have any 
effect on cells progressing through mitosis. As we have shown previously that inhibition 
of p38 in undamaged or unstressed cells has no discernable effect, it may not be 
surprising that a p38 inhibitor does not alter the kinetics of mitosis with Adriamycin in 
Hela cells. 
 
5.2.3  MMS damage during mitosis interrupts mitotic progression 
 As we were interested to investigate if p38 kinase activity had a role in response 
to DNA damage in mitosis, we explored if MMS, a strong alkylating agent was able to 
affect cells completing mitosis. HeLa cells were synchronized with CDK1 inhibitor (RO-
3306) block/release cycle as describe previously. Upon release, mitotic cells were 
collected using a mitotic “tap-off” procedure. Mitotic cells harvested in this manner were 
seeded onto 96 well plates in fresh growth media containing 0.02% MMS and a series of 
increasing doses of p38 inhibitor (80nM to 500nM). Cells were tracked for a 24 hours 
time series.  
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MMS damage of hela cells synchronized with CDK1 inhibitor block/release 
protocol while in mitosis lead to some interesting observations. We observed that the 
dynamics of p38 activation in response to MMS damage was very rapid, within 30mins 
of MMS treatment (Figure 5.4D). This contrasts with the onset of the markers of DNA 
damage ph-H2AX and that of ph-Chk1 (ser317), which was observed at 1hrs post MMS 
treatment respectively. This suggests that the dynamics of p38 activation precedes that of 
Chk1 and the classical marker of DNA damage ( H2AX).  
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Figure 5.4: MMS damage in mitosis leads to disruption of mitosis. (A) Mitotic index 
plot of Hela cells synchronized by CDK1i block/release and treated with 0.02% MMS in 
mitosis. (B) DNA damage (ph-H2AX ) in Hela cells treated with 0.02% MMS in mitosis. 
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(C) Select cell cycle states (DNA content: Propidium Iodide) of CDK1 block/release 
cells and CDK1 block released cells + 0.01% MMS.  (D) Corresponding western blots 
of Hela cells synchronized by CDK1i Block/Release and treated with 0.02% MMS in 
mitosis. 
 
 In terms of an effect on mitotic progression, we observed that unlike Adriamycin, 
MMS damage seemed to have a profound impact on cell cycle progression. MMS 
damage appeared to alter the ability of cells to complete mitosis. This observation stems 
primarily from the observation that a 2N (G1) peak was not observed within the 24 hour 
time series for this set of experiments (Figure 5.4C). We do however observe a temporary 
decrease in histone H3 phosphorylation within the first 8 hours of MMS damage, this 
decrease however was reversed by 12hours of MMS damage, and we observe that cells 
again have very high levels of ph-Histone H3, suggesting that cells were in mitosis again. 
However as we do not observe a return of the 2N peak within the same 24hr period, it 
may suggest that cells never leave mitosis. The oscillation of ph-histone H3 levels were 
observed in a careful time series experiment in both an acumen high content assay as well 
in traditional western blots. 
 Despite this observation of oscillations in the levels of histone H3, in a number of 
limited experiments we did not find that the biochemical inhibition of p38 having any 
effect on any of the markers under observation (ph-histone H3, & DNA content). It was 
observed that prolonged treatment of cells with MMS leads to dramatic induction of 
apoptosis. A possible explanation for these phenomena was that continuous exposure to 
MMS led to dramatic damage to the DNA, preventing cells from progressing through 
mitosis.  The last canonical checkpoint during mitosis is the spindle assembly checkpoint, 
which guards against improper and incomplete attachment of sister chromatids to the 
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mitotic spindle (485). While MMS acts as an alkylating agent, its activity may prevent 
the proper attachment of chromosomes to the spindle, halting progression in mitosis.  As 
further exploration of mitotic progression was not the primary focus of this thesis, an 
underlying mechanism to explain this observation is still not understood. Additional ideas 
and comments on this observation are provided in Chapter 7.  
  
5.3  Role of p38 in recovery from Adriamycin damage 
 The three usual outcomes of DNA damage are generally considered to be 
successful repair of damage and subsequent re-initiation of the cell cycle or unsuccessful 
repair, adaptation and re-initiation of the cell cycle or apoptosis. As cells have the ability 
to respond to DNA damage and either repair the damage or adapt to the damage, a 
signaling pathway to prepare cells for recovery and re-initiation of cell cycle is necessary. 
As p38 MAPK is strongly activated in conjunction to DNA damage in association with a 
G2 cell cycle arrest, it may play a role in recovery from DNA damage.  The majority of 
research on DNA damage response has focused on identifying the key signaling 
regulators for the initiation of the cell cycle checkpoint arrest. Less research has been 
done on the components responsible for the release and recovery from DNA damage 
induced checkpoint. As our data (Chapter 3) has shown that despite p38 being activated 
in response to DNA damage, its activity was not linked to the function of the G2 
checkpoint, we explored if p38 activity may be tied to recovery from DNA damage.  
 To explore this, we used the Hela cell system, and studied the kinetics of repair 
and release from low levels of Adriamycin damage. As Adriamycin is a potent Topo-II 
inhibitor, the dose range selection for DNA damage had to be chosen carefully as too low 
a dose of Adriamycin led to a leaky arrest and too high a dose led to unrecoverable DNA 
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damage arrest (for at least 48hrs). In addition to the dose, the duration of Adriamycin 
treatment was also an important factor that needed to be controlled. Too long an 
incubation even at lower doses, led to permanent checkpoint arrest within the 24 hour 
observation window. The optimal dose range for this recovery experiment was 
determined to be 80nM of Adriamycin for 9 hours in HeLa cells. In this experimental 
regime, HeLa cells were synchronized with double thymidine block and upon release 
were subsequently treated for 9hours at 80nM Adriamycin with or without 320nM p38 
inhibitor, following which Adriamycin was washed out with fresh growth media (3x), 
samples pre-treated with p38 inhibitor were re-incubated with 320nM p38 inhibitor. The 
recovery from Adriamycin was tracked over a 24 hour time series where the mitotic 
index (phospho-Histone H3) and the cell cycle state (DNA content) was tracked using a 
multi-parametric Acumen Explorer cytometry assay (Figure 5.5).  
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Figure 5.5: Recovery from Adriamycin Damage at G2. (A) Mitotic Index (ph-H3) of 
hela cells treated with 80nM Adriamycin or 80nM Adriamycin and 320nM LY479754 
(p38i). (B) Select cell cycle profiles of cells treated with 80nM Adriamycin or 80nM 
Adriamycin+ 320nM p38i.  
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 In thymidine synchronized Hela cells, 80nM of Adriamycin induces a sufficient 
G2 checkpoint arrest by the majority 4N peak (>75%) and low levels of ph-Histone H3 
(Figure 5.5). It was observed that washout of Adriamycin post 9hrs incubation, allowed 
cells to recover from Adriamycin induced G2 checkpoint arrest within 24hours of 
washout. It was also observed that inhibition of p38 with a potent biochemical inhibitor 
was able to inhibit recovery from Adriamycin. As can be observed from the cell-cycle 
profiles, and the mitotic index, cells treated with 320nM of LY479754 never recover a 
G1 (2N) peak nor do they exhibit high levels of ph-Histone H3 24hrs post washout.  
 This initial data suggests that p38 activity in response to DNA damage from 
genotoxics may also be linked to the ability of cells to recover from DNA damage. While 
we have made an observation that inhibition of p38 by a potent biochemical inhibitor has 
the ability to delay or prevent recover from DNA damage, we have not yet begun to 
explore any underlying mechanism that may explain this observation. Additional 
thoughts and comments on this topic were addressed in Chapter 7 of this thesis. 
 
5.4 Biochemical Inhibition of p38 leads to Apoptosis in conjunction with 
genotoxic agents 
 Analysis of TNF-α treated Calu6 cells in Chapter 4 strongly suggested that 
inhibition of p38 interfered with the ability of cancer cells to mount an immediate early 
response to apoptosis signals. Inhibition of p38 strongly decreased the expression of anti-
apoptotic BCL2 family proteins and also reversed inhibition of components of the pro-
apoptotic signaling pathway (Chapter 4). Given these observations, there was a strong 
interest to extend these findings to p38’s response to DNA damage. We reasoned that if 
p38 MAPK activity played a significant role in the regulation of apoptosis, inhibition of 
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p38 should have dramatic impact on the induction of apoptosis in response to genotoxic 
agents. To explore if there was any evidence that p38 activity was a critical regulator of 
apoptosis induction, unsynchronized HeLa cells were treated with increasing doses of 
p38 inhibitor (LY479754), with or without 160nM Adriamycin and fixed after 48 hours 
(Figure 5.6A). The degree of apoptosis induction was measured by levels of cleaved-
caspase3 in a multi-parametric Acumen cytometry assay. In this experimental regime, 
apoptosis induction was significantly induced with increasing doses of p38 inhibitor in 
combination with 160nM of Adriamycin. Yet cells treated with either the p38 inhibitor 
alone or with Adriamycin alone did not exhibit strong levels of cleaved-caspase3 signal. 
This data shows that inhibition of p38 in combination with a genotoxic agent leads to 
strong induction of apoptosis (Figure 5.6A) 
Follow up experiments in unsynchronized HeLa cells, showed in a western blot 
assay format, that inhibition of p38 kinase activity led to significant induction of 
apoptosis pathway in combination with Adriamycin (Figure 5.6B). Similar to results 
obtained from Acumen multi-parametric assays, western blot data showed that strong 
induction of cleaved-parp and cleaved caspase-3 in combination with Adriamycin was 
associated with inhibition of phospho-MK2, T334 levels (Figure 5.6B).  
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Figure 5.6: Apoptosis Induction in Hela cells in response to Adriamycin and varying 
doses of p38 inhibitor. (A) Apoptosis Index (c-casp3) of Hela cells at 48hrs post 
treatment with Adriamycin and varying doses(20nM to 2uM) of LY479754 (p38i). (B) 
Western blots of Hela cells treated with Adriamycin and varying doses (500nM to 2uM) 
of p38 inhibitor.  
 
5.4.1  Inhibition of p38 modulates BCL2 anti-apoptotic proteins 
As our initial results in HeLa cells showed a strong induction of apoptosis with 
p38 inhibition in combination with Adriamycin, we were interested to check if this 
observation could be extended beyond the HeLa cell model and Adriamycin damage. To 
test this, A549 NSCLC cells synchronized with 48 hours serum starvation were treated 
with 160nM of Adriamycin and 1 M p38 inhibitor (LY479754) for 48 hours (Figure 
5.7A). The combination of p38 inhibitor and Adriamycin leads to strong induction of 
cleaved parp and cleaved-caspase7 in A549 cells (Figure 5.7), whereas individual 
treatment of p38 inhibitor or Adriamycin did not produce a strong apoptotic response.  
This result is similar to phenotype observed in HeLa cells, suggesting that this 
phenomena is not unique to HeLa cells, but may instead be linked to a role for p38 in the 
regulation of apoptosis induction in cancer cells.  
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Figure 5.7: Inhibition of p38 induces apoptosis in A549 cells: (A) A549 cells 
synchronized with 48hrs serum starvation treated with Adriamycin and or 
Adriamycin+LY479754. (B) Multi-parametric Acumen Cytometry data, measuring 
cleaved-parp and PI (DNA content) of A549 cells treated with 160nM Adriamycin and 
160nM Adriamycin+1 M LY479754, 48hours. 
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Having observed an increase in apoptotic induction with the inhibition of p38 in 
response to Adriamycin, we asked if the apoptosis induction was specific to Adriamycin 
stress. To test this hypothesis, unsynchronized HeLa cells were treated with 0.01% MMS, 
a strong DNA alkylating agent and treated with 1 M p38 inhibitor. As p38 inhibition of 
TNF-α cells led to strong transcriptional repression of anti-apoptotic response in the early 
and mid-time points and MMS strongly induces apoptosis post 24hours, a short time 
series of experiment in HeLa cells was carried out (Figure 5.8A).  
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Figure 5.8: Apoptosis induction by MMS and LY479754 in HeLa & A549. (A) 
Western blot time series of 0.01% MMS+LY479754 in HeLa cells. (B) Western blot time 
series of 0.01% MMS +LY479754 in A549  
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Inhibition of p38 in combination with MMS in HeLa cells leads to strong early 
induction of apoptosis as seen by levels of parp cleavage (Figure 5.8A). Cleaved-parp is 
only strongly detectable in MMS only treated samples at the 10hour time point, versus 
the 3 hour time point in samples with 1 M p38 inhibitor added. In addition, inhibition of 
p38 again leads to strong inhibition of BCL2 and BCL-xl protein expression, suggesting 
inhibition of anti-apoptotic BCL2 protein expression as a mechanism of action. A follow-
up study conducted in A549 confirms a strong loss of BCL2 as a consequence of p38 
inhibition in combination with MMS damage (Figure 5.8B).  
Together this data suggests that biochemical inhibition of p38 may suppress some 
anti-apoptotic members of the BCL2 family, leading to loss of cell survival capacity in 
the presence of genotoxic agents.  
  
5.4.2  siRNA KD of p38 sensitizes cells to Adriamycin DNA damage 
To test that the chemo-sensitization data derived from the p38 inhibitor was not 
due to an off target effect, we conducted a series of siRNA ablation experiments to knock 
down the p38 pathway. We reasoned that if p38 plays a critical role in cell survival in 
response to DNA damaging agents, loss of p38 protein would be detrimental to the 
survival capabilities of cancer cells in response to DNA damaging agents such as 
Adriamycin.  
 Using Hela cells again as our experimental model, we knock-downed p38, MK2 
and Chk1 protein using validated Qiagen siRNAs oligonucleotides against the respective 
targets. As a control for transfection, we used random scramble siRNAs (NS-AS). 
Following 48hrs treatment with siRNA reagents (as per manufacturers instructions), we 
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dosed cells with in a paired fashion with 160nM of Adriamycin for 48hrs or DMSO 
control.  
Similar to what we observed using biochemical inhibitors, we observed 
significant apoptosis induction with the siRNA knock-down of p38 and its downstream 
kinase MK2 in response to Adriamycin damage (Figure 5.9). We observed strong 
induction of cleaved-parp as well as cleaved-caspase7  in the p38 and MK2 knock-down 
conditions but did not observe such an effect in Adriamycin alone or non-specific 
scramble (NS-AS) plus Adriamycin conditions. As a positive control, we observed that 
loss of Chk1 kinase also led to strong induction of apoptosis in conjunction with 
Adriamycin damage. Recent reports have highlighted the inhibition of Chk1 kinase as a 
new mechanism to enhance chemo-sensitization. Our findings in this study were in line 
with such reports, showing that inhibition and knock-out of Chk1 strongly induces 
apoptosis in cancer cells. In addition we also showed that knock-down of p38 also led to 
induction of apoptosis in combination with Adriamycin. While knock-down of Chk1 
induced apoptosis is likely linked to a defective G2 checkpoint, we have seen that 
reduction of p38 does not affect the ability of cancer cells to effectively mount a 
checkpoint response. We hypothesize that p38 activity may be an integral part of a 
general stress response, including stress induced by DNA damaging agents. This could 
suggest that p38’s activity in response to DNA damage is correlated to protecting cells 
from pre-mature apoptosis induction in response to stress.  
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Figure 5.9: Effect of Adriamycin and siRNAs.  (A) Western blot analysis of 48hrs 
siRNA knock-down of p38, MK2 and Chk1 followed by 160nM Adriamycin 
 
 This data in combination with the biochemical inhibitor data establishes a link 
between p38 activity in response to DNA damage and increased cell survival. Testing a 
hypothesis derived from gene expression analysis of TNF-α treated Calu6 cells, we show 
that inhibition of p38 in the context of DNA damage degrades a cancer cells’ ability to 
induce anti-apoptotic pathways, leading to induction of apoptosis. This data suggests an 
alternative role for p38 in response to DNA damage. We hypothesize that rapid activation 
of p38 in response to DNA damage in cancer cells activates a strong cell survival signal 
that prevents early induction of apoptosis. This anti-apoptotic response may allow cancer 
cells to escape pro-apoptotic induction during treatment with genotoxic agents. This pro-
survival mechanism possibly acts in concert with cell cycle checkpoint response, 
allowing cancer cells to activate the necessary stress and DNA repair pathways that allow 
the continued perpetuation of proliferation. Inhibition of p38 limits a cancer cells’ ability 
to escape apoptosis in combination with a genotoxic agent, leading to increased cell 
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death. This suggests that p38 may be an attractive target for combination therapy in 
treatment of cancers. 
 
5.5 Summary 
 In this chapter we examined alternative roles for p38 MAPK activity in response 
to DNA damage. Our results, presented in Chapter 3 showed that while p38 is strongly 
induced in response to DNA damage, its activity has no role in the establishment and 
maintenance of the G2 cell cycle checkpoint. While cell cycle checkpoint regulation is a 
critical aspect of DNA damage response, there are a number of other physiological 
processes that p38 activity may impact in response to DNA damage.  
 We found that despite being activated in unstressed mitotic progression, inhibition 
of p38 had no impact on unstressed cells progressing through and completing mitosis. 
This data suggests that while p38 is activated during mitosis, inhibition of its kinase 
function does not have an discernable impact on mitotic progression.  
 In exploring p38’s role in the recovery from DNA damage, we found that 
inhibition of p38 impacted a cell’s ability to recover from Adriamycin damage. Inhibition 
of p38 prevented cells from re-entering the cell cycle after low levels of Adriamycin 
damage. In a series of limited studies, we showed that inhibition of p38 prevented cells 
from recovering from low levels of Adriamycin damage. While inhibition of p38 in 
conjunction with Adriamycin prevented cells from recovering a 2N DNA state, and from 
entering mitosis, we had also found that inhibition of p38 in undamaged cells did not 
have an effect on cell cycle progression through mitosis. This suggests that the inability 
of cells to recover from DNA damage in the presence of p38 inhibitor may not 
necessarily be related to cell cycle progression and that the inability to recover from DNA 
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damage may be linked instead to disruption of DNA repair. Unfortunately there was 
insufficient time in this thesis to explore further the underlying mechanism underpinning 
this observation. We review our thoughts on additional future work on this topic in 
chapter 7 of this thesis.   
Lastly, our studies found a strong positive link between p38 activity in response to 
the DNA damage and increased cell survival. Biochemical inhibition of p38 and siRNA 
knock-down of p38 led to significantly increased levels of caspase activation and parp 
cleavage. We also showed that p38 inhibition led to modulation of the BCL2 family of 
anti-apoptotic proteins. We found that inhibition of p38 in conjunction with a genotoxic 
agent led to a decrease in BCL-XL and BCL2 expression. This suggests that p38 activity 
confers its cell survival protection on cancer cells through modulation of the BCL2 
family of apoptosis regulatory proteins.  
 We conclude from these studies that p38 may be an attractive target for cancer 
therapeutics especially in combination with genotoxic agents for the induction of 
apoptosis. This data highlights that p38 does not function as a principal controller of the 
G2 DNA damage checkpoint, hence inhibition of p38 is unlikely to induce apoptosis 
through a mitotic catastrophe type mechanism. Instead, this data shows that chemo-
sensitization effects of a potent p38 inhibitor are instead conferred through disruption of 
pro-survival signaling.
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Chapter 6:  Discussion and Conclusions 
The role of p38 MAPK in DNA damage response has been an area of growing 
interest in recent times. The idea that p38, a key responder to general stress also plays a 
role in the control of cell cycle progression is a strong and attractive idea for new and 
innovative treatments for many diseases especially cancer. Numerous publications in the 
past few years have implicated p38 as a potential new regulator of cell cycle progression, 
especially at the G2 checkpoint.  
A recent observation that p38 MAPK pathway is attenuated in transformed cancer 
cells (267), however, has called into question the role of the p38 MAPK pathway in the 
G2 checkpoint in cancer cells. Furthermore, both p38 and Chk1 are reportedly activated 
under similar circumstances in cancer cells and are both believed to directly inactivate the 
same CDC25 family of protein phosphatases in response to DNA damage at G2, keeping 
CDC2 in its inactive phosphorylated state, preventing mitotic entry (212,366). Prior work 
has focused primarily on either p38 or on Chk1, and has made arguments that in response 
to certain DNA damaging agents, inhibition of either p38 or Chk1 is sufficient to over-
come the G2 checkpoint (149,254,268,313). We aimed to gain a better understanding of 
the underlying mechanisms governing the function of the G2 DNA damage checkpoint 
by investigating the specific roles of p38 and Chk1 activity in cancer cells. A better 
understanding of the functioning of these proteins at the G2 cell cycle checkpoint could 
ultimately lead to superior therapeutic treatments for oncology in the future.  
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6.1  Inhibition of Chk1 but not p38 is critical to the maintenance of the G2 DNA 
damage checkpoint 
 In this study, we revisited the role of p38 activity in the context of the G2 DNA 
damage checkpoint. Specifically we were interested to understand if p38 activity was 
required for the activation and the maintenance of a G2 checkpoint arrest in response to 
DNA damage. To address these issues, a series of in-depth, cell-cycle focused 
experiments were conducted in different cancer cell-lines to examine the role of p38 in 
DNA damage-induced G2 checkpoint. In these studies, cells were synchronized at 
different stages of the cell cycle using various techniques including 48hour serum 
starvation (G1 phase), double thymidine block/release (G1/S phase), and the recently 
published CDK1 inhibitor block/release technique (G2 phase). The use of cell 
synchronization techniques and careful tracking of cell progression through the cell cycle 
allowed a relatively homogenous cell population prior to the addition of DNA damaging 
agents. As the context of cellular response to DNA damage is often framed in the context 
of the cell cycle state, a more homogenous cell population would be expected to exhibit a 
more uniform response.  
 In a series of studies, designed to understand p38’s and Chk1’s function at the G2 
DNA damage checkpoint, the checkpoint was activated with a low doses of Adriamycin, 
and effects of  the inhibition of p38 and Chk1 on the cells’ ability to maintain  
checkpoint-induced G2 arrest was ascertained.  A key aspect of the experimental design 
was the use of the lowest effective dose of Adriamycin that would trigger largely uniform 
G2 checkpoint arrest.  This allowed for controlled experiments on the G2 checkpoint 
without additional confounding effects of high doses of genotoxic agents. Indeed, it was 
observed that high concentrations of Adriamycin (>500nM) did not induce a G2 arrest, 
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instead damaged cells arrested in S-phase (Figure 3.4A). Hence the decision to use 
160nM of Adriamycin, instead of 5 to 10uM as previous publications had used (327).  
Contrary to previous published results, we found that the G2 DNA damage 
checkpoint induced in Hela cells by treatment with Adriamycin or UV could not be 
effectively abrogated through the inhibition of p38.  In Chapter 3, by using a potent and 
highly selective inhibitor, p38 kinase activity could be inhibited without significantly 
increasing the number of cells entering mitosis over a 24 hour period after initiation of an 
Adriamycin G2 checkpoint arrest. Furthermore, treatment of thymidine synchronized 
cancer cells with a p38 inhibitor showed that inhibition of p38 activity before cells even 
enter G2 phase, had no effect on the establishment of G2 checkpoint arrest. In contrast to 
the results of p38 inhibition, inhibition of Chk1, a key member of the ATM/ATR DNA 
damage checkpoint, with a potent and selective Chk1 inhibitor allowed cells to enter 
mitosis despite the continuous presence of DNA damage. In addition to the Chk1 
inhibitor, suppression of ATM/ATR response through the use of caffeine also achieved 
similar results. These results confirmed prior publications that showed that Chk1 is 
responsible for G2 checkpoint activation and maintenance in a p53 null environment 
(58,207,232).   
The inability of cells treated with a p38 inhibitor to escape a DNA damage G2 
cell cycle arrest shows that p38 activity is not required for the maintenance of the DNA 
damage G2 checkpoint. Furthermore, by successfully abrogating the G2 checkpoint with 
a selective Chk1 inhibitor and with caffeine, we were able to demonstrate that cells were 
able to enter mitosis despite high levels of phospho-p38 and phospho-MK2 activity, 
showing that high p38 activity does not prevent entry into mitosis. The results described 
showing inhibition of p38 having no effect on cancer cells mounting a DNA damage G2 
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checkpoint arrest were reproduced in Calu6 cells, a lung carcinoma cell-line, as well as 
A549 NSCLC cells and U2OS osteosarcoma cell-lines.  
The results in different cancer cell-lines diverged in terms of the effect of Chk1 
inhibition. In HeLa and Calu6 cells, inhibition of Chk1 led to dramatic abrogation of a 
DNA damage G2 checkpoint. In A549 and U2OS cells however, inhibition of Chk1 did 
not yield the same physiological outcome, in that no significant abrogation of G2 
checkpoint arrest was observed. While this result was surprising initially, a search of 
literature revealed that the underlying p53 functional status strongly influences the effect 
of Chk1 activity on the function of G2 checkpoint (217,249,408,426). Inhibition of Chk1 
in a p53 functional cell-line was not sufficient to over-come the G2 checkpoint, which 
was in-line with previous publications (217,249,408,426). The data from Calu6, A549 
and U2OS cells however were in agreement that the inhibition of p38 was insufficient to 
abrogate DNA damage induced G2 checkpoint arrest, corroborating the main body of 
results from Hela cells.  
We also briefly examined the hypothesis that p38 behaves as a checkpoint kinase 
through its interaction with CDC25B. It has been reported earlier (36) that in a p53 null 
environment, p38 binds to and phosphorylates CDC25B on its ser309 residue. This 
phosphorylation leads to the binding of CDC25B to the 14-3-3 proteins which leads to its 
sequestration in the cytoplasm away from its nuclear target CDC2.  While we did not 
directly study the phosphorylation state of CDC25B, due to a lack of good quality 
commercial antibodies, biochemical suppression of p38 was unable to dramatically affect 
CDC2, tyr15 phosphorylation in Adriamycin treated Hela cells (Figure 3.5C). While it is 
possible that p38 does phosphorylate and interact with CDC25B, it is also well studied 
that the CDC25 phosphatases are the primary targets of Chk1 mediated ATM/ATR DNA 
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damage response pathway. Inhibition of Chk1 in HeLa cells, led to a decrease in CDC2, 
tyr15 phosphorylation, and decrease in the abundance of Wee1 kinase, a phenotype not 
observed in p38 inhibited cells in response to Adriamycin damage (Figure 3.5C).  
 In addition to Adriamycin, we also tested UV damage and a DNA alkylating 
agent MMS to examine if the effects observed were unique to Adriamycin damage or 
whether similar effects could be observed from other common sources of DNA damage. 
Inhibition of p38 in response to UV or to MMS in HeLa cells had no statistically 
significant effect on the mitotic index within the observed 24hour time period.  
 To further corroborate the results from the p38 inhibitor, siRNA oligonucleotides 
were used to knock-down p38, its down-stream kinase MK2 and Chk1 followed by DNA 
damage with Adriamycin and UV. SiRNA knock-down of p38 and MK2 in conjunction 
with Adriamycin and UV damage did not have any dramatic effect on the ability of cells 
to mount an effective G2 checkpoint in Hela cells. This contrasted with the siRNA 
knock-down of Chk1 which again produced a dramatic phenotype in terms of abrogation 
of Adriamycin induced G2 checkpoint in HeLa cells.  
Taken together with biochemical inhibitor data, these results shows that in a p53
-/-
 
tumor environment, inhibition of Chk1, but not p38 in response to DNA damage leads to 
cells bypassing the G2 cell cycle checkpoint. 
Given the recent increase in work implicating the p38 MAPK as a critical kinase 
in the response to DNA damage, this set of results may seem surprising.  However, the 
findings of this study that p38 does not play a critical role in the establishment of G2 
checkpoint arrest is supported by work recently published by Mikhailov et al (267), who 
found that the p38 G2 arrest pathway is attenuated in cancer cells, but active in 
untransformed cells. Hela cells, one of our primary in-vitro models has been documented 
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to be both p53 and Retinoblastoma (Rb) negative (non-functional) (29,156,253). It is 
proposed that in this p53 and Rb functionally negative context, Chk1 kinase, but not p38 
is required for the establishment and maintenance of the DNA damage induced G2 
checkpoint arrest. Numerous prior publications studying the role of p38 in DNA damage 
G2 checkpoint have used untransformed human fibroblasts, and untransformed mouse 
embryonic fibroblast cells. Some of the discrepancies in our data and results previously 
published could be explained by the underlying differences between untransformed 
mouse and human fibroblast cells and transformed human endothelial cancer cells.  
The loss of heterozygosity of both the p53 and Rb gene is a common phenotype 
registered in numerous types of primary tumors, including cervical cancer.(119,125,197) 
Hence the use of selective Chk1 kinase inhibitors as a potential chemo-sensitizer and in 
combination therapy with chemotherapeutics may prove to be more effective in the 
context of bypassing G2 checkpoint and reducing an avenue that cancers cells use to 
escape cell death after chemotherapy treatment.   
 
 
6.1.1 Comparison of results for p38’s role at G2 checkpoint arrest with prior 
publications 
We showed that p38 activation was strongly induced by DNA damage and was 
correlated with G2 checkpoint arrest. Contrary to some prior publications (36,220,254), 
however, our data shows that p38 pathway activity is not necessary for the G2 checkpoint 
arrest in response to DNA damage  
We were interested in the exciting possibility of using potent and selective p38 
kinase inhibitors as chemo-sensitizers to enhance anticancer efficacy of chemotherapies. 
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Thus, lack of G2 checkpoint abrogation by a highly selective and potent p38 kinase 
inhibitor comes as a big surprise to us. A closer examination of earlier publications, 
however,  reveals a certain degree of discrepancies concerning the role of p38 in G2 
checkpoint control in response to different types of DNA damage and the function of p53 
(36,254,327).  In addition, earlier studies used older generation of p38 kinase inhibitors at 
very high concentrations (36,327). At such high concentrations these p38 kinase 
inhibitors would be most likely to have off-target activities as shown recently (16,103). 
Our data are consistent with a more recent report that demonstrates using the RNAi 
approach that only Chk1 but not Chk2 or MK2 is responsible for DNA damage-induced 
G2 checkpoint arrest in cancer cells (460). Furthermore, it is also recently shown that the 
p38 pathway response at the G2 checkpoint is strongly attenuated in transformed cells 
(267). Earlier studies that implicated p38 activity in DNA damage induced G2 checkpoint 
were performed in untransformed human cells and mouse embryonic fibroblasts 
(36,313,327). However, untransformed mammalian cells have intact p53 and Chk1 
functions.  Thus, it is inconceivable that normal, untransformed mammalian cells would 
depend on p38 for G2 DNA damage checkpoint function with functioning p53 and Chk1, 
but not cancer cells. Furthermore, if p38 MAPK plays an important role in the G2 
checkpoint control only in untransformed normal cells but not in transformed cancer 
cells, that would then rule out the feasibility of developing a p38 inhibitor as a chemo-
sensitizer to enhance efficacy of chemotherapies. Future follow-up on the observations 
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6.1.2 Requirement of Chk1 for G2 DNA damage checkpoint in p53 null cells 
 Inhibition of Chk1 through both biochemical and RNAi techniques led to the 
abrogation of the G2 checkpoint only in p53 functionally null cancer cells. While p53 
was not a central focus of this thesis, this observation warrants further investigation. As a 
p53 function is a central prosecutor of DNA damage response, it is feasible that the 
downstream pathways activated by p53 are sufficient to activate the G2 checkpoint, 
making the activity of Chk1 redundant.  
 Some possible mechanistic pathways downstream of p53 include the 
transcriptional activation of p21
waf1
, a known inhibitor of CDK1 function (52). In this 
context up-regulation of p21
waf1
 led to sequestering of CDC25b and prevented the 
dephosphorylation of CDK1 at Tyr15. In cancer cells that retain p53 functional activity, it 
is likely that this pathway works in conjunction with the ATM/ATR mediated activation 
of Chk1 to induce G2 arrest. When p53 is functionally inactivated as in >50% of tumors, 
ATM/ATR mediated Chk1 activity may be the last resort to impose the G2 arrest. This 
suggests that in cancer cells with functionally inactive p53, a combination of Chk1 
inhibitor with a chemotherapeutic agent could be a successful new therapeutic strategy. 
 
6.2  Inhibition of p38 degrades anti-apoptosis response to TNF-α in Calu6 cells 
 If p38 is not necessary for the execution or the maintenance of the G2 checkpoint 
in transformed cells, what is its role in DNA damage response? To understand the role for 
p38 activity in response to DNA damage, we returned to the original context of p38 
activation and investigated the nature of its involvement in response to inflammatory 
cytokines (TNF-α). TNF-α is a cytokine that is associated with the induction of 
inflammatory response, apoptosis and proliferation. An in-depth analysis of the 
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transcriptional pathways differentially modulated by p38 inhibition revealed p38’s role in 
many pathways and gene networks. P38 activity was critical for the rapid induction of 
genes and networks associated with immediate early stress response, cellular 
proliferation, production of inflammatory cytokines and the regulation of apoptosis and 
cell death. Of particular interest in this study was p38’s role in the rapid activation of the 
anti-apoptosis pathway in response to TNF-α treatment. The results highlighted in 
chapter 4 showed that TNF-α treatment resulted in a rapid up-regulation of an anti-
apoptosis response, including the rapid induction of inhibitor of apoptosis proteins (IAPs) 
and anti-apoptotic members of the BCL2 family and a concordant decrease in pro-
apoptotic components such as TRADD and FADD. Inhibition of p38 significantly 
degraded the anti-apoptosis transcriptional response, especially at the early time points. 
 Analysis of TNF-α and p38 inhibitor transcriptional data revealed the importance 
of p38 kinase activity in many key regulatory pathways including the regulation of 
apoptosis. Our data and analysis of p38’s role in TNF-α response provides a possible link 
between p38 activity and the induction of pro-survival signaling.  
 Given p38’s well documented role in promoting FAS-ligand, death domain 
receptor mediated apoptosis (157,435,442), it was surprising to find that inhibition of p38 
led to increased cell death in the context of DNA damage response. In the context of 
induction of extrinsic apoptosis pathway, increased p38 activity is associated with 
increased cell death in many untransformed cells including fibroblasts and macrophages. 
It is possible that p38’s response to FAS and other extrinsic stimuli depends on different 
cellular and environmental contexts. 
The nature of three-tiered p38 MAPK activation system makes it an efficient 
transducer of cell death signals from external sources. In transformed cancer cells 
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however, the p38 MAPK pathway may be subverted by other oncogenic proteins such as 
Ras to switch its signaling from pro-apoptotic to anti-apoptotic (293). In the context of 
DNA damage in cancer cells, the speed and intensity of p38 activation may also make it a 
suitable candidate for holding apoptosis induction in check, until other factors have 
determined that the damage is too severe and cell death is necessary. Our observations 
that p38 may play a cyto-protective role in cells is supported by other studies which have 
also found that p38 may be tied to the BCL2 family and to anti-apoptotic pathways 
(127,128,235,239,271,473). 
 
6.2 p38 MAPK activates cell survival pathways in response to DNA Damage 
 The traditional response to DNA damage is comprised of 3 main areas: cell cycle 
arrest, DNA damage repair and apoptosis. The classical response to DNA damage is 
believed to comprise of a series of decision tree like actions, where in response to DNA 
damage, cells immediately arrest, assess the damage, attempt to repair the damage and 
finally undergo apoptosis if the damage is too severe. It is well documented that p38 is 
rapidly activated in response to a plethora of exogenous stress signals. It has also been 
proposed that p38 MAPK may act as a central integrator of stress transduction signals, 
hence the topology of its 3 tier activation cascade. As shown in chapter 3, while p38 is 
strongly activated in response to DNA damage, its activity is not required for the proper 
execution of the G2 cell cycle checkpoint.  
 Transcriptional analysis of TNF-α treated Calu6 cells revealed that cancer cells 
induce strong anti-apoptosis signaling in response to TNF-α treatment and inhibition of 
p38 in this context leads to strong degradation of anti-apoptosis signaling. This suggested 
that p38 activity is an important component of the anti-apoptotic signaling pathway, 
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activated in response to TNF-α stress. To extend these observations to the context of 
DNA damage response, we explored the role of p38 activity in the regulation of apoptosis 
induction.  
We observed that inhibition of p38 in combination with a genotoxic agent such as 
Adriamycin led to a dramatic increase in apoptotic markers in both p53 functionally null 
as well as p53 wild-type cancer cell-lines. A dose titration exercise with a p38 inhibitor 
revealed that chemo-potentiation could be observed at doses as low as 80 to 160nM. In 
conjunction with apoptosis induction with a p38 inhibitor, we also showed that inhibition 
of Chk1 eventually leads to dramatic increase in apoptosis. The time dynamics of Chk1 
mediated apoptosis induction suggests that bypassing the G2 checkpoint and pre-mature 
entry into mitosis may be a necessary step for cells treated with a Chk1 inhibitor prior to 
the initiation of apoptosis. This would be in line with the hypothesis that inhibition of 
ATM/ATR signaling in conjunction with DNA damage would lead eventually to mitotic 
catastrophe. 
 Considering that inhibition of p38 in cancer cell-line models was unable to 
dramatically increase the percentage of cells bypassing the G2 cell cycle checkpoint 
mounted in response to DNA damage, cells undergoing apoptosis in combination with a 
genotoxic agent are mostly still stuck in G2 with 4N DNA content. This contrasts 
dramatically with the mitotic catastrophe phenotype observed with inhibition of 
ATM/ATR signaling, where premature entry into mitosis is believed to be the main 
trigger of apoptosis. As we found that cancer cells do not enter mitosis despite strong p38 
inhibition, apoptosis induction observed with a combination of a DNA damaging 
genotoxic agent and p38 inhibition must be triggered by a separate mechanism.  
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A possible mechanism for how p38 activity plays a role in regulation of apoptotic 
response is through modulation of the anti-apoptotic BCL2 family proteins. The 
decreased expression of BLC2 and BCL-xl was observed in association with p38 
inhibition and genotoxic agents like Adriamycin and MMS as seen in Chapter 5. This 
suggests that p38 activity in response to DNA damage plays an important role in the 
activation of pro-survival signaling, preventing the early onset of apoptosis. A possible 
biological explanation for this could be that p38’s cyto-protective role in the early 
response to DNA damage is to protect cells from pre-mature apoptosis while DNA 
damage repair pathways assess the extent of the damage. As increased cell-killing can be 
observed in both p53 functionally null (Hela) and in p53 wild-type cells (A549), we 
concluded that p38’s impact on apoptosis was not dependent on p53 status. Our 
suggestions that p38 plays a cyto-protective role in connection with DNA damage also 
implies that p38 functions through a stress induced but cell cycle independent 
mechanism. While we observed that p38 inhibition in conjunction with genotoxic agents 
modulates certain members of the BCL2 family of proteins. We do not discount other 
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6.4  A tentative new model for p38’s role in DNA Damage Response  
 Based on the results of Our study of p38’s role in DNA damage response, we 




Figure 6.1:  A new model of p38’s role in DNA damage response 
 
 While p38 activity is highly associated with the onset of DNA damage,our results 
suggest that its activity is not required for the functioning of the pathway. Instead, the 
link between inhibition of p38 activity and increased apoptosis in conjunction with DNA 
damage and with TNF-α stress suggests a role for p38 in cell survival signaling following 
stress. The results documented in Chapter 5 show that in cancer cells, p38 activity is most 
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likely linked with the up-regulation of cell survival pathways and that p38 activity 
prevents early onset of apoptosis.  
 
6.5 Role of p38 in Recovery from DNA damage 
 We explored a few other possible roles for p38 activity in response to DNA 
damage. As DNA damage cell cycle arrest is often reversible upon repair of the damage, 
we explored if p38 activity was necessary for cells to recover efficiently from DNA 
damage. Our initial data suggested that there may be a link between inhibition of p38 and 
irreversible cell cycle arrest with low levels of Adriamycin. Recovery from DNA damage 
is a relatively unexplored research area, and there are suggestions that p38 activity may 
be a necessary component of the recovery pathway.  
 
6.6 Conclusion 
In summary, we conclude that while p38 is highly associated with the onset of 
checkpoint arrest in G2, our findings show that p38 activity is not required for the 
successful mounting and maintenance of this checkpoint. We find that in a p53 
functionally null environment, ATM/ATR signaling culminating in Chk1 activity is 
required for a properly functioning G2 DNA damage checkpoint. We do, however, find a 
possible role for p38 in the protection of cells from apoptosis in G2, while cells are 
undergoing cell cycle arrest, and DNA damage repair. We find that p38 may play this 
cyto-protective role through regulation of the pro/anti apoptotic BCL2 family proteins. 
These findings suggest that p38’s early activity in G2 checkpoint activation is related to 
protection from apoptosis and not related to the establishment of cell cycle checkpoint 
arrest. The p38 MAPK, acting as a central integrator of external stress signals serves as a 
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central node in damage assessment and may ultimately help perpetuate cell growth and 
cell death signals in response to stress.  
The findings of this study suggest that biochemical inhibition of Chk1 in 
combination with a chemotherapeutic agent may have a strong therapeutic value in p53 
defective cancer cells. As the majority of cancer cells are p53 functionally deficient while 
untransformed cells have an intact p53 signaling pathway, synergy with a Chk1 inhibitor 
may provide an appropriate efficacy window for combination therapy with lower toxic 
side effects.  
Our findings also imply that a p38 inhibitor is a useful therapeutic agent in 
synergy with chemotherapeutic agents. The reversal of anti-apoptotic signaling response 
with a p38 inhibitor could significantly increase the efficacy of chemotherapeutic agents. 
Our results suggest that the efficacy of the p38 inhibitor in combination with a genotoxic 
agent is not dependent on the cell cycle state of the cell, possibly allowing a greater 
degree of flexibility in future combination therapy strategies. 
Chapter 7: Future Direction 
 
Author: Mark Phong   Page 244 of 291 
 
Chapter 7: Future Direction 
 As is often the case for extensive bodies of work such as this, this study contains 
some unresolved issues and raises numerous interesting questions to be tackled in the 
future. The multiple upstream regulators and down-stream substrates of p38 signaling, 
make it an extremely complicated pathway to study, especially in the context of cell cycle 
regulation and control of apoptosis. While this study addressed a number of fundamental 
issues involving the p38 pathway, the results generated from this study also produced a 
number of new/on-going questions especially in the area of underlying mechanism.  
 In the next few sections we will address a number of these issues and raise them 
as problems for future investigation.  
 
7.1  What is the mechanism of the pathway attenuation of p38 in G2 cell cycle 
checkpoint signaling? 
 While p38 is strongly activated in response to DNA damage in cancer cells, its 
activity is not required for the activation of a G2 DNA damage checkpoint arrest, as 
shown in this study. The fact that p38 signaling into the G2 cell cycle checkpoint is 
attenuated in transformed cancer cells was first reported by Mikhailov et al (267). In this 
paper, they attributed the loss of p38 pathway significance in transformed cancer cells to 
G2 checkpoint function, to increased Ras/Raf signaling and loss of p53/Rb status. Yet the 
underlying mechanism of how Ras/Raf signaling feeds into the CDC25/CDC2 checkpoint 
control is not understood. They and others report that in untransformed cells, activation 
of p38 significantly impedes entry into mitosis. Hence the process of transformation from 
a normal cell to a cancer cell, somehow mitigates the effect of the p38 pathway on the G2 
cell cycle checkpoint. 
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 An immediate follow-up to this thesis would be to investigate if the p38 pathway 
is required for G2 checkpoint activation in untransformed human fibroblast cells. Using 
the same strategies employed in cancer cell models, a careful cell cycle based 
investigation of the G2 checkpoint would validate the hypothesis that p38 pathway 
activity is only necessary in untransformed human cells, but not in transformed cancer 
cells.  
Gaining a better mechanistic understanding of how the p38 pathway is attenuated 
in relation to the cell cycle checkpoint, could have great therapeutic value for treatment 
of cancer. If the process of attenuation of p38 effect at G2 checkpoint could be restored, a 
new mechanism for halting uncontrolled cellular proliferation could be achieved. This 
would be an interesting question to address as a follow-up to results from this study. 
   
 
7.2 Transcriptional Analysis of Adriamycin Treated HeLa Cells 
 The microarray dataset used during this thesis explored the effect of p38 
inhibition on TNF  mediated stress in Calu6 cells. As this thesis was focused on DNA 
damage response, an improved microarray experiment exploring the effect of p38 
inhibition on the expression profile on cells arrested in G2 by adriamycin treatment 
should be conducted.  
 It will be interesting to see if p38 plays a role in modulating the immediate early 
response proteins and in transcriptional regulation of anti-apoptotic proteins such as 
BCL2 cells arrested in G2 by adriamycin treatment. The transcriptional network analysis 
suggested that the p38 signaling plays a role primarily at the early time points and may 
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play a role in prevention of early or pre-mature apoptosis. It will be important to see if 
these same transcriptional networks are also strongly induced by adriamycin treatment. 
 
7.2  Where does p38 signaling impinge upon apoptosis signaling? 
 
 In this study, inhibition of p38 in conjunction with genotoxic agents leads to 
dramatic increase in apoptotic induction. One possible mechanism for loss of pro-survival 
signaling was linked with p38 activity being required for induction of BCL2 and BCL-xl 
expression. However, inhibition of Chk1 in conjunction with genotoxic agents also leads 
to apoptosis induction, via pre-mature entry into mitosis (mitotic catastrophe). Induction 
of apoptosis through the inhibition of Chk1 pathway does not require inhibition of p38.  
 Furthermore, p38 MAPK signaling has been widely reported to play a role in pro-
apoptotic signaling in the context of death receptor signaling and DNA damage 
(176,375,413,468). Yet results from this study and others have shown that inhibition of 
p38 also leads to apoptosis. A possible explanation for this could be that the signaling 
pathways in transformed versus untransformed cells are fundamentally different.  
 Another possible explanation could be that p38 MAPK plays a dual role and 
depending on environmental cofactors, switches between a pro-survival and pro-
apoptotic phenotype. Clearly the underlying mechanism of how p38 behaves in different 
contexts for the regulation of apoptosis is not well understood. 
 Further exploration of the role of p38 signaling in the regulation of apoptosis 
would be an interesting question to pursue in the future.  
 
7.3 Exploring p38 and p53 interactions, especially at the G1/S cell cycle 
checkpoint transition  
 One question that was not addressed in this study due to insufficient time was the 
relationship between p38 and p53. Numerous publications have found a link between p38 
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activity and increased p53 activity, suggesting that p38 is an upstream mediator of p53 
signaling (31,163,180,327,356,362,379). It has been shown in these publications that p38 
can directly or via MK2, phosphorylate p53 on numerous N-terminal residues. This 
relationship between p38 and p53 may be especially relevant at the G1/S transition, 
which depends on a functional p53 and Rb pathway. In addition to regulating the G1/S 
transition point, p38 may have a role in p53 induced apoptosis following DNA damage. 
 The majority of the experiments for the cell cycle component of this study utilized 
HeLa and Calu6 cells, which are both p53 functionally null. However some very 
preliminary data in A549 cells suggests that p38 may modulate p53 signaling and thus 
impact the function of the G1/S restriction point in response to DNA damage.  
 The complexity of the p38 and p53 signaling pathways makes this a difficult 
study. The large number of potential up-stream regulators of p53 makes identifying a p38 
specific interaction with p53 difficult. It is likely that high degree of redundancy in the 
protein signaling networks leading to p53 activation would make deciphering of the 
pathway challenging. Yet gaining a greater understanding of p38’s role in G1/S 
transition, in a p53 wild-type environment would have potential therapeutic value. 
 
7.4 Understanding how p38 signaling affects recovery from DNA damage 
A relatively unstudied field in DNA damage response is the process of how cells 
recover from DNA damage and reinitiate the cell cycle. As shown in section 5.3, HeLa 
cells can recover from low levels of adriamycin damage (Figure 5.5). Inhibition of p38 in 
this context leads to cells not recovering from DNA damage. Due to time constraints we 
were unable to further delve into the mechanism of how p38 activity influences the 
process of recovery and reinitiation of cell cycle.  
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One possibility is that p38 may link the DNA damage response to the DNA repair 
pathway (149). Inhibition of p38 may impede the proper functioning of the DNA repair 
pathway, leading to cells not being able to sufficiently repair the damage and return to the 
cell cycle. Further investigation of the underlying mechanism of p38’s role in DNA repair 
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